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Background and research questions 
The studies in this thesis evaluated the physical activity (PA) in individuals with 
chronic obstructive pulmonary disease (COPD), identified strategies to optimise PA, 
determined the effects of a supervised walking training program on performance 
during the endurance shuttle walk test (ESWT) and determined the minimal 
detectable difference for the ESWT.  
The specific aims of the studies in this thesis, in individuals with COPD, were to:  
1. Determine the impact of exercise training on PA through a systematic 
review and meta-analysis. 
2. Evaluate the measurement properties of two novel motion sensors: the 
StepWatchTM Activity Monitor (SAM) and the ActivPALTM. 
3. Evaluate the effects of using a wheeled walker (WW), an assisted 
walking device, for use in the community on daily PA, health-related quality 
of life (HRQoL) and fear of falling. 
4. Examine the magnitude of change in clinical outcomes, namely ESWT 
performance and PA after a short-term, supervised, individually tailored, 
ground walking training program. 
5. Determine the minimal detectable difference (MDD) for ESWT 
performance. 
Methods 
Study 1: Systematic review and meta-analysis to evaluate the effect of exercise 
training on physical activity (addressing the first aim) 
Electronic searching of computerised databases, hand searching reference lists of all 
identified studies and clinical trials registries were undertaken to evaluate the impact 
of exercise training on PA in individuals with COPD. Quality assessment for the 
randomised controlled trials (RCTs) and randomised trials (RTs) was rated using the 
10-point PEDro scale while single-group interventional studies were rated using a 
modified Downs and Black tool. Consistency between reviewers for both quality 
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assessment methods was calculated using Kappa statistics. Due to the heterogeneity 
in PA outcome measures, the random-effects approach was used in the meta-
analysis. A funnel plot was assessed visually to detect publication bias. Effect sizes 
were calculated by dividing the differences in PA (before and after the intervention) 
by the pooled standard deviation (SD).  
Study 2: Measurement properties of the StepWatchTM Activity Monitor and 
ActivPALTM – A validation study (addressing the second aim) 
Some motion sensors have been shown to underestimate steps in individuals who 
adopt a slow walking speed. Measuring PA also appears to be particularly 
problematic in those who use a WW to assist with ambulation. This is likely to relate 
to the slower walking speeds characteristic of people who require gait aids. The 
simplest of motion sensors, namely pedometers, often lack the sensitivity to detect 
slow or shuffling gait patterns and thus tend to underestimate the number of steps 
taken by some patients with COPD. Further, for motion sensors that attach to the arm 
such as the SenseWear armband, the use of a WW stabilises the arm during 
ambulation, and therefore data received by the accelerometers within such devices 
are dampened. This serves to reduce the precision of any measurements. 
As slow walking is likely to diminish movement in the lower limbs to a lesser extent 
than movement at the centre of mass, motion sensors that attach to the leg, rather 
than the waist, may yield accurate measures in individuals with COPD who are 
known to adopt slower walking speeds during daily life. The measurement properties 
of two motion sensors, the SAM and the ActivPALTM that attach to the leg, were 
examined as they have yielded encouraging data in other clinical populations who 
walked slowly, including those who use a gait aid.  
Both the SAM and the ActivPALTM are small, easily concealed by clothing and 
simple to use; features that make them attractive for monitoring PA in both the 
research and clinical setting. Nevertheless, the capacity of these motion sensors to 
collect accurate information in people with COPD, who may use a WW to assist with 




Twenty participants (8 males, 40%) completed this cross-sectional validation study 
to evaluate the measurement properties of two motion sensors: the SAM and the 
ActivPALTM. The study was undertaken in the Perth metropolitan area, Western 
Australia, during which data collection for each participant was completed during a 
single 2-hour session. The SAM and ActivPALTM were attached to each participant 
and they completed five tasks, performed in a standardised order. The first four tasks 
were completed in the following order; supine lying for 5 minutes, sitting over the 
edge of a plinth for 5 minutes, 12 repetitions of transitioning between sitting and 
standing at their own pace and upright standing for 5 minutes. The fifth task was a 
set of four walking tasks of 5 minutes in duration each, performed within a 20 m 
level, enclosed corridor, separated by 30 minutes of seated rest. The first two 
walking tasks were undertaken at a speed considered to be ‘slow’ by the participants 
with the final two walking tasks undertaken at a speed considered to be ‘normal’ by 
the participants. The first walk at both speeds was completed without a WW and the 
second walk at both speeds was completed using a WW. The speed during each 
walking task was kept constant by using audio-signals that corresponded to a specific 
walking speed. During each walking task, for each participant, the investigator 
counted the number of steps taken over three separate 30-second intervals (i.e. at the 
beginning of the second, third and fourth minutes). The average of these three 
samples was used to determine the average step rate, for each participant, for each 
walking task.  
Data collected during each stationary task were examined to determine whether 
either activity monitor had recorded movement. Data collected during the transitions 
from sit to stand were examined to determine if steps were detected during the tasks 
and data from the ActivPALTM were examined to determine the number of changes 
in posture recorded from sedentary to upright. A repeated measures analysis of 
variance (ANOVA) was used to examine the effect of WW, walking speed and the 
interaction between the two, on the difference in step rate measured by the both 




Study 3: Effect of using a wheeled walker on physical activity – A cross over 
study (addressing the third aim) 
A prospective randomised cross-over study was conducted. A total of 19 participants 
with COPD were recruited from pulmonary rehabilitation programs (PRPs) within 
the Perth metropolitan area, Western Australia. All participants completed an 8-week 
hospital-based PRP. During the final 2 weeks of the PRP, two assessment sessions 
were undertaken in order to: (i) familiarise the participants with wearing the motion 
sensors that would be used to collect PA data and, (ii) collect descriptive baseline 
data. On completion of the PRP, participants were then randomised to one of two 
groups. Those allocated to Group 1 were provided with a WW for 5 weeks 
immediately following completion of the PRP but not the next 5 weeks. Participants 
allocated to Group 2 were not given a WW for the first 5 weeks but were thereafter 
provided with a WW for the next 5 weeks. In the final week of each 5-week period, 
two motion sensors were applied to participants in both groups to measure PA. 
Participants were instructed to wear both motion sensors 24 hours a day for 5 
consecutive days. At the end of this 5-day period, all participants were visited at 
home to collect the motion sensors and complete questionnaires pertaining to their 
HRQoL and fear of falling. During this home visit, Group 1 participants had their 
WW removed and were encouraged to continue with their home exercise program 
and attend the maintenance PRP, whereas Group 2 participants were provided with a 
WW to use for the following 5 weeks and provided with standardised instructions 
regarding its use (as per Group 1). In the final week of the 5-week period, the same 
motion sensors were applied to participants in both groups and participants were 
instructed to wear both motion sensors 24 hours a day for 5 consecutive days. At the 
end of this period, a final home visit was made to collect the motion sensors and 
repeat the questionnaires. 
The SAM was used to determine step rate as it has been shown to be accurate in 
those who walk slowly, including individuals who use a gait aid. The ActivPALTM 
was used to complement the SAM in order to quantify the time spent being less 
active (sitting and lying down) compared to the time spent being active (standing and 
walking). The primary outcome measure was PA, measured concurrently using two 
separate motion sensors: the SAM and the ActivPALTM. The secondary outcome 
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measures were HRQoL, fear of falling, the distance travelled by the WW over the 
data collection period and barriers to using the WW. 
Study 4: The impact of a supervised ground walking training program 
(addressing the fourth aim) 
A total of 143 participants were recruited from patients who had been referred to the 
PRPs in Sydney, New South Wales (86 participants) and Perth, Western Australia 
(57 participants) and randomised into one of three groups: a supervised ground 
walking training group (WG), a supervised ground walking training with post-
training feedback group (WFG) and a usual care group. Both the WG and WFG 
underwent an identical ground walking training intervention over an 8-week period. 
The initial training intensity prescribed was equivalent to 80% of the average 
walking speed achieved during the 6-minute walk test (6MWT) that yielded the 
maximum distance at the baseline assessment. The total exercise time (excluding 
rests) was 30 minutes at the commencement of the walking training program. This 
was progressed by increasing the distance walked during training by increasing the 
duration of exercise by 5 minutes after every sixth session to a maximum of 45 
minutes by session 19. During walking training, a rating of three (moderate 
breathlessness) to four (somewhat severe) on the modified Borg scale for dyspnea 
was used to titrate exercise intensity. After the 8-week period, the participants in both 
the WG and WFG were followed up over a 12-month period. The participants in the 
WG were provided with written instructions to walk for 45 minutes on at least 3 days 
a week and a weekly diary to record the duration of each walk. The participants in 
the WFG received biofeedback in the form of a pedometer and regular phone calls to 
set goals and provide support, in addition to the same written instructions and weekly 
diary to record the steps taken during each walk. The data of the participants in both 
the WG and WFG, relating to baseline and post effects of the 8-week walking 
training intervention, were used for Study 4 of this thesis. Participants randomised to 
the usual care group did not perform any exercise training and were not given any 
instructions regarding exercise. 
In all participants, the outcome measures were assessed before and immediately after 
the 8-week intervention period. These outcomes included exercise capacity measured 
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using three field-based walking tests, HRQoL, anxiety and depression, self-efficacy 
and daily PA. Analysis of covariance was conducted for the between-group 
comparisons with baseline values as the covariate. Intention-to-treat analyses were 
conducted regardless of the participants’ attendances to the exercise sessions with no 
imputation of missing values. Within this thesis, only data relating to the change in 
ESWT and PA measured immediately after the 8-week walking training intervention 
are reported in detail, thus data from both WG and WFG were combined as the 
participants in both groups underwent the same walking training during the 8-week 
period. 
Study 5: The minimal detectable difference of endurance shuttle walk test 
performance (addressing the fifth aim) 
The data from the supervised ground walking training program were used to 
determine the MDD for the change in performance during the ESWT, expressed in 
both time (sec) and distance (m). The anchor-based approach to determining the 
MDD comprised four steps. First, responses to the global rating of change (GRC) 
scale were collapsed from seven categories to three categories. The GRC scale is a 
balanced 15-point numerical scale, where individuals ranked their improvement or 
deterioration using the written descriptors ranging from a very great deal worse (-7) 
to a very great deal better (+7). Given the limited number of participants in some of 
the categories, the GRC scores were collapsed to three categories, where no change 
or a GRC score of 1 were categorised as no change, GRC scores of 2 to 3 were 
categorised as a small change and GRC scores of 4 to 7 were categorised as a 
substantial change. Second, the relationship between the collapsed GRC responses 
and the magnitude of change in ESWT performance following training was 
determined. Third, a receiver operating characteristics (ROC) curve was constructed 
to determine the optimal operating point which resulted in the best blend of 
sensitivity and specificity to discriminate between participants who rated their 
walking ability following training as ‘changed’ versus ‘unchanged’. Finally, the 
software package ‘R’ was used to establish the 95% confidence interval (CI) for this 
optimal operating point, using bootstrapping methods. Three separate distribution-
based approaches were used to estimate the MDD: half the SD of the baseline 
  
x 
measure; half the SD of change in measures collected before and after training and; 
the minimal detectable change (MDC), derived from the SEM.  
Results 
Study1: 
Seven relevant studies were identified from the literature search. Reviewers agreed 
on 100% of all PEDro items (Kappa statistic = 1). The mean±SD PEDro score for the 
RTs was 5±0 points. Reviewers agreed on 96% of all Downs and Black items with a 
Kappa statistic of 0.92. The mean±SD Downs and Black score was 19±3 points. 
Asymmetry was observed in the funnel plot for PA in the RTs and single-group 
interventional studies, suggesting that publication bias could not be excluded. Taken 
together, PA data entered into the meta-analysis from the RTs and the single-group 
studies were homogeneous (I2 = 0%, p = 0.60). The effect size for PA though 
significant was small (0.12; p = 0.01). 
This is the first systematic review and meta-analysis to evaluate the effect of exercise 
training on measures of PA in individuals with COPD. The important findings of the 
review are that; (i) there are no published RCTs that examine the effects of at least 4 
weeks of supervised exercise training on PA and, (ii) data from the RTs and single-
group interventional studies indicate that, in individuals with COPD, supervised 
exercise training confers a significant, but small effect on PA. 
Study 2: 
Twenty participants (8 males) aged 73.0±8.5 years with a 35±13% predicted FEV1 
(volume exhaled during the first second of a forced expiration) wore both the SAM 
and the ActivPALTM during the performance of five tasks. Neither the SAM nor the 
ActivPALTM detected any steps during the stationary tasks or during sit to stand 
transitions. Regarding data collected using the SAM, the ANOVA demonstrated no 
interaction (WW x walking speed; F1, 19 = 0.24; p = 0.63), effect of WW                
(F1, 19 = 0.12; p = 0.73) or walking speed (F1, 19 = 0.03; p = 0.86) on the difference 
between step rate derived using this motion sensor and via direct observation. This 
indicated that the difference between step rate derived using the SAM and direct 
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observation was similar across all walking tasks. Regarding data collected using the 
ActivPALTM, there was no interaction (WW x walking speed; F1, 19= 0.58; p = 0.46) 
or effect of WW (F1, 19 = 0.01; p = 0.91) on the difference between step rate derived 
using this device and via direct observation. This indicated that any difference 
between the step rate derived using the ActivPALTM and direct observation was not 
affected by the use of a WW. However, there was a significant effect of walking 
speed (F1, 19 = 5.75; p = 0.03) on the difference between step rate derived using the 
ActivPALTM and direct observation. This indicates that the difference between the 
step rate derived using the ActivPALTM and direct observation differed between 
walking speeds. Thus both motion sensors were able to detect the difference in step 
rate associated with changing walking speeds and using a WW.  
Study 3: 
Nineteen participants (11 males) aged 73±8 years with a 38±19 FEV1 % predicted 
were randomised to one of two groups, whereby those allocated to Group 1 were 
provided with a WW for 5 weeks but not the next 5 weeks while those allocated to 
Group 2 were not given a WW for the first 5 weeks but were thereafter provided with 
a WW for the next 5 weeks. For the SAM and ActivPALTM data, no order effect was 
found (F1, 16 = 3.11; p = 0.10 and F1, 14 = 2.00; p = 0.18, respectively), thus data from 
both groups were combined for the purpose of comparing outcomes between walking 
with a WW or without a WW. 
Using data collected by the SAM, compared with the period when the WW was not 
available, the mean number of steps taken daily significantly increased by 732±1,027 
steps (p < 0.02) when the WW was available. The mean time spent walking at a 
moderate intensity significantly increased by 9±13 min/day (p < 0.02) when the WW 
was available. Using the data collected by the ActivPALTM, compared with the 
period when the WW was not available, there was a trend for the mean time spent 
walking each day to increase by 7±16 min/day when the WW was available             
(p = 0.09). The difference in mean time spent standing each day when the WW was 
available was 9±25 min/day (p = 0.18). The mean time spent sitting and lying down 
when the WW was not available was similar to that measured when the WW was 
available (-15±35 min/day; p = 0.11). In the primary analysis, the magnitude of 
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change in PA was greater when data from the participants who had an exacerbation 
were removed from the analysis. 
Compared with the period when the WW was not available, the magnitude of change 
in HRQoL for all domains of the Chronic Respiratory Disease Questionnaire 
(CRDQ) when the WW was available did not reach statistical significance. Nine of 
the 19 participants expressed a fear of falling (i.e. scored > 0 on the Survey of 
Activities and Fear of Falling in the Elderly scale) and the use of a WW reduced this 
fear in seven of these nine participants. The greatest barrier towards the use of the 
WW was lifting a WW in and out of the car.  
Study 4: 
A total of 143 participants (84 males) aged 69±8 years with a 43±15 FEV1 % 
predicted were randomised into one of three groups: a walking training group (WG), 
a walking training with post-training feedback group (WFG) and a usual care group. 
A total of 95 participants were randomised to the walking training groups (WG and 
WFG) and 48 participants were randomised to the usual care group. The duration and 
distance achieved in the ESWT increased for participants in the walking training 
groups after the 8-week period by 245±313 sec and 289±376 m respectively (p < 
0.001), representing an improvement of 92±148 %. In contrast, the duration and 
distance achieved in the ESWT for the usual care group did not change significantly 
over time (38±229 sec and 54±325 m respectively [p = 0.26]; representing a 
difference of 34±102 %). 
A total of 61 participants in the walking training groups and 38 participants in the 
usual care group had at least 3 days of valid PA data before and after the 8-week 
intervention period, during which the SenseWear armband had been worn for at least 
85% of each day. The walking training groups increased their total energy 
expenditure (TEE) by 16±132 kilocalories (kcal) (p = 0.35) and steps per day by 
404±1,608 (p = 0.05), while the usual care group increased their TEE by 28±160 kcal 
(p = 0.29) and steps per day by 268±1,616 (p = 0.31). However there was no 
significant difference in TEE and steps taken per day between the walking training 
groups and the usual care group (p > 0.7).  
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Study 5:  
The data from 78 participants (44 males), aged 70±9 years with a 43±15 FEV1 % 
predicted, who were randomised to walking training (both WG and WFG) and who 
completed the ESWT before and after the 8-week walking training were used to 
determine the MDD for ESWT performance. The MDD for ESWT performance 
expressed in time and distance as determined by the anchor-based approach using the 
ROC curve were 113 sec (95% CI, 23 to 139 sec) and 192 m (95% CI, 60 to 200 m) 
respectively. The MDD for ESWT performance expressed in time and distance as 
determined by the distribution-based approaches ranged between 104 to 158 sec and 
162 to 189 m, respectively. The estimated consensus for MDD for ESWT 
performance on completion of an 8-week supervised, individually tailored, ground 
walking training program was approximately 113 sec (95% CI, 23 to 139 sec) or 192 
m (95% CI, 60 to 200 m).  
Discussion and conclusions 
Individuals with COPD are generally less active, most likely because they try to 
minimise dyspnea and fatigue in daily life. Inactivity leads to deconditioning and 
muscle weakness, both of which contribute importantly to the overall level of 
disability. Reduced PA is also likely to contribute to the increased risk of 
cardiovascular disease demonstrated in individuals with COPD and may be a 
predictor of survival. Despite the importance of increasing PA, the optimal 
measurement method is unclear. As individuals with COPD walk less and slower 
than healthy peers, suitable motion sensors that are responsive should be used to 
measure PA in these individuals. In the research setting, a comprehensive assessment 
of the measurement properties of the SAM and the ActivPALTM will determine 
whether or not these devices are appropriate to evaluate PA in the subgroup of 
individuals with COPD who require a WW to assist with ambulation. This in turn 
will allow the impact of a WW, provided to those with the greatest functional 
limitation, on PA to be accurately evaluated. 
As PA has been found to have a protective effect on the risk of hospitalisation for 
acute exacerbations and mortality, it is important to look at strategies that might 
improve PA levels in individuals with COPD. Therefore, it is possible that an 
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increase in the level of PA in response to the use of the WW may impact these 
important clinical events. The lower limb muscles in individuals with COPD are also 
weak and metabolically inefficient, thus endurance exercise of the leg muscles, such 
as walking is an essential component of exercise training during pulmonary 
rehabilitation. Walking training is particularly suitable as a method of exercise 
training for individuals with COPD as it is an activity that is part of their daily lives, 
inexpensive as no specialised equipment is required, serves as a form of transport 
and protects against mobility loss in older adults. Therefore, it is possible that 
walking training may impact exercise capacity in terms of endurance and may 
increase the level of PA.                      
The ESWT is an externally paced, constant workload field walking test that has been 
shown to be more responsiveness than other field-based assessments of exercise 
capacity. Determining the MDD for the ESWT using both anchor- and distribution-
based approaches will allow changes in endurance shuttle walking distance and 
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LIST OF ABBREVIATIONS 
a: accelerometer 
ActivPAL: ActivPALTM 
AEE: active energy expenditure 
ANOVA: analysis of variance 
AUC: area under the curve 
AUD: Australian dollar 
BMI: body mass index 
bpm: beats per minute 
BODE: body mass index, airflow obstruction, dyspnea and exercise capacity index 
cm: centimetres 
COPD: chronic obstructive pulmonary disease 
CRDQ: Chronic Respiratory Disease Questionnaire 
CI: confidence interval 
DALYs: disability-adjusted life years 
DLW: doubled labelled water 
ESWT: endurance shuttle walking test 
F: female 
FEV1: forced expiratory volume in one second 
FEV1/FVC: the ratio of forced expiratory volume at one second to forced 
vital capacity written as a percentage 
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Many individuals with chronic obstructive pulmonary disease (COPD) are inactive in 
daily life, most likely as a strategy to minimise dyspnea (1). The deleterious effects 
of inactivity are becoming increasing apparent and include impaired health-related 
quality of life (HRQoL), increased healthcare utilisation and possibly reduced 
survival (2-4). Evaluating and optimising function, including increasing physical 
activity (PA), is an important goal in the management of people with COPD. 
Possible strategies include the use of an assistive walking aid such as a wheeled 
walker (WW) and exercise training as part of pulmonary rehabilitation. However, 
little is known regarding the optimal methods to measure PA in this population. 
Further, exercise training has also been shown to reduce dyspnea and fatigue (5-7), 
increase exercise capacity and improve HRQoL (5-7). The improvements observed 
after exercise training must extend beyond showing changes that are statistically 
significant to demonstrating changes that are perceived as beneficial by the 
individual (8). Thus, this PhD comprises of studies that will explore the evaluation 
approaches and effectiveness of therapeutic interventions that aim at optimising daily 
PA in individuals with COPD, as well as determine the minimal detectable difference 
(MDD) of outcome measures, namely the endurance shuttle walk test (ESWT) 
performance and PA. 
This program of research consisted of four studies that were conducted in individuals 
with COPD. They were a systematic review and meta-analysis of the impact of 
exercise training on PA, a cross-sectional observational study that evaluated the 
measurement properties of two motion sensors, a prospective randomised cross-over 
study that examined the effects of the use of a WW on PA, HRQoL and fear of 
falling, as well as a prospective, single-blind, randomised controlled trial on the 
impact of supervised walking exercise training on ESWT performance and PA.  
1.1 Research questions 
• What is the impact of exercise training on PA in individuals with COPD? 
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• What are the measurement properties of two novel motion sensors: the 
StepWatchTM Activity Monitor (SAM) and the ActivPALTM in individuals with 
COPD? 
• What are the effects of using a WW, an assisted walking device, for use in the 
community on daily PA, HRQoL and fear of falling in individuals with COPD? 
• What is the magnitude of change in clinical outcomes such as functional 
exercise capacity and PA after a short-term, supervised, individually tailored, 
ground walking training program in individuals with COPD? 
• What is the MDD for the ESWT in individuals with COPD? 
This chapter presents an overview of the literature pertaining to the development of 
each primary research question. The hypotheses for each research question are 
described and the significance of the research program is discussed.     
1.2 Primary question 
Does exercise training increase PA in individuals with COPD? 
1.2.1 Hypothesis 
Exercise training will increase PA in individuals with COPD. 
1.2.1.1 Background 
The cornerstone of pulmonary rehabilitation is supervised exercise training (5) and 
exercise training is the intervention within a pulmonary rehabilitation program (PRP) 
that has been shown to be most likely to change PA. A systematic review and meta-
analysis was undertaken to determine the impact of exercise training on PA in 
individuals with COPD. 
1.3 Primary question 
Do the SAM and the ActivPALTM detect movement when individuals with COPD 
perform stationary tasks and during a sit to stand task, and are they accurate and 
responsive in detecting steps when individuals with COPD walk at slow and normal 
pace with and without a WW? 
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1.3.1 Hypothesis 
The first hypothesis is that both monitors will not detect steps when individuals with 
COPD perform stationary tasks, namely lying supine, sitting and standing as well as 
during the transition from sitting to standing. 
The second hypothesis is that both the SAM and ActivPALTM will be accurate and 
responsive at detecting steps in individuals with COPD during: 
i. slow and normal walking pace; 
ii. slow and normal walking pace when using a WW. 
1.3.1.1 Background 
In individuals with COPD, the level of daily PA has been demonstrated to influence 
healthcare utilisation, morbidity and mortality (9, 10). Despite the importance of 
optimising daily PA in this population, selecting an appropriate device to obtain valid 
measures remains a challenge. This is especially true for those individuals who walk 
slowly or use a WW to assist with ambulation (11-13). Some motion sensors 
underestimate steps in individuals who adopt a slow walking speed as there is 
insufficient magnitude of movement at the centre of mass to be detected by these 
motion sensors (13-15). Measuring PA also appears to be particularly problematic in 
those who use a gait aid to assist with ambulation (13). Following a review of the 
literature (11, 16-19), the measurement properties of two motion sensors that attach 
to the leg were explored as they have yielded encouraging data in other clinical 
populations. These motion sensors were the StepWatchTM Activity Monitor (SAM; 
OrthocareInnovations, Seattle, Washington, United States [US]) and the ActivPALTM 
(PAL Technologies Ltd, Glasgow, Scotland, United Kingdom [UK]). Nevertheless, 
the capacity of these motion sensors to collect accurate information in individuals 
with COPD, who may use a WW to assist with ambulation, is unknown. Further, the 
capacity of these motion sensors to detect a small increase in PA is unknown. This is 
particularly important if these motion sensors are used to evaluate the effect of 
therapies aimed at increasing PA in individuals with COPD.  
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1.4 Primary question 
Does providing a WW to individuals with COPD for home and community use 
increase PA, improve HRQoL and reduce the fear of falling? 
1.4.1 Hypothesis 
Individuals with COPD will benefit from the use of a WW in the home and 
community. Specifically, compared to a 5-week period without a WW, the use of a 
WW for 5 weeks will result in significant improvements in: 
i. PA; 
ii. HRQoL and; 
iii. Fear of falling. 
1.4.1.1 Background 
Individuals with COPD who are characterised by marked functional limitation due to 
intolerable dyspnea may benefit from ambulating with a WW (20). The use of a WW 
has been shown to decrease dyspnea and rest duration during a 6-minute walk test 
(6MWT) (21) and increase 6-minute walk distance (6MWD) (22).     
The improvements in 6MWD and dyspnea were greater in individuals with COPD 
with greater functional limitation. Solway et al (21) found that 6MWD significantly 
increased when individuals with COPD who walked < 300 m unaided in their 6MWT 
were provided with a WW (with a WW, 6MWD = 243±14 m versus without a WW, 
6MWD = 220±12 m; p = 0.02).  
The reasons for the improvements seen when walking with a WW most probably 
relate to the use of a forward lean position, the capacity to brace the arms on the WW 
and decreases in the metabolic cost of walking (23, 24).  
This reduction in dyspnea and improvement in functional capacity when using a WW 
may enable individuals with COPD to increase their PA. Despite the acute 
improvements in dyspnea and functional capacity which have been documented in 
the laboratory setting, no study has evaluated the effects of a WW on daily PA in the 
community. Further, it is possible that using a WW will decrease the fear of falling 
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and increase confidence when walking. This is particularly important given the 
evidence demonstrating a reduction in the balance and coordination of individuals 
with COPD (25-27) which is likely to result, at least in part, from a less active 
lifestyle.  
1.5 Primary question 
Does an 8-week supervised, individually tailored, ground walking training program 
change ESWT performance and PA in individuals with COPD? 
1.5.1 Hypothesis 
In individuals with COPD, functional exercise capacity, namely ESWT performance, 
as well as PA will improve after participating in an 8-week supervised, individually 
tailored, ground walking training program. 
1.5.1.1 Background 
Pulmonary rehabilitation has been shown to be effective at increasing exercise 
capacity, improving HRQoL and reducing hospital admissions in individuals with 
COPD (5). In pulmonary rehabilitation, exercise training is of paramount importance 
(5). The lower limb muscles in individuals with COPD are weak (28), thus endurance 
exercise of the leg muscles, such as walking (ground-based or treadmill) and 
stationary cycling is an essential component of exercise training during pulmonary 
rehabilitation (5). Walking training is particularly suitable as a method of exercise 
training for individuals with COPD as it is an activity that is part of their daily lives 
(29), is inexpensive as no specialised equipment is required, serves as a form of 
transport and protects against mobility loss in older adults (30).  
Despite the strong evidence that supervised exercise training reduces dyspnea and 
fatigue (7), increases exercise capacity as well as improves HRQoL (5-7), the impact 
on PA seems modest ((31-38)). Exercise training is muscle and activity specific. 
Walking training has been shown to improve outcomes in field walking tests to a 
greater extent than cycling training (39) and upper limb training (40). Thus, it is 
possible that walking as a sole modality of exercise training may confer greater gains 
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in daily PA than other exercise modalities such as cycling as walking is an integral 
part of daily life for individuals with COPD (9). 
In summary, there is little evidence that supervised, individually tailored ground 
walking training alone, in which the exercise intensity is progressed to ensure 
optimal training responses, is effective at improving exercise capacity and PA in 
individuals with COPD. This gap in evidence is important to address as, if found to 
be effective, a walking program has the advantage over cycling training in that it is 
low cost and requires few resources. This in turn would support the widespread 
establishment of walking training programs, particularly in rural and remote areas, as 
well as in programs run in metropolitan areas. This would potentially provide a large 
number of individuals with COPD access to such programs, which could be 
conducted independent of expensive exercise equipment.  
One of the studies presented in this thesis was part of a multi-centre trial conducted 
in Sydney, New South Wales and Perth, Western Australia, that sought to determine 
the effect of supervised ground walking training on the exercise capacity and 
HRQoL of individuals with COPD. The impact of a short-term, supervised, 
individually tailored, ground walking training as a sole exercise modality on ESWT 
performance and PA in individuals with COPD has been presented in this thesis. 
1.6 Primary question 
What is the MDD for ESWT performance using both anchor-based and distribution-
based approaches in individuals with COPD? 
1.6.1 Hypothesis 
The hypothesis for this study is that there will be a significant relationship between 
objective measurement of the change in ESWT performance and the subjective 
global rate of change (GRC) ratings as perceived by the individuals with COPD after 
an 8-week supervised, individually tailored, ground walking training program. It is 
hypothesised that the estimate of the MDD derived using anchor-based approaches 
will be similar to the estimate of the MDD derived using distribution-based 
approaches (calculated using statistical methods).     
Chapter 1: Introduction 
7 
1.6.1.1 Background 
The MDD has been defined as the smallest difference in the outcome of interest that 
is noticeable to an individual after treatment (41). This term is often used 
interchangeably with terms such as the minimal important difference (MID) and 
minimal clinically important difference (MCID). The main difference between these 
terms is that the MDD is the smallest difference noticeable (or detectable) by an 
individual, whereas, both the MID and MCID aim to ensure that the magnitude of 
this difference is important to the individual (8).  
The MDD has been determined using two approaches, namely anchor- and 
distribution-based approaches (8). Anchor-based approaches relates the magnitude of 
change in an outcome measure following an intervention to an objective external 
criterion (8). For example, several studies have related the magnitude of change in 
field-based measures of exercise capacity, following pulmonary rehabilitation, with 
self-report scores on the GRC scale (42-44). Specifically, a GRC scale is simple to 
use and administer, and asks individuals to rank their improvement or deterioration 
using a balanced 7-point numerical scale with written descriptors ranging from a 
very great deal worse (-7) to a very great deal better (+7) (45). Distribution-based 
approaches establish the MDD using some measure of variability in the outcome of 
interest. Distribution-based approaches are not anchored to a GRC scale and 
therefore do not take into consideration an individual’s perception of the change. 
There have been several distribution-based approaches that have been used to 
determine the MDD for outcomes commonly used to evaluate the effects of 
pulmonary rehabilitation. These comprise calculating an effect size, the standardised 
response mean (SRM) or standard error of measurement (SEM) (8). Effect size has 
been defined as the standardised measure of change obtained by dividing differences 
in the outcome measure of interest (i.e. from baseline to post-intervention) by the 
standard deviation (SD) of the baseline value (8). An effect size of 0.5 is considered 
to be moderate (8) and the MDD is calculated by multiplying the SD of the baseline 
measure by 0.5. The SRM has been defined as the changes in a group of values or 
scores obtained by dividing differences in the outcome measure of interest (i.e. from 
baseline to post-intervention) by the SD of the change in the outcome measure (46). 
Half a SD of the change in the outcome of interest was used to estimate the MDD. 
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The SEM is the measure of within individual variability (8), as it estimates the 
standard error in a set of repeated scores. It is defined as variability between an 
individual’s observed score and the true score, and can be calculated using an intra-
class correlation coefficient (ICC) or via repeated measures analysis of variance 
(ANOVA) (47).  
The only study to date to attempt to estimate the MDD for ESWT performance 
reported the SRM using a distribution-based approach (48). The authors did not 
attempt any anchor-based approaches due to the weak relationship between the 
ESWT performance and the GRC scores after rehabilitation (r < 0.4) which was 
attributed to either recall bias or the high level of commitment and personal 
investment required to complete the 7-week pulmonary rehabilitation program; both 
of which were likely to affect the individual’s perception of his or her exercise 
performance (48).  
In this thesis, besides distribution-based approaches, the anchor-based approach of 
determining the MDD for ESWT was determined as the value that confers the 
optimal blend of sensitivity and specificity using a receiver operating characteristic 
(ROC) curve to discriminate between individuals who rate themselves as changed 
versus unchanged at the end of an intervention (8). In addition to not being 
dependent on a moderate to strong relationship between GRC ratings and 
improvement in ESWT, using the ROC method has the advantage of accommodating 
all available data and not being influenced to small number of values within a 
category of the GRC scale (49).  
1.7 Significance and novelty of the research 
Individuals with COPD are less active during their daily life (1, 50). This inactivity 
imposed by the fear-provoking symptom of dyspnea limits individuals with COPD 
from participating in life to the fullest (51). Inactivity leads to deconditioning and 
muscle weakness, both of which contribute importantly to the overall level of 
disability (52). Reduced PA is also likely to contribute to the increased risk of 
cardiovascular disease demonstrated in COPD (53, 54) and may be a predictor of 
survival (9). Therefore, it is possible that an increase in the level of PA in response to 
therapies such as the use of a WW and high-intensity walking training may impact 
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these important clinical events.                      
Despite the importance of increasing PA, the optimal measurement method is 
unclear. In the research setting, a comprehensive assessment of the measurement 
properties of the ActivPALTM and the SAM will determine whether or not these 
motion sensors are appropriate to evaluate PA in the subgroup of individuals with 
COPD who require a WW to assist with ambulation. This in turn will allow the 
impact of a WW, provided to those with the greatest functional limitation, on PA to 
be accurately evaluated.  
Although exercise training is paramount in pulmonary rehabilitation, the 
effectiveness of a solely walking exercise on ESWT performance and PA is lacking 
and this gap in knowledge is important to address as this would support the 
establishment of such cost effective exercise program. The MDD for changes in 
ESWT performance following PRP has also not been convincingly established using 
anchor-based approaches. Determining the MDD for ESWT performance will allow 
changes in these outcomes to be evaluated in terms that are meaningful to patients 
with COPD. 





This literature review is divided into five parts. Part 1 (Section 2.2) includes 
information regarding the definition, prevalence, burden and impact of chronic 
obstructive pulmonary disease (COPD). Part 2 (Sections 2.3 to 2.4) describes the 
literature which has reported on the physical activity (PA) of individuals with COPD 
and the various approaches for measuring PA. Part 3 (Sections 2.5) reviews literature 
which has described strategies to increase PA in individuals with COPD, focussing 
on two possible strategies [the use of a wheeled walker (WW) and undertaking a 
pulmonary rehabilitation program (PRP)]. Part 4 (Section 2.6) comprises a 
systematic review and meta-analysis of data pertaining to the impact of exercise 
training on PA in individuals with COPD. This section has been published in a peer-
reviewed scientific journal (55). Part 5 (Section 2.7) pertains to the methodologies 
reported for determining the minimal detectable difference (MDD) for outcome 
measures commonly used to evaluate the effectiveness of interventions in individuals 
with COPD. 
PART 1 
This part will first provide a definition for COPD and discuss the prevalence of the 
disease. In addition, the impact and costs associated with COPD are described. 
2.2 Definition of COPD 
Chronic obstructive pulmonary disease is characterised by progressive airflow 
obstruction due to a loss of elastic recoil and airway narrowing that is not fully 
reversible with bronchodilators (56). Fixed airflow obstruction is diagnosed via post-
bronchodilator spirometry and is defined as the ratio of the volume exhaled during 
the first second of a forced expiration (FEV1) to the forced vital capacity (FVC) of 
less than 0.70 (56). In those with evidence of fixed airflow obstruction, the severity 
of the disease is determined by expressing the FEV1 as a percentage of the predicted 
value in healthy individuals (Table 2-1) (56). The main risk factor for developing 
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COPD is cigarette smoking (56), however only 45-50% of smokers progress to 
develop COPD (57). Other risk factors for COPD include occupational exposure to 
dusts or chemicals, childhood respiratory infections and alpha-1-antitrypsin 
deficiency (56).  
2.2.1 Prevalence of COPD 
Chronic obstructive pulmonary disease is one of the most common lung disorders in 
the world (58). A study by Buist et al (2007) (58) measured lung function in 600 
adults from 12 sites around the world, including Australia (Sydney), and found the 
prevalence of COPD that was at least of moderate severity to be 10%. In Australia 
solely, the prevalence of COPD was estimated to be 7.5% for individuals aged 40 
years and above and 29.2% in those aged 75 years and above (59). In 2008, COPD 
was estimated to affect more than 2.1 million Australians (nearly 1 in 5 aged over 40 
years), of whom 1.2 million described symptoms that affected their daily lives (60). 
Notably, COPD is the fifth leading cause of death and third most burdensome disease 
in Australia (61). The World Health Organisation Global Burden of Disease study 
estimated COPD to be the fifth leading cause of death worldwide in 2002 (62). By 
2030, it is envisaged that COPD will become the third leading cause of death 
worldwide (62). According to the Australian Bureau of Statistics, in 2011, COPD 
was directly responsible for the death of 5,878 Australians aged 55 years and above 
(i.e. 4% of all deaths) and there was 59,265 hospitalisations for COPD in 2011-2012 
(63).  
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Table 2-1: Classification of the sever ity of air flow limitation by Global Initiative 
for  Chronic Obstructive Lung Disease (based on post-bronchodilator  FEV1) in 




I Mild COPD FEV1 ≥ 80% predicted 
II Moderate COPD 50% ≤ FEV1 < 80% predicted 
III Severe COPD 30% ≤ FEV1 < 50% predicted 
IV Very severe COPD FEV1 < 30% predicted or < 50% with 
chronic respiratory failure 
COPD, chronic obstructive pulmonary disease; FEV1, volume exhaled during the 
first second of a forced expiration; FVC, forced vital capacity; GOLD, Global 
Initiative for Chronic Obstructive Lung Disease; %, percent. 
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2.2.2 Cost of COPD 
The direct costs associated with COPD in the United States (US) have been 
estimated to be AUD $15.7 billion per annum (64). This cost is driven largely by 
hospital admissions (64) and the medical management of the disease, which includes 
outpatient visits and medications (65). Indirect costs associated with COPD include 
loss of work time and productivity as well as the toll on the family and society 
resulting from the disease (65). In Australia, the direct cost of COPD was estimated 
to be AUD $8.8 billion in 2008 with an additional cost of AUD $89.4 billion due to 
loss of quality of life (60). Disability-adjusted life years (DALYs) are defined as the 
number of healthy years lost due to ill-health, disability or premature death (66). In 
2010, the global ranking of the burden of COPD measured in DALYs was 9th (67) 
and was projected to increase to the 7th position by 2030 (68).  
2.2.3 Impact and burden of COPD 
Dyspnea and fatigue are symptoms experienced by individuals with COPD (69). 
Muscle weakness is also a major problem in individuals with COPD, affecting 
exercise tolerance (70). Mood disturbances are also prevalent (71) and there is 
increasing recognition of the importance of co-morbid conditions among individuals 
with COPD (72). These symptoms and conditions are described in the following 
paragraphs. 
Dyspnea is the main complaint among individuals with COPD (56). In people with 
COPD, expiratory flow limitation leads to air trapping and an increase in lung 
volume, known as pulmonary hyperinflation. As the ventilatory demand increases 
during exercise, air trapping worsens; a process known as dynamic hyperinflation 
(73). This process is characterised by a progressive increase in end-expiratory lung 
volume which results in the tidal volumes being generated along the less compliant 
portion of the pressure-volume curve of the respiratory system, as well as a 
shortening and flattening of the diaphragm (74). When inspiratory reserve volume 
decreases to 0.5 litres (L), dyspnea becomes intolerable (74). This is because the 
large elastic loads on the respiratory muscles coupled with their reduced mechanical 
advantage serve to create disequilibrium between efferent outflow to the respiratory 
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muscles and the corresponding afferent input from the respiratory system (74). This 
is perceived as unrewarded inspiration, or dyspnea.  
Another prominent symptom of COPD is fatigue (75). The increased work of 
breathing and dyspnea lead to deconditioning of muscles and fatigue (76). The 
systemic inflammation that occurs in people with COPD may also contribute to 
fatigue (77). Of note, fatigue was found to be a strong predictor of the risk of 
hospitalisation independent of the severity of airflow obstruction (78). The length of 
hospital stay was found to increase by a factor of almost four for every unit increase 
in fatigue experienced measured using an Identity-Consequences Fatigue Scale, a 
self-reported validated questionnaire to assess feelings of fatigue (78). Both dyspnea 
and leg fatigue could limit the ability to perform exercise in individuals with COPD 
(79) and impair health-related quality of life (HRQoL) (80).  
Weakness of the lower extremity muscles has been associated with the decline in 
exercise capacity in individuals with COPD (81, 82). There is evidence to confirm 
the loss of skeletal muscle mass and strength, in particular of the quadriceps muscles, 
in individuals with COPD (82, 83). This muscle atrophy is caused by a number of 
factors, including low levels of PA, chronic inflammation, malnutrition, the side 
effects of medications such as statins, blood-gas abnormalities as well as 
compromised oxygen delivery due to right heart dysfunction (83). The quadriceps 
muscles are one of the main muscles used for ambulation and there is a significant 
reduction in quadriceps endurance capacity in individuals with COPD (84, 85). 
Computed tomography scans of the thigh muscles in individuals with COPD have 
demonstrated a loss of skeletal muscle mass compared to healthy individuals (86). 
Individuals with COPD are also more susceptible to leg fatigue (87). The impact that 
muscle weakness and leg fatigue have on exercise intolerance was demonstrated by 
Hamilton et al (88) where those patients with weaker muscles reported more leg 
fatigue and demonstrated reduced peak exercise capacity. Saey et al (89) showed that 
in individuals with COPD, the presence of leg fatigue during cycling exercise 
prevented optimal bronchodilatation from increasing exercise tolerance. Thus, both 
muscle weakness and leg fatigue limit cycle-based exercise tolerance  in individuals 
with COPD (88). 
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It is also reported that mood disturbances such as depression and anxiety disorders 
are common among those with COPD, with the prevalence ranging from 10 to 96% 
depending on the criteria used to define them (90). Mood disturbances are often 
associated with increased disability and morbidity (71), and have a major impact on 
HRQoL (91, 92). One study reported that the incidence of depression and anxiety 
disorders was doubled in those who were physically less active (93). Physical 
inactivity due to depression, anxiety, dyspnea and fatigue leads to muscle weakness 
and deconditioning, further contributing to inactivity and disability (52).   
There are also systemic consequences and co-morbidities associated with COPD 
with the most common being cardiovascular disease, hypertension, lung cancer, 
anaemia, osteoporosis, and metabolic diseases such as diabetes and obesity (72, 94, 
95). The aetiological factors for these co-morbidities in individuals with COPD are 
likely to be multifactorial and inter-related, including systemic inflammation (96) 
associated with exposure to cigarette smoke, tissue hypoxia, oxidative stress and 
inactivity (97). These co-morbidities have a negative impact on hospitalisation and 
healthcare costs in COPD (98). 
In summary, COPD results in symptoms that include dyspnea and fatigue as well as a 
decrease in exercise intolerance, and is associated with mood disturbances and co-
morbidities. The impact and burden of these symptoms and associated disorders can 
be observed in the daily lives of individuals with COPD.  
PART 2 
This part reviews the literature pertaining to the levels of daily activity seen in 
individuals with COPD, the impact of low levels of PA, as well as the various 
methods used to measure PA. 
2.3 Low levels of physical activity in individuals with COPD 
Physical activity is defined as any bodily movement produced by skeletal muscle that 
results in energy expenditure beyond the resting state (99). There is robust evidence 
showing that individuals with COPD participate in less PA when compared with age 
and gender-matched healthy individuals (1, 100-103). Specifically, individuals with 
COPD appear to walk slower and for less time per day (1, 100, 102, 104). Pitta et al 
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(1) used a tri-axial accelerometer to measure PA, and found that individuals with 
moderate to severe COPD walked for a mean±standard deviation (SD) of          
44±26 minutes and stood for 191±99 minutes per day. This was significantly           
(p < 0.05) less than age-matched healthy individuals who walked for 81±26 minutes 
and stood for 295±109 minutes per day (105). Further, individuals with COPD spent 
more time sitting and lying down than the healthy individuals (374±139 versus 
306±108 minutes per day sitting; p = 0.04 and 87±97 versus 29±33 minutes per day 
lying down; p = 0.004) (1). Data pertaining to levels of daily PA in individuals with 
COPD were reviewed by Vorrink et al (100), who concluded that the duration and 
counts of daily PA in individuals with COPD were affected more markedly than the 
intensity of PA. This review concluded that, on average, individuals with COPD 
were approximately 40% less active than their healthy counterparts (100). 
Individuals with COPD also walked approximately 25% slower when compared to 
age-matched healthy individuals (1, 100). In a study by Hernandes et al (102), 
individuals with COPD walked at a slower intensity compared to healthy individuals 
(1.9±0.4 versus 2.3±0.6 m/s2; p = 0.004). These data were consistent with earlier 
work by Pitta et al (1) who demonstrated that individuals with COPD walked with 
lower movement intensity when compared with age and gender matched healthy 
individuals     (1.8±0.3 versus 2.4±0.5 m/s2; p < 0.0001). 
Although decrements in PA have been reported among individuals with mild COPD, 
it appears that those with more advanced disease have more profound impairments. 
For example, Watz et al (106) found that PA levels were lower in those individuals 
with more advanced COPD, measured using a multi-component index that considers 
the systemic manifesations of COPD (i.e. the BODE index which represents body 
mass index (BMI), airflow obstruction, dyspnea and exercise capacity index). Other 
studies have shown that the walking speed of individuals with COPD decreases with 
increasing disease severity (106-108).  
There are also some data pertaining to the way in which PA is accumulated among 
individuals with COPD showing that individuals with COPD walk in short 
intermittent bursts rather than long continuous walking (33, 108). For example, Jehn 
et al (108) in a study involving 107 individuals with COPD, demonstrated that the 
time spent walking each day was accumulated in short intermittent bouts of less than 
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5 minutes. Similarly, Pitta et al (33) found that before and after pulmonary 
rehabilitation, walking time during daily life accumulated largely in very short bouts 
(up to 1 minute).  
In summary, individuals with COPD are less active and move slower than their 
healthy counterparts. These decrements in PA worsen with advancing disease.  
2.3.1 Clinical outcomes associated with low levels of physical activity in 
individuals with COPD 
The adoption of a sedentary lifestyle by individuals with COPD is presumably a 
strategy to minimise dyspnea and fatigue during daily life (1). This reduced daily PA 
has been associated with impaired skeletal muscle endurance (84), muscle strength 
(1) as well as the severity of the respiratory impairment (105, 106). The 
consequences of this inactive lifestyle are likely to include cardiovascular (4, 109) 
and peripheral muscle de-conditioning (84, 110) which in turn can impact on 
exercise capacity and HRQoL (111).  
Besides being less active than their healthy peers, individuals with COPD have 
increased functional disability and reduced exercise capacity (81, 82). Several studies 
have demonstrated a relationship between decreased PA and functional disability in 
COPD (93, 112). A population-based cohort study of 206 individuals with COPD 
showed that lower baseline PA was a strong indicator of increased disability (93). In 
this study, disability was measured using the Value Life Activities scale, which 
assessed the difficulty performing 28 activities such as cooking, visiting with family 
and getting around the neighbourhood (93). The results showed that physical 
inactivity was a strong predictor of a prospective increase in disability (odds ratio 
[OR] 2.5, confidence interval [CI] 1.1 to 5.3) (93). That indicates that the odds of an 
increase in disability were 2.4 times higher among individuals who were inactive at 
baseline (93). Daily PA, expressed as walking time, has been shown to be correlated 
with 6-minute walk distance (6MWD) and quadriceps force (r = 0.76 and 0.45, 
respectively; both p < 0.05) (1). Similar associations with 6MWD have been 
demonstrated between steps taken each day and the number of minutes spent 
participating in moderate PA (r = 0.63 and 0.47, respectively; both p < 0.001) (106).  
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Low levels of PA have been associated with the reduced HRQoL in people with 
COPD (113). Jehn et al (114) demonstrated that time spent walking at more than      
5 km/h, measured using a motion sensor, was the only independent predictor of the 
physical function, role physical and general health domains of the Medical Outcomes 
Study 36-Item Short Form Health Survey (SF-36) (r = 0.4, r = 0.28 and r = 0.27, 
respectively; all p < 0.05). The time spent walking at more than 5 km/h was also a 
significant independent predictor of the activity domain of the Saint George’s 
Respiratory Questionnaire (SGRQ) (r = -0.4; p < 0.001) (114). These results indicate 
that individuals with COPD with the lowest daily walking intensities had the poorest 
HRQoL.  
Reduced levels of PA in individuals with COPD also appear to be associated with 
increased healthcare utilisation (115) and mortality (116). A large (n = 2,386) cohort 
study found that individuals with COPD who reported performing at least 2 hours a 
week of walking or cycling (as determined by a self-report questionnaire) had a 
significantly 30 to 40% lower risk of hospital admissions due to exacerbations as 
well as a greater survival rate over a 20-year period (9). These data concur with those 
of Benzo et al (115) who, in 610 individuals with COPD, found that a minimum of   
2 hours of self-reported PA per week had a protective effect against all cause 
hospitalisation. Specifically, their data showed that the odds of being hospitalised 
were significantly lower in individuals with COPD who reported undertaking           
≥ 2 hours of PA per week (OR 0.60, 95% CI, 0.41 to 0.88, p = 0.01) (115). In another 
study, where 340 individuals with COPD were followed up for 1 year, the risk of re-
admission was reduced in those individuals with PA levels which burnt more than 
232 kilocalories per day (kcal/day) compared to individuals with PA levels of           
< 79 kcal/day or between 79 to 232 kcal/day (117).  
There is also a link between regular PA and reduced risk of all-cause mortality in 
COPD (9). In a prospective cohort study of 170 individuals with stable COPD, 
Waschki et al (116) found that the best predictor of all-cause mortality was PA, when 
compared to other possible factors including lung function, 6MWD, cardiovascular 
status, nutritional and muscular status, systemic inflammatory markers, MMRC 
dyspnea grade, SGRQ and mortality scores. These authors found that every 0.5 SD 
increase in the number of daily steps (equivalent to 1845 steps), measured using a 
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multi-sensor accelerometer, was associated with a significantly lower risk of 
mortality (hazard ratio 0.49, 95% CI, 0.34 to 0.69) (116). Another study that looked 
at the prognostic value of PA, measured using a tri-axial accelerometer in 173 
individuals with moderate to severe COPD, found that for every increase in PA of 10 
vector magnitude units (VMU), mortality and hospitalisation risks decreased by 14% 
and 11% respectively after adjusting for confounders such as gender, age, BMI, 
current smoking, Charlson co-morbidity index and treatment with inhaled 
corticosteroids or long term oxygen therapy use (118).   
In summary, low PA among individuals with COPD has a negative impact on 
exercise capacity, HRQoL, healthcare utilisation and mortality.  
2.4 Measuring physical activity 
Physical activity can be measured by subjective or objective methods (119), each 
with their own specific advantages and disadvantages. These are discussed in the 
following paragraphs.  
2.4.1 Subjective methods to measuring physical activity 
Subjective methods of measuring PA refer to asking an individual to self-report their 
level of activity through the use of questionnaires, diaries or logs, surveys or 
interviews (120). These subjective approaches are inexpensive and quick to 
administer (121). However, the information they yield appears to be inaccurate (3) as 
individuals with COPD tend to overestimate the time spent walking and 
underestimate the time spent standing (105), reflecting recall and social desirability 
bias (122). Garfield et al (123) tested the validity of four PA questionnaires (i.e. 
Stanford 7-day Physical Activity Recall Questionnaire, Baecke Questionnaire, 
Physical Activity Scale for the Elderly, and Zutphen Physical Activity 
Questionnaire) in individuals with COPD. Only the Stanford 7-day Physical Activity 
Recall Questionnaire was found to correlate with measures obtained using a 
validated multi-sensor accelerometer (r = 0.54; p < 0.001). Even so, PA measured 
using this questionnaire lacked precision as demonstrated by the inability of the 
questionnaire to accurately quantify the amount of PA for individuals (123). Further, 
the measurements obtained using PA questionnaires did not correlate (r < 0.3) with 
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objective measures of light or moderate intensity PA (3, 124). One other alternative 
is the Multimedia Activity Recall for Children and Adults (MARCA), a computer 
based time instrument that records and construct detailed daily PA through a 
structured interview format (125). The MARCA has been found to be reliable and 
valid in individuals with COPD (126). However the measures obtained using the 
MARCA is not as precise as motion sensors that record exact movements (126). 
Notwithstanding these limitations, questionnaires are often the only method available 
to clinicians to measure PA due to their low cost and simplicity (106).   
2.4.2 Objective methods to measuring physical activity 
Objective methods for measuring PA most commonly use motion sensors to detect 
body movement, with devices ranging from simple pedometers to more advanced tri-
axial accelerometers (3). These devices are used to objectively quantify PA over a 
period of time, thus they are more accurate in providing individualised and detailed 
information of body movement and walking than questionnaires (3). Further, 
individuals with COPD are characterised as less active, thus the use of motion 
sensors will result in greater precision in detecting slow or low intensity activities 
(3). In the following text, pedometers and accelerometers are described, with 
particular emphasis on that the devices that were used in the studies undertaken as 
part of this thesis.  
2.4.2.1 Pedometer 
Pedometers, which constitute the simplest motion sensors, are inexpensive and easy 
to use. They record the number of steps taken (127). Most models comprise a 
horizontal spring lever that detects vertical displacement of the waist during walking. 
However other movements in the vertical plane, such as vibrations when seated in a 
car (3, 50), may also trigger the device and inaccurately record it as a step. Most 
pedometers are relatively accurate for recording step counts when compared to direct 
observation among individuals who walk at speeds equivalent to 80 m/min (127). 
However, pedometers often lack the sensitivity to detect slow or shuffling gait 
patterns (127, 128) and thus tend to underestimate step count in many individuals 
with COPD (11, 16). For example, the study by Furlanetto et al (14) involving 
individuals with COPD, found that the number of steps recorded by a pedometer was 
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significantly lower than that observed on video at slow walking speeds of       
23.3±5.0 m/min (26±26 versus 79±17 steps; p < 0.05). This was similarly observed 
when pedometer readings were compared to video recordings at a faster walking 
speeds of 48.3±8.3 m/min (73±35 versus 105±20 steps; p < 0.05) (14).  
2.4.2.2 StepWatchTM Activity Monitor  
The StepWatchTM Activity Monitor (SAM) (OrthocareInnovations, Seattle, 
Washington, US) not only is able to record step counts at walking speeds beyond    
80 m/min (129), it also overcomes some of the problems associated with the 
pedometer underestimating steps during slow walking. This monitor has a dual axis 
microprocessor-controlled step counter and records steps taken in a variety of gait 
styles and cadence (18). The SAM is a small (2 x 7.5 x 5 cm) and lightweight (38 g) 
step counter that attaches to the right ankle and has a sampling frequency of 128 
Hertz (Hz) (130). The SAM costs approximately AUD $525 each, and the computer 
interface docking station costs AUD $2,500. The SAM has been shown to accurately 
measure step counts in populations who walk very slowly at < 48m/min (with up to 
99% accuracy) (11, 16) including individuals who use mobility aids to ambulate 
(17). Further, measurements of the number of steps obtained using the SAM was 
accurate at 99.7±0.7 % when compared to manual counting at various walking 
speeds ranging from 27 to > 80 m/min (129). Step counts derived from the SAM in 
22 healthy participants have also yielded excellent intra-device reliability (intraclass 
correlation coefficient [ICC] = 0.96) (131). Despite the accuracy of the SAM 
demonstrated by these studies (11, 16-18, 129), gait speed was not controlled during 
testing in two of the studies (11, 17). Further, the accuracy of these devices has not 
been explored in individuals with COPD, who are known to walk slowly during daily 
activities.  
2.4.2.3 Accelerometers 
Accelerometers are technologically more advanced motion sensors that measure 
acceleration along an axis to record rate and intensity of body movement in up to 
three planes, namely anterior-posterior, medio-lateral and vertical (130). These 
sensors are either uni-axial or multi-axial and they generate an electrical output 
proportional to the acceleration detected (132). The advantage of using 
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accelerometers is their ability to accurately determine the quantity and intensity of 
movement (133). Some accelerometers have the capacity to discriminate brisk 
walking from other domestic activities (134).  
Uni-axial accelerometers detect motion along the vertical plane only (35). The 
ActivPALTM (PAL Technologies Ltd, Glasgow, Scotland, United Kingdom [UK]) is 
one such uni-axial device that is small (0.7 x 5.3 x 3.5 cm) and lightweight (20 g) 
(135). The ActivPALTM costs AUD $550 for each unit with associated costs 
including software licence which costs AUD $3,100. The ActivPALTM attaches to 
the anterior aspect of the right thigh (130). The ActivPALTM combines data 
pertaining to gravitational acceleration and acceleration from segmental movement 
of the thigh (136) and has been shown to yield accurate measurements of the time 
spent being less active (supine/sitting) versus active (standing/walking) in 
community-dwelling older adults (19). Step counts derived from the ActivPALTM in 
22 healthy individuals have yielded excellent intra-device reliability (ICC = 0.95) 
(131). The ActivPALTM was also found to be 99% accurate when compared to video 
recordings for measuring the cadence of 20 healthy individuals walking at speeds 
ranging from 54 to 119 m/min (136). The accuracy of the ActivPALTM compared to 
video observations in 10 healthy individuals carrying out a range of activities ranged 
from 88% to 100% (137), with accuracy the lowest for short duration walks 
separated by short intervals of standing lasting only 1 to 2 sec (137). Of note, these 
studies were all conducted in a laboratory setting with healthy individuals and thus 
may not reflect activity in real time in the community, especially for those 
individuals who walk slowly or with altered gait patterns. Uni-axial accelerometers 
are also known to be inaccurate at detecting PA with static trunk movements, such as 
cycling (35).  
2.4.2.4 SenseWear armband 
Technology in the area of multi-sensor motion devices is advancing rapidly and a 
new generation of sensors have become available. The SenseWear armband 
(BodyMedia Inc., Pittsburgh, Philadelphia, US) is one such device and is worn on the 
bulk of the triceps brachii muscle. It measures 2.4 x 8.8 x 5.6 cm, weighs 82g (135), 
and is considered to be a portable metabolic monitor that integrates multi-axial 
accelerometry with non-invasive physiologic sensors that detect galvanic skin 
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resistance, heat flux, body temperature and near body ambient temperature (138). 
The galvanic skin response is the conductivity of the wearer’s skin which varies 
dependent on physical and emotional stimuli. The heat flux sensor measures the 
amount of heat dissipated by the body by measuring the heat loss along a thermally 
conductive pathway between the skin and a vent on the side of the SenseWear 
armband. The body temperature and near body ambient temperature are measured by 
sensitive thermistors. The SenseWear armband combines the signals from all the 
sensors and utilises pattern detection algorithms to estimate energy expenditure 
across the spectrum of activities of daily living (139, 140). The SenseWear device 
costs approximately AUD $1,355 per device and an additional AUD $1,765 for the 
USB dongle key and software licence. Compliance with wearing this device has been 
found to be excellent. For example, the median wearing time of the SenseWear 
armband in 134 individuals with COPD in the Netherlands and UK was at least 98%, 
with at least 94% of individuals wearing the armband for a minimum of 5 days 
(duration each day ≥ 22 hours) (141).  
The SenseWear armband has been shown to provide an accurate estimate of energy 
expenditure when compared to indirect calorimetry (142) and energy expenditure 
measured using the doubly labelled water (DLW) technique (143) in healthy adults. 
In the study by Jakicic et al (142), the ICC of total energy expenditure between 
indirect calorimetry and SenseWear armband data for aerobic exercises was > 0.8. In 
the study by Johannsen et al (143), regression analysis showed significant 
associations for total energy expenditure measured using the SenseWear armband 
and DLW (R2 = 0.68; p < 0.001). In studies involving individuals with COPD, Hill et 
al (13) found that the SenseWear armband was sensitive and accurate in measuring 
energy expenditure while completing five tasks comprising supine lying, sitting, 
standing and walking at two different speeds. In this study, the SenseWear armband 
was able to detect small changes in energy expenditure that accompanied a modest 
increase in walking speed of 14 m/min (13). The overall difference between energy 
expenditure measured using the SenseWear armband and indirect calorimetry was 
small (-0.2 metabolic equivalents [METs]) with a limit of agreement of 1.3 METs 
(13). 
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Although the SenseWear armband has been shown to be accurate at measuring 
energy expenditure, it appears to significantly underestimate step count compared to 
manual counting and video observation. Langer et al (12) found that, compared to 
manual counting, the SenseWear armband underestimated step counts during           
53 minutes of walking by 465 steps (95% CI, -717 to 213 steps). Similarly, 
Furlanetto et al (14) found that the SenseWear armband significantly underestimated 
step count when compared to video observation at walking speeds ranging from 
23.3±5.0 to 80.0±13.3 m/min. When compared to direct observations, Hill et al (13) 
found step rate recorded by the SenseWear armband was lower at slow walking 
speeds of 51.4±11.1 m/min (77±26 versus 87±9 steps/min; p = 0.04), but at faster 
walking speeds of 65.4±12.4 m/min, the steps recorded were similar to that observed 
(93±22 versus 99±10 steps/min; p = 0.22). Besides underestimating steps at slow 
walking speeds, the SenseWear armband has also been shown to underestimate the 
number of steps taken when a WW was used during walking (13). The lack of 
movement of the upper arm and body position when arms are fixed on the WW may 
dampen the input from the accelerometry in the SenseWear armband, thus reducing 
the step rate compared to direct observation (24±29 versus 87±9 steps/min; p < 0.01) 
(13).  
2.4.3 ‘Gold standards’ of measuring physical activity 
There are several ‘gold standards’ for measuring PA and these include direct 
observation, video recording, global positioning system (GPS) and energy 
expenditure measured using DLW.  
Direct observation of PA involves observers watching or video-recording PA in 
order to quantify activities undertaken by individuals (144). However, such direct 
observation is intrusive on the individual’s privacy and time consuming, thus 
impractical in the home environment (3, 145).  
Global positioning system technology uses radio signals broadcast from satellites 
orbiting the earth to identify structures such as transportation and green space to 
address questions about PA (146). Although GPS technology is portable, non-
intrusive and is able to measure movement continuously outdoors, the number of 
GPS satellites available limits the ability to detect PA in an individual (145). The 
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other disadvantage for GPS receivers are that they are limited in detecting radio 
signals especially indoors (139). Thus the GPS technology is recommended to be 
used in conjunction with accelerometers to augment measurements of PA in the adult 
population (145). 
The DLW method of measuring energy expenditure is an isotope-based technique to 
estimate carbon dioxide production during the interval between the first and last 
body fluid samples, and thus energy expenditure (147). This method is often 
described as the ‘gold standard’ for the measurement of total energy expenditure, but 
its usefulness is limited by its laboratory setting, technical demands, participant 
burden and excessive cost (approximately AUD $1,500 per person) (139, 145, 147).  
2.4.4 Optimising the measurement of physical activity 
Overall, the measurement of PA is known to be highly variable (148). Several factors 
appear to influence the measurement of PA including the number of days over which 
PA is monitored (149), whether measurements are taken over weekdays versus 
weekend days (150) as well as the impact of seasonal variation (151). 
In order to minimise individual burden and reliably measure daily average PA 
outcomes that reflect an individual’s habitual activity, it is necessary to determine the 
minimum number of days individuals are required to wear a motion sensor to 
measure PA (147, 149). Habitual activity is highly variable among healthy adults 
(148, 150) and therefore 3 to 7 days of accelerometer monitoring has been 
recommended to obtain a reliable estimate of usual PA (148-150). However, 
individuals with moderate to severe COPD have been shown to have a smaller day-
to-day variation in PA compared with their healthy counterparts and therefore a 
minimum of 3 days of PA data collection has been suggested to be sufficient to 
adequately capture average daily activity for individual with moderate to severe 
COPD (106). In the study by Pitta et al (1), a between-day ICC of ≥ 0.70 was 
considered acceptable to determine the number of days required to obtain a reliable 
measure of PA in individuals with COPD. These authors found a very low 
measurement error of the motion sensor that they were using (Dynaport activity 
monitor), and found that only 2 weekdays of PA monitoring were necessary to 
accurately assess the time spent in various postures (lying down, sitting, standing and 
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walking) and movement intensity during walking for the 33 individuals which 
included 18 with mild to very severe COPD [GOLD grades I to IV] and 15 age-
matched healthy peers (1). However, Watz et al (106) found that for an ICC of ≥ 
0.70, at least 3 days of PA monitoring were necessary for individuals with mild to 
severe COPD (GOLD grades I to III), while those individuals with very severe 
COPD (GOLD grade IV) only required 2 days of PA monitoring. Another study 
found that at least 3 days of data were required for motion sensor to provide a stable 
comparison with an activity recall questionnaire (ICC = 0.69) to measure of PA in 
individuals with moderate to severe COPD (106, 152). Thus, a minimum of 3 days of 
PA data collection would be appropriate to adequately capture average daily activity 
for individuals with COPD. 
Although majority of the above studies suggest that a minimum of 3 days of PA 
monitoring is required in order to provide an accurate assessment of PA, it is 
important to determine whether consecutive days or a combination of any 3 days are 
required in order to gain a reliable measurement of PA in individuals with COPD. 
Some studies involving healthy adults have demonstrated that reduced PA occurs on 
Sundays compared to other days of the week (150, 153). However, earlier work 
showed that there was little day to day variability in PA in sedentary individuals with 
COPD (50). A more recent study involving 23 individuals with COPD with Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) grades ranging from II to 
IV, found that accelerometer activity counts were similar between three within-week 
measurement periods or between weekdays and weekend days (r > 0.97; p < 0.001) 
(103). Based on these results, it would seem that any 3 days of PA measurement, 
regardless of weekdays or weekend days, were sufficient to assess PA in individuals 
with COPD. 
Seasonal variation may also affect PA, with lower levels of PA being observed 
during winter compared to summer (p = 0.02) (151). In the UK, individuals with 
COPD who started a PRP in winter attained a greater change in daily PA compared 
to those who commenced a PRP in summer (p = 0.04) (151). In this study by Moy et 
al (154), individuals with COPD who had their baseline visit in winter and follow-up 
in spring, experienced a significant increase in step count, while those who had their 
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baseline visit in autumn and follow up in winter had a decline in step count, after 
controlling for baseline step count (p = 0.013).  
In summary, individuals with COPD appear to be relatively less active and tend to 
walk slower than their healthy peers. This inactivity has a negative impact on clinical 
outcomes, such as exercise capacity and HRQoL. There are different approaches to 
measuring PA and a minimum of 3 days may be sufficient to assess PA in 
individuals with COPD. 
PART 3 
Given that individuals with COPD are generally less active (1, 104), which can 
impact on health care utilisation (115), it is important to enhance PA in these 
individuals. The following sections describe strategies that may increase PA among 
those with COPD. 
2.5 Strategies that may increase physical activity in individuals with COPD 
Physical inactivity in individuals with COPD appears to be related to important 
healthcare outcomes such as the frequency of exacerbations, hospitalisations and 
mortality (118, 155). Strategies that have the potential to increase PA levels include 
the use of ambulatory oxygen, pharmacotherapy such as bronchodilators, lung 
transplantation, the use of a WW and pulmonary rehabilitation. 
Ambulatory oxygen 
The provision of ambulatory oxygen to individuals with COPD has been shown to 
confer significant acute increases in exercise tolerance (156-159). For example, 
compared with exercise testing performed with the individuals breathing room air, 
the time to symptom-limited cycling at work rates equivalent to 75% of peak work 
rate increased by 5.2 minutes when breathing supplemental oxygen (p < 0.05) (156). 
Similarly, the use of 2 L/min of ambulatory oxygen increased 6MWD equivalent to 3 
to 20% of baseline measures, depending on the severity of airflow (157). Such 
improvements appear to be dose-dependent, with maximal gains achieved using a 
fraction of inspired oxygen equivalent to 0.5 (160). The mechanisms underpinning 
the gains in exercise tolerance with ambulatory oxygen relate mainly to reductions in 
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ventilatory demand, dynamic pulmonary hyperinflation and dyspnea at submaximal 
exercise intensities (73). Further, during cycle-based activity, the administration of 
ambulatory oxygen has been shown to optimise oxygen delivery to quadriceps and 
increase the anaerobic threshold (161). Despite these gains, which were 
demonstrated in the laboratory setting, the effects of providing ambulatory oxygen 
for use in the home setting on PA are limited. There were only two randomised 
controlled trials (RCTs) that investigated the effect of ambulatory oxygen provided 
in the home over an 8-week period (162) and over a 12-week period (163). Neither 
demonstrated any change in PA. This may be related, at least in part, to the fact that 
the individuals with COPD were expected to transport their oxygen cylinders using 
back-packs and the weight may have offset any advantage derived from the use of 
ambulatory oxygen during PA (162). Other possible reasons include the poor 
portability of the cylinder, difficulty with changing the regulator, fear of dependence 
on oxygen and embarrassment when using ambulatory oxygen (163). Of interest, this 
study reported an increase in oxygen cylinder usage over the 8-week study period, 
suggesting that individuals may have been gradually perceiving a benefit or became 
dependent on the oxygen, but this was not evident at the time the follow-up 
assessments of PA were completed (162). Additionally, ambulatory oxygen did not 
significantly increase domestic activity or activity spent outside the home, at least in 
the short term (162). 
Bronchodilators 
There is a lack of evidence regarding the effect of bronchodilators on PA. In theory, 
bronchodilators have the potential to improve PA by their effect of increasing airway 
calibre and alleviating airflow limitation (164), thereby reducing the work of 
breathing and dyspnea. Only one study was identified that evaluated PA when a 
bronchodilator (tiotropium) was given in conjunction with pulmonary rehabilitation 
(165). In this study where all participants completed a 12-week PRP, the group that 
received tiotropium improved self-reported PA by 262±96 minutes from baseline     
(p = 0.013), while the placebo group improved PA  by 60±93 minutes (p = 0.529) 
(165). 
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Lung transplantation 
One intervention that appears to be effective at increasing PA is lung transplantation, 
particularly when combined with exercise training. A cross-sectional study 
demonstrated that lung transplant recipients (66±48 months post- transplant) were 
significantly more active compared to individuals awaiting lung transplantation 
(6,642±2,886 versus 1,407±1,166 steps/day; p < 0.001) (166). In another study where 
PA was assessed 3 months post-lung transplantation, the participants receiving usual 
care where they were only advised to increase participation in daily PA increased 
daily step count by 750 steps whereas the participants who received supervised 
exercise training three times weekly increased their daily step count by 2,100 steps; a 
difference of 1,376 steps/day (95% CI 481 to 2,269 steps/day; p = 0.004) (167). Both 
groups continued to increase their PA at 1 year post-transplant although the group 
that had post-transplant rehabilitation for 3 months increased their PA significantly 
more than the control group (3,017 steps/day; 95% CI 1,185 to 4,849 steps/day;        
p = 0.002) (167). This implies that in individuals with COPD who underwent 
transplantation, rehabilitation post-lung transplantation may augment daily PA.  
Other strategies 
Other strategies that may optimise daily PA in individuals with COPD include the 
use of a WW and participation in supervised exercise training. The effects that these 
two strategies have on PA form the basis of two studies within this thesis. Therefore 
the following sections provide a detailed description of the potential mechanisms by 
which these interventions may confer gains in PA in individuals with COPD.  
2.5.1 Effects of wheeled walkers on respiratory muscle mechanics 
A WW, also called a rollator frame, is a gait aid that has four wheels, hand brakes, a 
basket for carrying items and a seat for rest (22, 168). Individuals with COPD often 
report less dyspnea when pushing a shopping trolley due to the forward lean position 
and fixed shoulder girdle (169). As early as 1957, a case report of a patient with 
emphysema described that the use of a portable walking aid with the forward lean 
posture allowed the individual to increase tidal volume and exercise tolerance (170). 
Adopting a forward lean position optimises the pressure-generating capacity of the 
inspiratory muscles, most likely because it improves the length-tension relationship 
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of the diaphragm (171, 172). O’Neill et al (172) demonstrated that the forward lean 
position was the most effective of six different positions (i.e. standing, supine, 
upright seated, seated leaning forward at a 45° angle as well as right and left lateral 
decubitus) at relieving dyspnea in 40 individuals with COPD. This forward lean 
position is likely to decrease the level of neuromechanical dissociation, defined as 
the mismatch between the afferent input from the mechanoreceptors of the 
respiratory system and the efferent output or motor output to breathe, which is 
perceived by the individual as a reduction in dyspnea (173). Besides this, the arm 
bracing posture when using a WW in the standing position has been shown to 
increase maximum voluntary ventilation (MVV) (168, 174), which may also 
contribute to a reduction in dyspnea (22, 174). The increased ventilatory capacity 
associated with arm bracing is most likely due to the increased capacity to use the 
accessory muscles of respiration, namely the serratus anterior, scalenes and 
sternocleidomastoid (175). Thus, the arm bracing posture adopted when using a WW 
may allow individuals with COPD to rely on the accessory muscles to assist in 
respiration (176). This reduction of dyspnea would likely explain the improvement in 
functional capacity observed when a WW was used in individuals with COPD (21, 
22, 177, 178).  
2.5.1.1 Effect of wheeled walkers on 6-minute walk distance 
Three studies have shown that the use of a WW in individuals with COPD increased 
the 6MWD as compared to walking unaided (22, 177, 178). In two of these studies, 
both of crossover design, participants increased their 6MWD when walking with a 
WW compared to walking without a WW ([259±28 versus 226±28 m; p < 0.005 
(177)] and [462 m (interquartile range 424 to 477 m) versus  416 m (interquartile 
range 396 to 435 m); p = 0.04 (22)]). This improvement in 6MWD was also 
demonstrated in a RCT where 6MWD was higher in participants randomly allocated 
to walk with a WW than those allocated to walk without a WW (baseline: 292±67 
versus 263±67 m, p = 0.013; post 8 weeks of being provided with a WW: 283±65 
versus 259±68 m, p = 0.013) (178). This positive impact of the WW on 6MWD was 
however not seen in one randomised crossover study involving 40 individuals with 
COPD (312±17 m without WW versus 317±16 m with WW; p = 0.3) (21). However, 
a sub-analysis in this study demonstrated that greatest gains were conferred when a 
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WW was used by participants who had the lowest unaided 6MWD. In this sub-
analysis, 19 participants who walked < 300 m unaided improved their 6MWD from 
220±12 m without a WW to 243±14 m with a WW (p = 0.02) (21).  
2.5.1.2 Effect of wheeled walkers on the fear of falling 
Wheeled walkers are often recommended to improve ambulation and reduce the risk 
of falls among the elderly (179). Individuals with COPD have a susceptibility to 
falls, with approximately 32% of 101 participants with COPD in an observational 
cohort study reporting at least one fall over a 6-month period, with most of these falls 
occurring during an outdoor walking activity (25). This finding is particularly 
important given data demonstrating a reduction in the balance and coordination of 
individuals with COPD (27, 180), an impairment that is likely to result, at least in 
part, from their less active lifestyle (26).  
It is possible that as well as decreasing the risk of falling, using a WW may decrease 
the fear of falling and thus increase confidence with walking. Among 80 individuals 
with COPD, 45% of those who had experienced a prior fall reported a fear of falling, 
while only 23% who had not experienced a prior fall expressed this fear (181). 
Among those participants who expressed a fear of falling, 50% reported activity 
avoidance because of this fear whereas there was no activity avoidance reported by 
those without a fear of falling (181). Solway et al (21) in a study involving 40 
individuals with COPD, found that 60% reported feeling safer when using a WW 
during the 6-minute walk test (6MWT).  
Therefore, it seems possible that individuals with COPD who have marked 
functional limitation due to intolerable dyspnea or fear of falling, may be able to 
walk more during daily life if provided with a WW (20). 
2.5.2 Pulmonary rehabilitation for individuals with COPD 
Pulmonary rehabilitation is defined as an evidence-based, multidisciplinary and 
comprehensive intervention for individuals with COPD (5, 6), where exercise 
training is the cornerstone of pulmonary rehabilitation (5). Exercise training has been 
shown to reduce dyspnea and fatigue (5-7), increase exercise capacity and improve 
HRQoL (5-7).  
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2.5.2.1 Effect of pulmonary rehabilitation on exercise capacity 
Randomised controlled trials of pulmonary rehabilitation have demonstrated that 6 to 
12 weeks of lower limb training increased field-based walking tests distance up to  
80 m, treadmill endurance by 10 minutes and cycle ergometer time at submaximal 
work rates by 5 minutes in individuals with COPD (182). A meta-analysis of 16 trials 
that used 6MWD as an outcome in individuals with COPD favoured exercise training 
over control (no exercise training) with a weighted mean improvement of 48 m (7). 
Exercise training such as walking or cycling can lead to clinical improvement in 
exercise capacity (39, 183).   
In individuals with COPD, physiological adaptation of the quadriceps to exercise 
training has been shown via muscle biopsies (184, 185). Following a PRP, there is a 
significant increase in the mean cross sectional area of quadriceps muscles as well as 
an increase in oxidative muscle fiber type in individuals with COPD (186). In 
addition, exercise training also improves oxidative enzyme capacity in muscles (185, 
187), increases capillary and mitochondrial density (188), and reduces lactic acidosis 
for a given work rate (189). The improvement in exercise capacity and the 
morphological adaptations of the quadriceps muscles to exercise training has been 
shown to be consistent across GOLD grades II to IV (186). Further, Gosselin et al 
(188) showed that physically active individuals with COPD also had the capacity to 
further improve their exercise capacity after PRP. The improvement in oxidative 
capacity of the quadricep muscles from exercise training has the potential to lead to 
less alveolar ventilation which may reduce dynamic hyperinflation and thus decrease 
exertional dyspnea and fatigue (6). However the aforementioned studies were 
conducted using only cycle based training (185-189) which is dependent on the 
availability of the cycle equipment and space, unlike walking which is a cheap and 
easily available training modality (39). 
Walking exercise training as compared to cycling training has been shown to result 
in greater improvements in exercise capacity for individuals with COPD. In the study 
by Leung et al (39) which compared supervised ground walking training to cycling 
training over 8 weeks, the participants randomised to ground walking demonstrated 
an improvement in endurance shuttle walk test (ESWT) performance to a greater 
extent than those participants randomised to supervised cycling training (279 sec; 
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95% CI 70 to 483 sec). There are a number of studies that have studied the effect of 
walking training on exercise capacity, but in many of these studies walking training 
was part of a comprehensive exercise training program (7, 190, 191). There are two 
randomised controlled studies that had a solely supervised walking training program 
(40, 192). Both of these studies reported an improvement in 6MWD (40, 192). As 
walking is an integral part of daily life for individuals with COPD (9), it is possible 
that walking as a sole modality of supervised exercise training may confer greater 
gains in daily PA than other exercise modalities such as cycling. 
2.5.2.2 Effect of pulmonary rehabilitation on dyspnea and fatigue 
Dyspnea and fatigue are the two most common symptoms experienced by individuals 
with COPD (193). In a Cochrane review of 11 RCTs, pulmonary rehabilitation was 
shown to be effective at relieving dyspnea and fatigue as determined from the forest 
plots of the dyspnea and fatigue scores of the Chronic Respiratory Disease 
Questionnaire (CRDQ) (mean difference of 1.0 points per item and 0.92 points per 
item, respectively) (7). The improved exercise capacity may explain the reduction in 
these symptoms (5). Desensitisation may also be one possible mechanism to explain 
the benefit of pulmonary rehabilitation on dyspnea and fatigue, with the hypothesis 
that fear is alleviated by repetitive performance of the same exercise in a safe and 
supervised environment (194).   
2.5.2.3 Effect of pulmonary rehabilitation on health-related quality of life 
and feelings of anxiety and depression 
The health status of individuals with COPD has been shown to improve with 
pulmonary rehabilitation (5), with a meta-analysis showing that at least 4 weeks of 
exercise training is sufficient to result in an improvement in HRQoL (195). 
Measurement of HRQoL using disease-specific questionnaires, namely the CRDQ 
and SGRQ has been found to provide a valid measure that is responsive to the effects 
of pulmonary rehabilitation (7, 196).  
In individuals with COPD, feelings of anxiety and depression are common (197). 
There have been numerous studies that have found that exercise training can 
significantly reduce anxiety and depression. A meta-analysis found that a 
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comprehensive PRP that included exercise sessions up to three times a week along 
with education and psychosocial support, reduced anxiety and depression more than 
standard medical care in individuals with COPD (198). Another meta-analysis by 
Coventry et al (199) found that exercise interventions, with or without psychological 
components within PRP, were the only sub-group intervention that reduced both 
depression and anxiety.   
In summary, strategies such as the use of ambulatory oxygen, the use of 
bronchodilators, lung transplantation, the use of a WW and pulmonary rehabilitation 
may have the potential to increase PA among those with COPD.  
PART 4 
The cornerstone of pulmonary rehabilitation is supervised exercise training (5) and 
exercise training may be able to change PA. Therefore, a systematic review and 
meta-analysis was undertaken on the impact of exercise training on PA in individuals 
with COPD as part of this PhD research. This systematic review and meta-analysis 
has been published (55) and is reproduced in the following sections.  
2.6 Systematic review and meta-analysis 
The aim of this review was to systematically search the literature and undertake a 
meta-analysis of data from studies that have evaluated the effect of exercise training 
on PA in individuals with COPD. 
2.6.1 Data source 
Study identification began with electronic searching of computerised databases, 
namely MEDLINE, PubMed, EMBASE, CINAHL, Physiotherapy Evidence 
Database (PEDro) and Cochrane Central Register of Controlled Trials from inception 
to week 27 in 2010 (Table 2-2). The subject headings used in the search were 
‘COPD/chronic obstructive pulmonary disease’, ‘therapy’ and ‘exercise’ with key 
terms comprising of ‘accelerometer’, ‘pedometer’, ‘physical activity’, and ‘energy’. 
Secondary searches included hand searching reference lists of all identified studies 
and PubMed ‘related articles’ function. Clinical trials registries were also reviewed 
to identify any RCTs that may have been ‘in press’. 
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2.6.2 Study selection 
Studies were eligible for inclusion if they: (i) were written in English, (ii) recruited 
individuals with COPD, (iii) investigated the effect of supervised exercise training of 
at least 4 weeks in duration on PA, (iv) measured PA using motion sensors and, (v) 
reported PA in absolute values such as steps or activity counts. Studies that utilised 
any design other than case reports were eligible for inclusion. Where necessary, 
authors were contacted to obtain PA data in absolute values. If the authors did not 
respond, the study was excluded from the meta-analysis.  
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Table 2-2: Search strategy (L imits: Humans; English language). 
Searches Database No. of 
records 
1 = Chronic obstructive pulmonary disease (COPD) 
2 = Therapy (Occupational therapy / Relaxation 
therapy / Behavior therapy / Exercise therapy / 
Respiratory therapy / Physical therapy/ Combined 
modality therapy ) 
3 = Motor activity 
4 = Accelerometer / Pedometer 
 
1 +  2 + 3 + 4 
MEDLINE  
1950 to 7th July 
2010 
5 
1 = Chronic obstructive pulmonary disease (COPD) 
2 = Exercise (Treadmill exercise / Leg exercise / Open 
kinetic chain exercise / Breathing exercise / Aerobic 
exercise / Static exercise / Aquatic exercise / Exercise 
intensity / Dynamic exercise / Isokinetic exercise / 
Anaerobic exercise / Isotonic exercise / Closed kinetic 
chain exercise / Arm exercise / Exercise tolerance / 
Exercise / Stretching exercise / Muscle exercise / 
Isometric exercise) 
3 = Activity (Motor activity / Physical activity / Daily 
life activity) 
4 = Therapy ( Respiratory therapy student / 
Maintenance therapy / Therapy effect / Therapy / 
Therapy delay / Recreational therapy / Physical therapy 
education / Physical therapy student / Movement 
therapy / Device therapy / Occupational therapy 
practice / Occupational therapy education / 
Occupational therapy student / Therapy resistance) 
 
1 +  2 + 3 + 4 
EMBASE  
1988 to 6th July 
2010 
385 
COPD AND Physical activity PEDro 
Accessed on 
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Table 2-2: Continued  
1 = Chronic obstructive pulmonary disease (COPD) 
2 = Therapy ( Respiratory therapy student / 
Maintenance therapy / Therapy effect / Behavior 
therapy / Therapy / Therapy delay / Recreational 
therapy / Physical therapy education / Physical therapy 
student / Movement therapy) 
3 = Physical activity 
4 = Exercise (Treadmill exercise / Leg exercise / Open 
kinetic chain exercise / Breathing exercise / Aerobic 
exercise / Static exercise / Aquatic exercise / Exercise 
intensity / Dynamic exercise / Isokinetic exercise / 
Anaerobic exercise / Isotonic exercise / Closed kinetic 
chain exercise / Arm exercise / Exercise tolerance / 
Exercise / Stretching exercise / Muscle exercise / 
Isometric exercise) 
5 = Accelerometer / Pedometer 
 
1 +  2 + 3 + 4 + 5 
EMBASE 1988 
to 6th July 2010 
9 
1 = Pulmonary  
2 = Disease 
3 = Therapy   
4 = Physical OR Motor 
5 = Activity 
6 = Accelerometer OR Pedometer 
 
1 +  2 + 3 + 4 + 5 + 6 
PUBMED  
Accessed on 7th 
July 2010 
891 
1 = COPD 
2 = Exercise 
3 = Activity  
 
1 + 2 + 3 
PUBMED  
Accessed on 8th 
July 2010 
330 
COPD and physical activity in Keywords Cochrane 
Central Registry 
of Controlled 
Trials  Accessed 
on 7th July 2010 
171 
1 = Pulmonary  
2 = Therap* 
3 = Physic* OR Motor* 
4 = Activ* 
5 = Accelerometer OR Pedometer 
 
1 +  2 + 3 + 4 + 5 
CINAHL  
2003 to 2008  
Accessed on 7th 
July 2010 
3 
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2.6.3 Quality of articles 
Data were independently extracted using a standardised assessment form. Quality 
assessment for the RCTs and randomised trials (RTs) was rated using the 10-point 
PEDro scale (200). This scale uses criteria related to blinding, randomisation, and 
loss to follow-up with a higher score indicative of superior internal validity (200). 
Quality assessment for the single-group interventional studies was rated using a 
modified Downs and Black tool (201). This tool consists of 27 questions, that relate 
to study description, external validity, internal validity and statistical power (201). 
To minimise ambiguities, the question pertaining to statistical power was assigned 
one point if prospective sample size calculations were provided (and 0 points if these 
details were absent), which resulted in a maximum score of 28 for the Downs and 
Black tool. This modification has been used previously (202). 
2.6.4 Data extraction and analysis 
Consistency between two reviewers for both quality assessment methods was 
calculated using Kappa statistics. Due to the heterogeneity in PA outcome measures, 
the random-effects approach was used in the meta-analysis. Effect sizes were 
calculated by dividing the differences in PA (before and after the intervention) by the 
pooled SD. Regarding interpretation, ≤ 0.2 was considered small, 0.5 was considered 
moderate and ≥ 0.8 was considered large effect sizes (203). The I2 test was used to 
quantify statistical heterogeneity of the studies (204). A value of ≤ 25% reflects low 
heterogeneity, 50% moderate and 75% high heterogeneity. A p value of < 0.1 was 
used to indicate that the heterogeneity was not due to chance alone and it would be 
inappropriate to combine the results in a summary. A funnel plot was assessed 
visually to detect publication bias where a symmetric inverted funnel shape indicates 
that bias is unlikely. Comprehensive Meta Analysis version 2.2.050 (BiostatTM, New 
Jersey, US) was used for meta-analysis.  
2.6.5 Results 
The search strategy yielded 1,840 records of which 128 (7%) were duplicates and 
thus excluded (Figure 2-1). Of the remaining 1,712 records, 1,686 (98%) were 
excluded based on title or abstract and 19 (1%) were excluded after reviewing the 
full text. There were no RCTs that met our study criteria. A total of seven studies met 
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the criteria for inclusion; two (29%) were RTs in which two groups of participants 
received different interventions, both of which were designed to optimise PA, and 
five (71%) were single-group interventional studies in which all participants received 
the same intervention (Figure 2-1). Authors of two of the studies were contacted for 
PA data in absolute values. 
2.6.5.1 Quality of articles 
Tables 2-3 and 2-4 present the quality assessment score for each of the RTs and 
single-group studies. Reviewers agreed on 100% of all PEDro items (Kappa statistic 
= 1). The mean±SD PEDro score for the RTs was 5±0 points. Reviewers agreed on 
96% of all Downs and Black items with a Kappa statistic of 0.92. The mean±SD 
Downs and Black score was 19±3 points.  
2.6.5.2 Participants characteristics 
Tables 2-3 and 2-4 summarise the participant characteristics of the RTs and single-
group interventional studies. The sample sizes ranged from 8 (31) to 116 (36). 
Considering all studies together, the participants were predominantly male               
(n = 419/582, 72%). Based on the FEV1 expressed as a percentage of the predicted 
normal value, participants in most studies had severe airflow obstruction (205).  
  


















Figure 2-1: Flow of information through the different phrases of the systematic 
review.  
n, number of articles.
Literature search 
Databases: MEDLINE, PubMed, EMBASE, CINAHL, Physiotherapy Evidence 
Database (PEDro) and Cochrane Central Register of Controlled Trials 
Limits: Humans & English language 
 
1839 records identified through 
database searching 
1 additional record identified 
through ClinicalTrials.gov 
(article in press) 
1712 records after duplicates removed 
1686 records excluded on 






19 full-text articles 
excluded, with reasons: 
• Non-objective 
measurements of 
physical activity (n=3) 
• Physical activity as an 
intervention and not an 
outcome measure (n=1) 
• Interventions not related 
to rehabilitation or 
exercise  training (n=5) 
• Less than 4 weeks of 
rehabilitation or 
exercise training (n=3) 
• Observational study on 
daily activity (n=6) 
• Description of protocol 
(n=1) 
 































































Individually targeted exercise program (ITEP) performed twice 
a week.  One day comprised aerobic exercise and the other day 
comprised exercises based on daily functional activities 
identified during the Canadian Occupational Performance 
Measure + 2 hours of education per week 
 
General exercise program (GEP) performed twice a week. One 
day comprised aerobic exercise and the other day comprised 
standard exercises including step-ups, sit to stand and stationary 
cycling, wall push-ups, small and large arm circling and 
shoulder shrugs trunk flexion, trunk rotation and pelvic tilt + 2 
hours of education per week  
 



























Pulmonary rehabilitation exercise program + dietary + 
psychosocial-education modules + lifestyle PA counselling 
based on pedometer data 
 
Pulmonary rehabilitation exercise program + dietary + 
psychosocial-education modules 
 
Data are mean±standard deviation. BMI, body mass index; F, female; FEV1, forced expiratory volume in one second; kg, kilograms; L, litres; M, male; m, 
metres; n, number of participants; %pred, percent predicted.
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14 38 37/1 63.7±7.8 87±4.6 kg 1.2±0.5  
(39±17%) 
 
Twice weekly exercise classes. On completion of the first 2 to 3 
weeks of the program a home exercise program was given and 
encouraged at least 3 days a week 










Multi-disciplinary rehabilitation including education, support and/or 
counselling, circuit exercise training (cycling, walking, strength 
training for quadriceps, pectoralis and triceps, arm cranking and stair 
climbing) 
Months 1 to 3, exercise was performed 3 times a week; months 4 to 











2 supervised + 1 unsupervised exercise sessions per week comprising 











Exercise classes 2 to 3 times per week.  
Multi-modality aerobic and strength training of lower and upper 



















Twice a week rehabilitation-progressive resistance exercises with 
hand weights, elastic resistance tubing, and/or weight machines. 
Cardiovascular/ endurance training included use of treadmills, 
stationary cycles, NuStep, and upper extremity ergometers. 
Data are mean±standard deviation. *COPD participants who had an exacerbation during the study; †COPD participants who had no exacerbation during the 
study; 10 participants did not complete the study. COPD, chronic obstructive pulmonary disease; BMI, body mass index; F, female; FEV1, forced expiratory 
volume in one second; kg, kilograms; M, male; m, metres; n, number of participants; %pred, percent predicted.
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2.6.5.3 Interventions and methods for measuring physical activity 
The duration of supervised exercise training ranged between 6 weeks and 6 months 
(31-34, 36, 38, 206). The monitors used to measure PA comprised the NL-2000 
pedometer (32), the Yamax Digi-Walker SW-200 pedometer (31), the DynaPort 
Activity Monitor (33), the Z80-32K Activity Monitor (34), the Actiwatch (38), the 
TriTrac-R3D® accelerometer (206) and the RT-3 accelerometer (36). 
2.6.5.4 Effects on physical activity 
Tables 2-5 and 2-6 summarise the findings of the RTs and single-group studies. In 
the RTs, both groups received exercise training. One study compared an 
individualised targeted exercise program (ITEP) based on daily activities with a 
general exercise program (GEP) (34), and the other investigated the effect of using a 
pedometer to provide feedback regarding walking targets, over and above a program 
of supervised exercise training (31). As both treatment groups in these two studies 
examined the effect of exercise training on PA, we entered the data from each arm 
into the meta-analyses. The intervention for all five single group studies comprised 
supervised exercise training at least twice a week. Asymmetry was observed in the 
funnel plot for PA in the RTs and single-group interventional studies (Figure 2-2), 
suggesting that we could not exclude publication bias. Taken together, PA data 
entered into the meta-analysis from the RTs and the single-group studies were 
homogeneous (I2 = 0%, p = 0.60). The effect size for PA though significant was 
small (0.12; p = 0.01) (Figure 2-3).  
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Improvement of 40.6%, p=0.02 
 
























Improvement of 1535 steps/day (75%) 
 
Improvement of 673 steps/day (29%) 
 
p=0.24 between groups 
 
Data are mean±standard deviation. GEP, general exercise program; ITEP, individualised targeted exercise program; p, probability; PA, physical 
activity. 
γData from 8 participants were assessed over 4 days without rehabilitation including 1 weekend day. The 4 days data was used in the meta-
analysis as it had a greater effect size than that of the 6 days without rehabilitation (including 2 weekend days) data and 7 days data was excluded 
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8 weeks 5  
 
 
 82±34 VMU 
 













After 3 months; 7% improvement in 
walking time, p=0.21 
After 6 months; 20% improvement in 








































No within group data. 
p=0.56 between those that had an 
exacerbation and those that did not 
Data are mean±standard deviation. hr, hour; min, minutes; p, probability; PA, physical activity; VMU, vector magnitude units. VMU and activity 
scores rounded to the nearest whole number.
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Figure 2-2: Funnel plot of  physical activity as an outcome measures in the 
randomised tr ials and single-group interventional studies.  
The tendency for data points to fall predominantly on the right of the 0 suggests a 







Figure 2-3: Forest plot for  physical activity measured in the two randomised tr ials and five single-group interventional studies. 
Legend: 
 Square represents effect of individual study. The size reflects the relative weight of a particular study on the overall analysis. 
─ Black line represents the confidence interval of each study. 
 Diamond represents the overall effect. The outer edges of the diamond represent the confidence interval. 
The two interventions in both randomised trials have been entered separately into this plot where ^ represents the group that completed a 
general exercise program, # represents the group that completed an individualised targeted exercise program, + represents the group that 
completed pulmonary rehabilitation and * represents the group that completed pulmonary rehabilitation with counselling and feedback 
based on pedometer data. a, accelerometer; df, degree of freedom; p,  pedometer; p-value, probability value; 
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2.6.6 Discussion of findings related to a systematic review and meta-analysis 
This is the first systematic review and meta-analysis to evaluate the effect of exercise 
training on measures of PA in individuals with COPD. The important findings of our 
review are that; (i) there are no published RCTs that examine the effects of at least    
4 weeks of supervised exercise training on PA and, (ii) data from the RTs and single-
group interventional studies indicate that, in individuals with COPD, supervised 
exercise training confers a significant, but small effect on PA.  
Regarding the RTs included in this review, the two intervention groups in both RTs 
demonstrated a similar magnitude of change in PA following the intervention period. 
This is perhaps not surprising as both groups in these studies received an intervention 
that aimed to increase PA and it was the effectiveness of an additional strategy (such 
as feedback using pedometer data or individualisation of exercises) that was being 
examined. Thus, any difference between the two groups was likely to be small. 
When the results of the five single-group studies included in this review were 
considered individually, two (40%)  reported a significant increase in PA on 
completion of the intervention period (33, 38). Relative to baseline measures, one 
reported an improvement of 20% (p = 0.008) (33) while the other reported a 
difference of 36±49 (x103 ) counts/hour or approximately 40% (p = 0.002) (38). 
Although the remaining three of the single-group studies reported an improvement in 
PA, this was not significant (32, 36, 206). When these results of the RTs and single-
group studies were combined the effect size for PA was small, but significant (0.14; 
p = 0.04). Exclusion of the data from the RTs from the meta-analysis produced a 
trivial change in the magnitude of the overall effect size (i.e. from 0.14 to 0.12). To 
appreciate this change in real terms, using the study by Pitta et al (33) as a reference, 
an overall pooled effect size of 0.12 or 0.14 is equivalent to an increase of 
approximately 4.6 or 5.4 minutes of walking per day following the intervention. In 
addition to this small effect, the wide 95% CIs for data pertaining to five of the seven 
studies in Figure 2-3 indicates that there was considerable variability in PA between 
individuals. Our data revealing a modest effect size together with substantial 
variability suggests that future RCTs that aim to demonstrate an effect of supervised 
exercise training on PA will require very large sample sizes. 
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It is possible that the capacity of individual studies to demonstrate a significant 
increase in PA may be influenced not only by the nature of the intervention, but by 
other factors such as; (i) the method used to measure PA, (ii) the frequency of 
supervised exercise training and, (iii) the clinical stability of participants over the 
duration of the study period. Regarding the outcome measures, earlier work has 
demonstrated that in individuals with COPD, questionnaires do not yield an accurate 
measure of PA (1) and pedometers lack the sensitivity to detect steps at the slow 
walking cadence characteristic of this clinical population (11, 16). In contrast, 
accelerometers yield accurate measures of PA in individuals with COPD and have 
emerged as a more reliable choice (3). Given the superior accuracy of accelerometers 
at measuring PA, we considered the possibility that those studies that utilised an 
accelerometer to measure PA may have been more likely to demonstrate 
improvements in PA. Examination of Figure 2-3 revealed that of the five studies 
which measured PA using an accelerometer, three (60%) demonstrated a significant 
effect (33, 34, 38). Differences in the nature of interventions and potentially the 
effectiveness of the interventions used in each of the studies preclude us from 
drawing conclusions regarding the superiority of an accelerometer as an outcome 
measure. However, future studies may have a greater likelihood of demonstrating 
change if reliable, valid and responsive accelerometers are used in preference to 
pedometers or self-report methods.  
Regarding the possibility that the frequency of supervised exercise training impacted 
on PA, both studies that utilised exercise training three times a week, for at least       
8 weeks demonstrated a significant improvement in PA (33, 38). In contrast, of the 
five studies that offered exercise training only twice a week, only one demonstrated a 
significant improvement in PA (34). This suggests that more frequent exercise 
training may be necessary to result in a significant increase in PA. The data from 
Pitta’s study (33) suggests that the duration over which exercise training is offered is 
also important. Specifically, the participants in his study demonstrated a small non-
significant increase in PA after 3 months of supervised exercise training, with an 
additional three months of training required to confer a significant increase in PA. 
These results are in line with a recent review which concluded that PRPs that exceed 
12 weeks in duration were more likely to promote long-term maintenance of training 
effects (207). Earlier work suggests that at least 3 months is required for most 
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individuals with COPD to change a habit (208) and therefore, studies that investigate 
interventions offered over an extended period that comprises frequent supervised 
exercise training are perhaps the most likely to show significant improvements in 
outcomes.  
Regarding the impact that the clinical stability of study participants may have had on 
PA levels, only Steele et al (36) separated those who experienced an acute 
exacerbation during the follow-up period from those who did not, with participants 
who experienced an acute exacerbation in the study by Steele et al (36) were the only 
subgroup to demonstrate an effect suggestive of deterioration in PA. This is 
consistent with earlier work that reported a dramatic decline in PA among 
individuals with COPD following an exacerbation (209). Notably, this deterioration 
in PA has been shown to persist for several weeks (209).  
As this systematic review did not find any published RCTs that examine the effects 
of supervised exercise training on PA, this is a gap in evidence to address the 
effectiveness of a supervised exercise training on PA in individuals with COPD. 
PART 5 
When interpreting outcomes in research, a statistically significant difference is 
desirable as it implies that the change is unlikely to be caused by chance. Although 
statistical significance may be achieved, the magnitude of change in the outcome 
measure of interest might be too small to be noticed by the individual (210). This 
section will define and address this improvement or change that is noticeable or 
perceived by the individual (46, 211). This term, MDD, is used throughout this thesis 
to define the smallest change in an outcome measure detected by individuals with 
COPD. 
2.7 Definition of the minimal detectable difference 
The MDD is defined as the smallest difference in the outcome of interest that 
individuals perceive or detect as either beneficial or harmful, and this can lead the 
individual or clinician to consider a change in the management (41, 212). The MDD 
can be determined by both anchor- and distribution-based approaches (212). Other 
terms used to define this meaningful change include the minimal clinically important 
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difference (MCID) and minimal important difference (MID). The term MCID was 
first introduced by Jaeschke et al in 1989 (213). The word ‘clinical’ has since been 
omitted from the term ‘MCID’ as greater weight has been placed on the preferences 
of patients than clinicians in determining the MID (41). The MDD is often used 
interchangeably with MID and MCID. The main difference between these terms is 
that the MDD is the smallest difference noticeable (or detectable) by an individual, 
whereas, both the MID and MCID aim to ensure that the magnitude of this difference 
is important to the individual (8). Importance is related to a judgement by the 
individual that the magnitude of benefit is considered to be worth the effort, 
inconvenience or cost associated with completing the treatment (8). Alternatively, 
importance may be related to a reduction in the risk of some clinical event (e.g. 
mortality or hospitalisation). The MDD does not link the magnitude of change with 
whether or not the individual perceives the change to be important; it is simply the 
magnitude of change that is noticeable or detectable by the individual (8).  
The word ‘detectable’ was later used to replace the word ‘important’. This is because 
many of the studies estimating this minimal difference described a detectable level of 
change or effect (214), either using statistical calculations or having individuals 
indicate their perception of the change, rather than requiring the individual to 
indicate if the change was important (46). Some authors have used the term minimal 
detectable change (MDC) to define the amount of change at an individual level that 
must be observed before it is considered above the boundaries of measurement error 
(215, 216). 
2.7.1 Relevance of the minimal detectable difference 
In a study, a statistically significant difference is desirable as it implies that the 
change observed is unlikely to be due to chance and that the sample size tested is 
appropriate to demonstrate this (8). However, even small changes following an 
intervention may meet the threshold for statistical significance if there was minimal 
variability in response to the intervention and/or data were available for a large 
number of participants (8). The concept of the MDD evolved to represent a change 
that is noticeable to an individual and it can be determined using two approaches, 
namely the anchor- and distribution-based approaches (8). These are explained in 
detail below. Anchor-based approaches compare a change in the outcome of interest 
Chapter 2: Literature review 
52 
to some other measure of change which is considered an anchor or an external 
criterion (8). Distribution-based approaches are based solely on statistical criteria and 
depends on the effect estimate and its relationship to a measure of variability (217). 
The concurrent use of both approaches is recommended to evaluate the effects of the 
intervention on the final estimate of the MDD (215).   
2.7.1.1 Anchor-based approaches for determining the minimal detectable 
difference 
Anchor-based approaches for determining the MDD compares the magnitude of 
change in the outcome of interest with an external criterion or anchor such as the 
global rate of change (GRC) scale or an assessment tool with an established MDD 
(8). One method is the use of Pearson correlations to determine the magnitude of 
change in the outcome of interest to the anchor (212). This relationship needs to be 
reasonably strong (i.e. r > 0.5) to proceed with the plotting of a linear regression 
model between the anchor and the change in the outcome of interest to estimate the 
MDD (217, 218). The external criterion or anchor can be based on clinician 
judgement, individual perception, an anchor with an established MDD or a specific 
health criterion. Another method is to use a receiver operating characteristic (ROC) 
curve to discriminate between individuals who rated themselves as changed versus 
unchanged at the end of an intervention (8). These methods that can be used in the 
anchor-based approaches to estimate the MDD are described in the following 
paragraphs.  
First, the external criterion or anchor can be based on clinician judgement and this 
has been used for estimating the MDD of outcomes including the CRDQ (213) and 
SGRQ (219) in individuals with COPD. In these studies, a group of clinicians were 
consulted to achieve consensus of what constitutes a MDD for these HRQoL 
questionnaires based on their clinical experience with the questionnaires and 
management of people with COPD (214).  
Second, the MDD can be defined as the change in the outcome of interest based on 
the individual’s perception of their change using an external criterion, using, for 
example, a GRC scale (213). The GRC scales are simple, easy to administer, have a 
high face validity and can be made relevant to any health condition (45). The GRC 
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scales are used by individuals to rate themselves as ‘better’, ‘unchanged’ or ‘worse’ 
over time or in response to an intervention (45).The MDD represents the mean 
change in the outcome measure of interest achieved by those individuals who rate 
themselves as having changed by ±2 or ±3 points, defined as ‘a little or somewhat 
better or worse’, on a 15-point GRC scale (220). This method was used by Jaeschke 
et al (213) to confirm the clinicians’ judgements concerning the MDD of the CRDQ. 
Similarly, this GRC scale has been used to determine the MDD for the Asthma 
Quality of Life Questionnaire (220). The GRC scale was shortened and used to 
estimate the MDD for the outcomes of walking based tests, namely the incremental 
shuttle walk test (44), ESWT (48) and 6MWT (43). A different methodology was 
used in studies by Redelmeier et al (42, 221) which relied on between-individual 
ratings on the GRC scale where individuals were asked to rate themselves against 
others. The MDD for 6MWD and FEV1were determined using the mean difference 
in values between those individuals who rated themselves as ‘a little better’ rather 
than ‘about the same’ (42, 221). In some studies, arbitrary cut-offs by combining 
several levels of the GRC scale were used to define MDD (45). An example is the 
study by Holland et al (43) who collapsed a 7-point GRC  scale into three categories, 
where the scores of 0 to 1 of the GRC scale were combined as no change, scores of 2 
to 3 combined as small change and scores of 4 to 7 combined as substantial change. 
Although combining levels on a scale is common when determining MDD, the 
decision of which levels to combine is arbitrary (8). Further, the use of a GRC scale 
may be prone to recall bias (222). 
Third, the MDD can be estimated using linear regression analysis between the 
change in the outcome and the change in an anchor that has an established MDD 
(217). For example, the CRDQ, which has an established MDD of 0.5 points per 
item (218, 223) and the SGRQ domain and total scores which have an established 
MDD of 4 points (217), can be used as an anchor to estimate the MDD for exercise 
tests (217, 223) and the Hospital Anxiety and Depression scale (218) in individuals 
with COPD. 
Fourth, a specific health criterion can be used as an anchor to estimate the MDD and 
this may include hospital admissions, death, the need for a major change of treatment 
or a change in the clinical state of the individual (214). This method has only been 
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used for HRQoL as HRQoL is assumed to be worse in individuals who have a major 
health event compared to those who do not (214). This method was used to 
determine the MDD of the SGRQ based on hospital re-admissions (224) and the 
MMRC dyspnea grade (225). 
Fifth, the MDD can be defined as the value that confers the optimal blend of 
sensitivity and specificity using a ROC curve to discriminate between individuals 
who rate themselves as changed versus unchanged at the end of an intervention (8). 
That is, sensitivity is defined as the proportion of individuals who reported an 
improvement using the GRC scale and demonstrated an improved in the outcome of 
interest (i.e. true positive), while specificity is defined as the proportion of 
individuals who did not report an improvement using the GRC scale and the outcome 
of interest did not improve (i.e. true negative) (8). This technique was used by 
Holland et al (43) to determine the MDD for the 6MWD after pulmonary 
rehabilitation in individuals with COPD. It has the advantage of accommodating all 
available data, independent of the number of responses in each category of the GRC 
scale (49).  
2.7.1.2 Distribution-based approaches for determining the minimal 
detectable difference 
Distribution-based approaches for the MDD use statistical methods. These methods 
include the effect size or half a SD of the baseline measure, the standardised response 
mean (SRM) and the standard error of measurement (SEM) (8). These statistical 
methods are described in the following paragraphs. 
The effect size is the measure of change obtained by dividing differences in values 
from baseline to post intervention by the SD of the baseline values (8). Regarding 
interpretation, an effect size of 0.2 is considered small, 0.5 is moderate and  0.8 is 
large (203). The estimate of the MDD for change in outcomes of HRQoL in 
individuals with COPD has been shown, in a systematic review, to fall close to half 
of a SD (46). As an effect size of 0.5 is considered to be moderate (8), the MDD is 
calculated by multiplying the SD of the baseline measure by 0.5. 
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The SRM has been defined as the changes in a group of values or scores obtained by 
dividing differences in the outcome measure of interest (i.e. from baseline to post-
intervention) by the SD of the change in the outcome measure (46, 226). The SRM is 
also known as another form of effect size (226) and some authors have used the 
definition of SRM synonymously with the term effect size (217, 223). The criteria 
for moderate change of half a SD of change in the outcome of interest was also used 
for the SRM to estimate the MDD (46, 226). 
The SEM is defined as the variability between an individual’s observed score and the 
true score and is computed as the baseline SD multiplied by the square root of one 
minus the ICC (47). It can also be calculated via repeated measures analysis of 
variance (ANOVA) (47). The important property of the SEM is that it is invariant 
(227) as it based on internal consistency or test-retest method of the outcome 
measure (212). The statistical formula for using the SEM is sometimes termed MDC: 
1.96 x SEM x √ 2, which relates to the smallest change that can be considered 
outside random variation (i.e. measurement error) (8). The SEM has been able to 
identify clinically meaningful intra-individual change in the CRDQ in individuals 
with COPD (227).  
The limitation with using a distribution-based approach for determining the MDD is 
that it is based solely on statistical calculations (212). Further, the distribution-based 
approach is cohort specific, thus dependent on the variability of scores in the cohort 
(8). Distribution-based approaches are considered inferior to anchor-based 
approaches (212) as they do not consider the individual’s perception or opinion of his 
or her outcome. 
2.7.1.3 Approaches used previously to determine clinical importance for 
outcomes in individuals with COPD 
In individuals with COPD, the MDD for field walking tests and HRQoL have been 
estimated using both anchor- and distribution-based approaches. These are listed in 
Tables 2-7 and 2-8)  
The 6MWD is widely used as an outcome measure in clinical trials involving 
individuals with COPD (228). Thus change in 6MWD following an intervention is 
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most often used to determine the clinical importance of a study’s findings. 
Redelmeier et al (42) were the first to determine the MDD for the 6MWD using 
between-individual comparisons after a PRP. A difference of 54 m                        
(95% CI 37 to 71 m) in 6MWD was required in order for an individual to stop rating 
themselves as ‘about the same’ and start rating themselves as either a ‘little bit 
better’ or a ‘little bit worse’ compared to others (42). In the National Emphysema 
Treatment Trial (NETT), the anchor-based estimate of the MDD for the 6MWD was 
26±2 m (217). This study involved 1,218 individuals and used the SGRQ and the 
University of California San Diego Shortness of Breath Questionnaire as external 
criterions for the anchor-based MDD estimation (217). This MDD for 6MWD from 
the NETT trial was similar to the 25 m determined by Holland et al (43) using the 
ROC curves and the GRC scale. Both the NETT trial (217) and the study by Holland 
et al (43) found that distribution based estimates for determining the MDD for the 
6MWD yielded similar values to their anchor-based estimates. However, the MDD 
of 54 m determined by Redelmeier et al (42) was double that of the NETT trial (217) 
and Holland et al (43). Puhan et al (223) conducted a pooled analyses of nine studies 
with a total of 460 individuals with COPD and estimated the MDD for 6MWD as   
35 m using distribution-based approaches (effect size and SEM). This range of 
values for the MDD of the 6MWD may be explained by the different methods used 
in the estimation as well as the nature of the interventions or treatments provided to 
the individuals with COPD in these studies.  
There is only one study that attempt to estimate the MDD for performance on the 
ESWT. In the study by Pepin et al (48), the MDD for the ESWT outcomes (i.e. time 
or distance walked) were very different when comparing the response to a PRP and 
following administration of inhaled bronchodilators. The distribution-based method 
of SRM for outcomes in ESWT in response to PRP suggested an MDD of 186 sec or 
203 m, while the planned anchor-based approach could not be used as the correlation 
( r) between the GRC scale and ESWT performance was < 0.4 (p < 0.001) (48). The 
poor correlation between the GRC scale and ESWT performance was speculated to 
be due to poor recall over the 7-week PRP period and because rehabilitation required 
a level of commitment and personal investment in the treatment, thus individuals 
were expecting more from rehabilitation than from an inhaled bronchodilator (48). 
The anchor-based estimate for the MDD for the outcomes in ESWT in response to a 
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bronchodilator was 65 sec (95% CI 45 to 85 sec) or 85 m (95% CI 60 to 115 m), 
supporting the use of ESWT in clinical trials evaluating the effectiveness of such 
medications (48). There was also only one study that estimated the MDD for 
incremental shuttle walk test (ISWT) using the GRC scale. In this study, the MDD 
was estimated to be 47.5 m which was the mean improvement in ISWT distance by 
the individuals with COPD who perceived their exercise tolerance as ‘slightly better’ 
after a 7-week PRP. 
 
 
Table 2-7: Summary of studies that determined the minimal detectable difference (MDD) in field walking tests in individuals with 
COPD. 
Field walking tests 
Outcome Study Sample 
size (n) 





112  PRP Between individuals comparison 
using GRC scale 
54 m - - 










35 m  
(95% CI 30 to 42 m) 
29 m 
35 m  
(threshold 29 to 42 m) 
 Holland  
2010 (43) 
75  7-week PRP GRC scale and ROC analysis 24.5 m  





 Puhan  
2011 (217) 
1,218  6 months follow-up after 
completing PRP 
 
SGRQ impact domain as anchor 
 
SGRQ activities domain as anchor 
 
SGRQ total score as anchor 
 
UCSD Shortness of Breath 
Questionnaire total score as anchor 
18.9 m  
(95% CI 18.1 to 20.1 m) 
24.2 m  
(95% CI 23.4 to 25.4 m) 
24.6 m  
(95% CI 23.4 to 25.7 m) 
26.4 m  





25.7 m  
 
26.8 m  
 
30.6 m  
 
 Polkey  
2013 (229) 
2,112 Over 1 yr as a function of 
mortality and 
hospitalisation 
Death and hospitalisation 
 
30 m - - 
ISWD Singh  
2008 (44) 
372  7-week PRP GRC rating of slightly better 47.5 m 





2011 (48)  
132 7-week PRP - - SRM 186 sec or 203 m 
   69 Bronchodilatation GRC scale and linear regression 65 sec 
(95% CI 45 to 85 sec)  
85 m 
(95% CI 60 to 115 m) 
SRM 70 sec or 115 m 
CI, confidence interval; COPD, chronic obstructive pulmonary disease; ESWT, endurance shuttle walk test; GRC, global rating of change; ISWD, incremental shuttle walk distance; m, metres; 
n, number of participants; PRP, pulmonary rehabilitation program; ROC, receiver operator curve; sec, seconds; SEM, standard error of measurement; SGRQ, Saint George’s Respiratory 
Questionnaire; SRM, standardised response mean; UCSD, University of California San Diego; 6MWD, 6-minute walk distance.58 
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Table 2-8: Summary of studies that determined the minimal detectable difference (MDD) in HRQoL in individuals with COPD. 
HRQoL 
Outcome Study Sample 
size (n)  
Intervention Anchor-based approach MDD Distribution-based 
approach 
MDD 
CRDQ Jaeschke  
1989 (213) 
 
- - Survey of individuals with 
experience using the 
CRDQ (consensus panel) 
Dyspnea 0.6 ppi 
Fatigue 0.5 ppi 







31 24 weeks  after 
inpatient PRP 
GRC scale of  ±1 to ±3 
(almost the same to 




Dyspnea 0.43 ppi 
(range 0.28 to 0.62) 
Fatigue 0.64 ppi 
(range 0.55 to 0.7) 
Emotion 0.49 ppi 






112 PRP Between individuals 
comparison using GRC 
scale  
Dyspnea 0.09 ppi 
Fatigue 0.5 ppi 
Emotion 0.87 ppi 





393 Nil - - SEM 
 
Dypnea 0.51 ppi 
Fatigue 0.52 ppi 
Emotional 0.44 ppi 




51 PRP - - Effect size Dyspnea 0.61 ppi 
Fatigue 0.67 ppi 
Emotional 0.60 ppi 
Mastery 0.60 ppi 
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Table 2-8: Continued  
HRQoL 
Outcome Study Sample 
size (n)  
Intervention Anchor-based approach MDD Distribution-based 
approach 
MDD 
SGRQ Jones  
1991 (219) 
152 Nil Consensus panel made up of 
clinicians who used the SGRQ 
(minimal difference between 
two hypothesised populations 
based on frequency of cough, 
frequency of wheeze, level of 
dyspnea, level of depression and 
6MWD using multivariate 
model) 
SGRQ total score 3.9 units - - 
 Jones  
1997 (231) 




Patients rated the use of 
Salmeterol as effective 
treatment using a scale worded 
as ‘no effect’, ‘satisfactory’, 
‘effective’ and ‘very effective’  
SGRQ total score 4.3 units 
(95% CI 1.8 to 6.9) 
- - 
 Bestall  
1999 (225) 
64 Nil Based on MMRC dyspnea grade 
as criterion (Grade 5 
[housebound] versus Grade 4 
[non-housebound]) 
SGRQ total scores 3.9 
units  




84 PRP Using CRDQ dyspnea domain 
(0.5 ppi) as anchor 
SGRQ total score 3.05 
units  
(95% CI 0.39 to 5.71) 
- - 
CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRDQ, Chronic Respiratory Disease Questionnaire; GRC, global rating of change; HRQoL, health-related quality of life; 
MMRC, Modified Medical Research Council; n, number of participants; ppi; points per item; PRP, pulmonary rehabilitation program; SEM, standard error of measurement; SGRQ, Saint 
George’s Respiratory Questionnaire; 6MWD, 6-minute walk distance.
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The MDD has been estimated for some outcomes of HRQoL following a PRP in 
individuals with COPD, namely for the CRDQ and SGRQ. Using the GRC scale of 
‘almost the same’ to ‘somewhat better or worse’, Jaeschke et al (213) estimated the 
MDD for CRDQ to be 0.5 points per item for each domain. Redelmeier et al (230) 
using between individual global ratings, had an estimated MDD for the domains of 
CRDQ ranging from 0.09 (dyspnea domain) to 0.87 (emotional function domain), 
with a pooled MDD across domains of 0.42 (95% CI of 0.32 to 0.53). The estimated 
MDD for all domains of the CRDQ for a moderate effect size ranged between 0.52 to 
0.64 points per item (232). A systematic review by Schünemann et al (41) 
summarised the above studies and suggested that the MDD estimate for the CRDQ 
was 0.5 points per item for each domain. As for the SGRQ total score, the MDD 
estimate determined in individuals with COPD was approximately 4 units regardless 
of treatment, namely the use of Salmeterol or after discharged from hospital 
following an acute exacerbation (214).  
2.7.1.4 Uses and misuses of the minimal detectable difference 
The MDD is useful as it can be used to make clinical decisions based on the 
magnitude of change seen in an outcome and for sample size calculations (212, 233). 
However, the MDD calculated on a group average is often extrapolated to 
individuals (211), where individuals who improve beyond the MDD are considered 
‘responders’ (234). This is a misuse of the MDD as measures, especially of exercise 
capacity, have inherent variability and if this variability is greater than the MDD, 
using the MDD to classify ‘responders’ is inappropriate (234). Further, 
approximately 30% of individuals with COPD do not appear to show any clinical 
improvement in terms of exercise capacity or HRQoL after a PRP (235, 236). Thus, 
an individual’s improvement when benchmarked against established MDD values 
may not be reflective of the change perceived on an individual level (233). 
In individuals with COPD, different estimates for MDD for outcomes have been 
reported and are dependent on the methods used. One example is the 6MWD where 
the estimated MDD ranged from 25 m using ROC analysis (43), 35 m using the SEM 
(223) and 54 m using between-person comparisons (42). These different MDD 
estimates would identify different number of responders to a treatment, thus 
highlighting the limitation of applying group data to the interpretation of the outcome 
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in an individual (234). Another example is the MDD for the CRDQ emotional 
function domain which ranged from 0.49 points per item for within-person 
comparison estimated by Jaeschke et al (213) to 0.87 points per item for between-
person comparison estimated by Redelmeier et al (230). Likewise this is seen for the 
MDD for the CRDQ dyspnea domain which ranged from 0.09 points per item (230) 
to 0.6 points per item when perceived by a panel of clinicians (213, 237). Yet, the 
consensus for the MDD for this outcome has been agreed at 0.5 points (211).  
Conversely, the distribution-based approaches use statistical methods to calculate a 
value that could be considered beyond the intrinsic variability of the test (233). 
2.8 Conclusion 
Chronic obstructive pulmonary disease is one of the most common lung diseases in 
the world and is the third leading cause of disease burden in Australia (238). 
Individuals with this disease are generally less active than their healthy peers, most 
likely because they try to minimise dyspnea and fatigue in daily life (1). As PA has 
been found to have a protective effect on the risk of hospitalisation (239), it is 
important to look at strategies that might improve PA levels in individuals with 
COPD. Possible strategies include the use of an assistive aid such as a WW and 
exercise training as part of pulmonary rehabilitation. As individuals with COPD walk 
less and slower than healthy peers (1, 100), suitable motion sensors that are accurate 
and responsive must be used to measure PA in these individuals. Exercise training 
has been shown to reduce dyspnea and fatigue (5-7), increase exercise capacity and 
improve HRQoL (5-7). The improvements observed after exercise training must go 
beyond statistical significance and also be perceived by the individual (8). Various 
outcomes measures used in the assessment of individuals with COPD have had their 
MDD determined and these MDD values will assist in the management of 
individuals with COPD in the clinical setting. 
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CHAPTER 3 
MEASUREMENT PROPERTIES OF THE 
STEPWATCHTM ACTIVITY MONITOR AND 
ACTIVPALTM IN INDIVIDUALS WITH CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE 
3.1 Overview 
In people with chronic obstructive pulmonary disease (COPD), the level of daily 
physical activity (PA) has been demonstrated to influence healthcare utilisation, 
morbidity and mortality (9, 10). Despite the importance of optimising daily PA in 
this population, selecting an appropriate device to obtain valid measures remains a 
challenge. This is especially true for those individuals who walk slowly or use a 
wheeled walker (WW) to assist with ambulation (11-13). Some motion sensors 
underestimate steps in individuals who adopt a slow walking speed as there is 
insufficient magnitude of movement at the centre of mass to be detected by these 
motion sensors (13-15). The simplest of motion sensors, namely pedometers, often 
lack the sensitivity to detect slow or shuffling gait patterns (127, 128) and thus tend 
to underestimate the number of steps taken by some patients with COPD (11, 16). 
Measuring PA appears to be particularly problematic in those who use a WW to 
assist with ambulation (13). This is likely to relate to the slower walking speeds 
characteristic of people who require gait aids. Further, for motion sensors that attach 
to the arm such as the SenseWear armband, the use of a WW stabilises the arm 
during ambulation, and therefore data received by the accelerometers within such 
devices is dampened. This serves to reduce the precision of any measurements (13).  
As slow walking is likely to diminish movement in the lower limbs to a lesser extent 
than movement at the centre of mass (130), we proposed that motion sensors which 
attach to the leg, rather than the waist, may yield accurate measures in individuals 
with COPD who are known to adopt slower walking speeds during daily life (1). 
Following a review of the literature (11, 16-19), we decided to explore the 
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measurement properties of two motion sensors that attach to the leg as they have 
yielded encouraging data in other clinical populations.  
Data reported by Resnick and colleagues (17) suggested that the StepWatchTM 
Activity Monitor (SAM; OrthocareInnovations, Seattle, Washington, United States 
[US]) may yield accurate measures of PA in individuals who walk slowly, including 
those who use a gait aid. This device attaches to the ankle. Similarly, the 
ActivPALTM (PAL Technologies Ltd, Glasgow, Scotland, United Kingdom [UK]) 
has been shown to yield accurate measures of PA in a healthy elderly population who 
walked at slow speeds (19). This device attaches to the anterior aspect of the thigh. 
Both the SAM and the ActivPALTM are small, easily concealed by clothing and 
simple to use; features that make them attractive for monitoring PA in both the 
research and clinical setting. Nevertheless, the capacity of these motion sensors to 
collect accurate information in people with COPD, who may use a WW to assist with 
ambulation, is unknown. Further, the capacity of these motion sensors to detect a 
small increase in PA is unknown. This is particularly important if these motion 
sensors are used to evaluate the effect of therapies aimed at increasing PA in people 
with COPD.  
The main analysis presented in this chapter has been published (240). However, 
additional information and data have been added to this chapter (namely the data 
pertaining to static tasks and a sit to stand activity). These data were not included in 
the original publication due to space limitations imposed by the journal. 
3.2 Methodology 
3.2.1 Overall aim 
Evaluate the measurement properties of two motion sensors: the SAM and the 
ActivPALTM. 
3.2.2 Research questions 
i. Do the SAM and the ActivPALTM detect movement when people with COPD 
perform stationary tasks and during a sit to stand task? 
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ii. Are the SAM and the ActivPALTM accurate and responsive in detecting steps 
when people with COPD walk at slow and normal pace with and without a 
WW? 
3.2.3 Research hypotheses 
The first hypothesis is that both motion sensors will not detect steps when people 
with COPD perform stationary tasks, namely lying supine, sitting and standing as 
well as during the transition from sitting to standing. 
The second hypothesis is that both the SAM and ActivPALTM will be accurate and 
responsive at detecting steps in people with COPD during: 
i. slow and normal walking pace; and 
ii. slow and normal walking pace when using a WW. 
3.2.4 Study design 
A cross-sectional observational study was undertaken during which data collection 
for each participant was completed during a single 2-hour session. The study was 
approved by the following Human Research Ethics Committees: Curtin University 
(HR 86/2009), Sir Charles Gairdner Hospital (2009-044), Royal Perth Hospital (RA-
10/007), Bentley Hospital (S/10/192),  and Swan Districts Hospital (Ref no: 032). 
Written, informed consent was obtained from all participants prior to data collection.  
3.2.5 Participants 
Participants were recruited from referrals to out-patient pulmonary rehabilitation 
programs in the Perth metropolitan area. 
3.2.5.1 Inclusion and exclusion criteria 
Inclusion criteria comprised of a diagnosis of COPD and functional limitation 
defined as a 6-minute walk distance (6MWD) ≤ 450 m prior to rehabilitation. In 
people with COPD, a 6MWD of > 451 m has been shown to reflect mild functional 
impairment as it is consistent with a volume of peak rate of oxygen consumption 
between 20 and 25 ml/kg/min, measured during cardiopulmonary exercise test (241). 
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Hence, in this study a 6MWD threshold of ≤ 450 m was chosen in order to identify a 
population of people with COPD with more severe functional impairment. Potential 
participants with any co-morbidity such as musculoskeletal or neurological 
conditions that limited mobility were excluded from the study. 
3.2.6 Activity monitors 
The two motion sensors used in this study were: the SAM and the ActivPALTM. Both 
motion sensors measure physical activity in terms of steps. The ActivPALTM also 
identifies time spent in sedentary activity (sitting and lying), standing and stepping.  
3.2.6.1 StepWatchTM Activity Monitor 
The SAM is a sealed, waterproof, microprocessor controlled device which responds 
to time and movement. It is small (20 x 75 x 50 mm) and light (38g) and was 
attached to the participant’s right ankle using a Velcro® strap (Figure 3-1). The SAM 
has a sampling frequency of 128 Hertz (Hz) and data are available in 1-minute 
epochs. As it reports the number of steps taken by one leg, the measurement was 
doubled to calculate the total number of steps taken during a walking task. Prior to 
data collection, the SAM was initialized for each participant. Specifically, the 
participant’s height (in centimetres) was entered and the settings that pertained to 
‘range of walking speed’ and ‘leg motion’ were selected as ‘moderate’ and ‘normal’, 
respectively. For each participant, the first 40 steps taken whilst wearing the SAM 
were observed to ensure that the device was detecting steps, as indicated by a 
flashing light emitting diode on heel strike (242).  
3.2.6.2 ActivPALTM 
The ActivPALTM is a small (7 x 35 x 53 x mm), light (20g) uni-axial piezoresistive 
accelerometer (Figure 3-2). It was attached to the anterior aspect of the right thigh 
and held in position using a 10 by 14 cm transparent film dressing (3M TegadermTM, 
3M, St. Paul, Minnesota, US). The ActivPALTM has a sampling frequency of 10 Hz 
and data are available in 15-second epochs. 
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3.2.7 Procedures for data collection 
Once written informed consent was obtained, measurements were collected of height 
and weight. Participants were also asked to rate their level of functional limitation 
resulting from dyspnea using the Modified Medical Research Council (MMRC) 
dyspnea grade. The most recent measurements of the volume exhaled during first 
second of a forced expiration (FEV1) and forced vital capacity (FVC) as well as 
6MWD were extracted from the medical notes. The 6-minute walk test (6MWT) was 
conducted in accordance to American Thoracic Society guidelines (243). The SAM 
and ActivPALTM were then attached to each participant and they completed five 
tasks, performed in a standardised order. The tasks comprised; lying in supine, sitting 
and standing, a sit to stand task and four separate constant pace walking tasks. 
3.2.7.1 Stationary tasks 
Participants were required to complete three stationary tasks, each for 5 minutes, in 
the following order; supine lying, sitting over the edge of the plinth and upright 
standing.   
3.2.7.2 Sit to stand 
Participants were instructed to carry out 12 repetitions of transitioning between 
sitting and standing at their own pace. A stop watch was used to measure the time 
taken to complete the task. 
3.2.7.3 Walking tasks 
All walking tasks were 5 minutes in duration and performed within a 20 m level, 
enclosed corridor and were separated by 30 minutes of seated rest; a time period 
previously used to allow cardio-respiratory responses to return to resting values 
between successive walking-based assessments of exercise capacity in people with 
COPD (244). The first two walking tasks were undertaken at a speed considered to 
be ‘slow’ by the participants with the final two walking tasks undertaken at a speed 
considered to be ‘normal’ by the participants. This method was chosen to allow each 
participant to walk at an individualised slow and normal pace, which, in contrast to 
arbitrary walk speeds selected by the investigators, was more likely to be reflective 
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of daily life (13). The first walk at both speeds was completed without a WW and the 
second walk at both speeds was completed using a WW. 
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Figure 3-1: StepWatchTM Activity Monitor
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Figure 3-2: ActivPALTM and the USB docking station.
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The process used to ensure that a constant pace was maintained during each walking 
task has been described elsewhere (13). Briefly, the time taken for each participant 
to; (i) walk for 40 m at a pace that they considered to be slow and, (ii) walk for 40 m 
at a pace that they considered to be normal were used to calculate the slow and 
normal walking speeds, respectively. Thereafter the 20 m corridor was marked at 5 m 
intervals with orange traffic cones. The speed during each walking task was kept 
constant by using audio-signals that corresponded to a specific walking speed. That 
is, each audio-signal emitted a beep corresponding to when the participant needed to 
pass a cone in order to maintain the speed. The audio signals were made based on 
various speeds ranging from 25 to 75 m/min (Appendix A). For example, the audio 
signal corresponding to a speed of 25 m/min emitted a beep every 12 sec. The 
investigator walked with each participant for the first minute to provide verbal 
feedback regarding the use of the audio-signals. All participants were encouraged to 
maintain the pace dictated by the audio-signals, but to adopt a natural walking 
pattern. During each walking task, for each participant, the investigator counted the 
number of steps taken over three separate 30-second intervals (i.e. at the beginning of 
the second, third and fourth minutes). The average of these three samples was used to 
determine the average step rate, for each participant, for each walking task.  
3.3 Data management and analyses 
Analyses were performed using the Statistical Package for Social Sciences (SPSS 
version 17.0; Chicago, Illinois) with probability (p) < 0.05 used to denote statistical 
significance. The distribution of all data was examined using Shapiro-Wilk Test as 
well as using frequency histograms to test for normality. Data are expressed as 
mean±standard deviation (SD) unless otherwise stated. Raw data from the SAM and 
ActivPALTM were exported to Microsoft Excel® for further analyses.  
3.3.1 Data collected during stationary tasks, sit to stand task and walking tasks 
Data collected during each stationary task were reviewed to determine whether either 
device had recorded movement. Data collected during the transitions from sit to 
stand were reviewed to determine if steps were detected during the tasks and data 
from the ActivPALTM were reviewed to determine the number of changes in posture 
recorded from sedentary to upright. For all analyses undertaken of data collected 
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during the walking tasks, data available during complete consecutive minutes only 
were averaged and converted into step rate. 
3.3.2 Accuracy during walking tasks 
A repeated measures analysis of variance (ANOVA) was used to examine the effect 
of WW, walking speed and the interaction between the two, on the difference in step 
rate measured by the SAM and direct observation. The same procedure was 
undertaken using data collected from the ActivPALTM. Agreement analyses were 
undertaken according to the methods described by Bland and Altman (245). 
3.3.3 Responsiveness during walking tasks 
To determine if the SAM and ActivPALTM could detect a difference in step rate 
between walking speeds with and without the WW, a repeated measures ANOVA 
was used to examine the effect of WW, walking speed and the interaction between 
the two, on step rate. 
3.3.4 Sample size calculation 
Prospective sample size calculations were conducted to attain a precision around the 
estimate of the limit of agreement (LOA) of ≤ 6 steps/min. This value was chosen as 
earlier work demonstrated that an increase of 12 steps/min during self-selected 
walking tasks was perceived as the difference between slow and normal paced 
walking in people with COPD (13). Therefore we speculated that a difference less 
than half this value would not be perceived as a different walking speed by the 
average person with COPD. Using data available in the literature, we estimated the 
SD of the difference between slow and normal paced walking to be 3 steps/min (52 
steps/20 minutes) (12). Using the methods described by Bland and Altman (245), a 
sample size of 20 participants was needed for the 95% confidence interval (CI) 
around the LOA to span 5 steps/min. 
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3.4 Results 
3.4.1 Baseline characteristics 
Twenty-two participants consented to participate in this study. The characteristics of 
the 20 participants who completed the study are summarised in Table 3-1. Five 
(25%) participants used a WW in their home environment. Six (32%) of the 
participants were on ambulatory oxygen. 
3.4.2 Data collected during stationary tasks 
Neither the SAM nor the ActivPALTM detected any steps during the stationary tasks 
for any participant. 
3.4.3 Data collected during sit to stand task 
The average time taken for the participants to perform 12 repetitions of transitioning 
from sitting to standing was 45±15 sec. Both the SAM and ActivPALTM did not 
detect any steps during this task. The ActivPALTM recorded this activity as sedentary 
time for each participant. 
3.4.4 Data collected during walking tasks 
Data from two (9%) participants were excluded as they were unable to complete the 
walking tasks without resting and therefore, their walking cadence was not constant 
during the tasks. All other participants were able to maintain a constant walking 
speed during each task. Figure 3-3 a-b illustrates the step rate calculated using the 
three 30-second samples of direct observation for walking tasks undertaken at slow 
speed and normal speed, respectively. 
3.4.4.1 Accuracy of the SAM and ActivPALTM 
Regarding data collected using the SAM, the ANOVA demonstrated no interaction 
(WW x walking speed; F1, 19 = 0.24; p = 0.63), effect of WW (F1, 19 = 0.12; p = 0.73) 
or walking speed (F1, 19 = 0.03; p = 0.86) on the difference between step rate derived 
using this device and via direct observation. This indicated that the difference 
between step rate derived using the SAM and direct observation was similar across 
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all walking tasks and therefore we grouped data from all four walks in the Bland-
Altman analysis (Figure 3-4). The mean difference (i.e. bias) between the step rate 
derived using the SAM and direct observation was 2 steps/min, with a LOA of 6 
steps/min. The upper and lower LOA occurred at 8 (95% CI; 6 to 9) and -4 (95% CI; 
-5 to -2) steps/min, respectively.  
Regarding data collected using the ActivPALTM, there was no interaction (WW x 
walking speed; F1, 19= 0.58; p = 0.46) or effect of WW (F1, 19 = 0.01; p = 0.91) on the 
difference between step rate derived using this device and via direct observation. 
This indicates that the difference between the step rate derived using the 
ActivPALTM and direct observation was not affected by the use of a WW. However, 
there was a significant effect of walking speed (F1, 19 = 5.75; p = 0.03) on the 
difference between step rate derived using the ActivPALTM and direct observation. 
This indicates that the difference between the step rate derived using the 
ActivPALTM and direct observation differed between walking speeds and therefore, 
separate Bland-Altman plots were prepared for slow and normal walking speeds 
(Figure 3-5a and 3-5b, respectively). The mean difference (i.e. bias) in step rate 
derived using the ActivPALTM and direct observation at slow walking speeds was     
7 steps/min with a LOA of 10 steps/min. The upper and lower LOA occurred at 17 
(95% CI; 14 to 20) and -4 (95% CI; -7 to -1) steps/min, respectively. The mean 
difference in step rate derived using the ActivPALTM and direct observation at 
normal walking speeds was 4 steps/min with a LOA of 5 steps/min. The upper and 
lower LOA occurred at 10 (95% CI; 8 to 11) and -1 (95% CI; -3 to 0) steps/min, 
respectively.  
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Table 3-1: Character istics of study par ticipants (n=20; 8 males). 
Variable Mean±SD 
Age (years) 73.0±8.5 
Height (m)  1.67±0.09 
Weight (kg) 69.0±20.2 
BMI (kg/m2) 24.6±6.2 
FEV1 (L)  0.84±0.30 
FEV1 (% predicted)# 35±13 
FVC (L)  2.17±0.63 
FVC (% predicted)# 63±20 
FEV1/FVC (%) 40±12 
6MWD (m)  338±85 
6MWD (% predicted)† 55±14 
Slow walking speed (m/min) 34±6 
Normal walking speed (m/min) 46±10 
MMRC dyspnea grade (0 – 4)*  2.5 (2 – 3) 
BODE score* 4.5 (4 – 6) 
Data are mean±standard deviation (SD). #, percent predicted based on NHANES 
(246). †, percent predicted based on formula obtained from Jenkins et al (247).*, 
median (inter quartile range). BMI, body mass index; BODE, body mass index, 
airflow obstruction, dyspnea & exercise capacity index; FEV1, volume exhaled 
during first second of a forced expiration; FVC, forced vital capacity; kg, kilograms; 
L, litres; m, metres; min, minutes; MMRC, Modified Medical Research Council; % 
precent; 6MWD, 6-minute walk distance.  
Time between participation in the study and most recent measurement of 6-minute 
walk distance and lung function and was 4±3 and 2±3 months, respectively.
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Figure 3-3: Average step rate calculated using the three 30-second samples of 
direct observation for  walking tasks undertaken at slow speed (a) and normal 
speed (b). 
Each participant contributed two lines to Figure 3-3a and 3-3b (i.e. for the walking 
task performed with and without the wheeled walker). Also shown are the group 
mean (closed circles) and standard deviation (error bars) for the 1st and 3rd 30-
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Figure 3-4: Bland-Altman plot for  step rate obtained via direct observation and 
via the StepWatchTM Activity Monitor  (SAM).  











































Average step rate obtained via direct observation and 
SAM, (steps/min) 
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3.4.4.2 Responsiveness of the StepWatchTM Activity Monitor and 
ActivPALTM 
For data collected using the SAM, there was no interaction (WW x walking speed; 
F1, 19 = 0.23; p = 0.63) but a significant effect of WW (F1, 19 =12.39; p = 0.02) and 
walking speed (F1, 19 = 88.69; p < 0.01) on step rate. This indicates that the SAM was 
able to detect the difference in step rate associated with changing walking speeds and 
using a WW. Likewise, for data collected using the ActivPALTM, there was no 
interaction (WW x walking speed; F1, 19 = 0.01; p = 0.93) but a significant effect of 
WW (F1, 19 = 12.10; p = 0.003) and walking speed (F1, 19 = 102.86; p < 0.001) on step 
rate. This indicates that the ActivPALTM was able to detect differences in step rate 
associated with changing walking speeds and using a WW. The step rate for each 
walking task is presented in Table 3-2. 
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Average step rate obtained via direct observation and ActivPALTM, 
(steps/min) 
Figure 3-5: Bland-Altman plots for  step rate obtained via direct observation and 
the ActivPALTM at (a), slow walk speed (with and without wheeled walker) and 
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Table 3-2: Step rates (in steps/min) for  all walking tasks. 
 Observed SAM ActivPALTM 
Slow walk* 75±8 73±8 68±11 
Normal walk* 85±10 85±10 83±11 
Difference (normal-slow)* 12±7 12±6 14±7 
Walk without wheeled walker† 83±12 80±11 74±12 
Walk with wheeled walker† 79±11 77±10 77±14 
Difference (without - with wheeled 
walker)† 
3±3 3±4 3±5 
Data are mean±standard deviation. *, includes data collected irrespective of whether 
a wheeled walker was used. †, includes data collected irrespective of walking speed.
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3.5 Discussion 
This is the first study to examine the measurement properties of the SAM and 
ActivPALTM in people with COPD during stationary tasks, sit to stand as well as at 
two self-selected walking speeds. Further, this study determined whether or not the 
use of a WW to assist with ambulation affected the accuracy or responsiveness of 
these motion sensors. The important findings of this study are; (i) both the SAM and 
the ActivPALTM did not detect any movement during the stationary tasks as well as 
during the 12 repetitions of sit to stand, (ii) the capacity of the SAM to detect steps 
was similar regardless of walk speed or WW use, (iii) the capacity of the 
ActivPALTM to detect steps was affected by walk speed but not WW use and, (iv) 
both motion sensors were able to detect small changes in step rate.  
3.5.1 Accuracy of the motion sensors 
Neither the SAM nor the ActivPALTM recorded steps during the stationary tasks or 
during the transition from sitting to standing. This is consistent with the SAM only 
recording steps, which did not occur during these tasks. In contrast, the ActivPALTM 
records steps, but also includes time spent being inactive versus active, outcomes 
related to posture changes. The ActivPALTM had demonstrated good agreement with 
counting by direct observation during practice session of sit to stands in 
rehabilitation in patients with stroke (248, 249). Similarly, an earlier study by Grant 
et al (137) found the ActivPALTM to be a reliable device to detect postures and 
motion in everyday living. That conclusion was based on data showing that the 
ActivPALTM accurately detected transitions from sitting to standing while 
participants were carrying out six random everyday tasks such as making a telephone 
call, removing rubbish and washing and drying dishes, each task lasting between 2 to 
9 minutes (137). However, this was not case in this study as it was not able to detect 
the task of sit to stand. One possible reason for this was the fact that task of sit to 
stand was done repetitively in a continuous manner by the participants and the 
ActivPALTM records data only at 15-second epochs. Thus it is likely that the 
participants did not spend sufficient time in the standing position for the ActivPALTM 
to detect the new posture. Therefore, the data of this study suggests that the 
ActivPALTM was not sensitive to measure transitions between sitting and standing if 
the new posture was not sustained. 
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For the walking tasks, the data revealed that the capacity of the SAM to measure step 
rate was similar at slow and normal walk speeds, regardless of whether or not a WW 
was used. The mean difference between step rate derived using the SAM and direct 
observation was 2 steps/min, which is trivial compared with that reported for other 
commercially-available for motion sensors such as the Minimod, SenseWear 
armband and Digiwalker pedometer (12, 14). The excellent agreement in step rate 
derived using the SAM and direct observation extends the findings of Resnick et al 
(17) who reported a strong correlation between these variables (r = 0.98) in a group 
of elderly people (aged 86±6 years) of whom 22 (73%) used a walking aid to assist 
with ambulation. Although a strong correlation indicates that these measures were 
related, Bland-Altman analyses are needed to demonstrate agreement and therefore 
mean difference (i.e. bias) and LOA were reported. In contrast with the SAM, the 
data indicate that the capacity of the ActivPALTM to detect steps was impaired at 
slow walking with the bias increasing from 4 to 7 steps/min between normal and 
slow walking speeds respectively. It is likely that the shorter stride lengths associated 
with walking at slower speeds (250) reduced movement at the thigh and thus 
impaired the capacity of the ActivPALTM to detect steps. The shorter stride lengths 
will reduce movement at the ankle to a lesser extent; a factor that may explain why 
the SAM, which attaches to the ankle, had a similar capacity to detect steps at both 
walking speeds (251). In addition to the position of the motion sensors, the difference 
in the capacity of the SAM and ActivPALTM to detect steps at the two walking 
speeds may also reflect the superior sampling frequency of the SAM (128 Hz) 
compared with the ActivPALTM (10 Hz).  
Although the data indicates that the ActivPALTM underestimated step rate at slow 
walk speeds, it is important to note that the walk speed selected by the participants 
for both the ‘normal’ (46±10 m/min) and ‘slow’ (34±6 m/min) walks was 
considerably slower than that used in other studies. For example, in the study by 
Langer et al (12), the participant who walked the slowest at 42 m/min was considered 
an outlier and excluded from the statistical analysis. In this individual, the Minimod 
underestimated step rate by approximately 39 steps/min, and SenseWear armband 
underestimated step rate by approximately 56 steps/min (12). The ActivPALTM 
which underestimated step rate by 7 and 15 steps/min with the WW and 4 and 26 
steps/min without the WW in the two participants who walked the slowest (25 
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m/min) in this study; a speed considerably slower than the outlier in the study by 
Langer et al (12), is more favourable than the above monitors. Therefore, although 
ActivPALTM does underestimate steps at very slow walking speeds, it seems to 
outperform other popular, more expensive, commercially-available motion sensors, 
such as the Minimod and SenseWear armband. 
An important and novel finding of this study is that the use of a WW did not affect 
the capacity of the SAM or the ActivPALTM to detect step rate. People with COPD 
who are characterised by a low 6MWD and marked dyspnea on exertion benefit from 
using a WW both in terms of exercise capacity and reduction in dyspnea (21, 22). 
Further, there is a high level of satisfaction associated with their use in the 
community (252). Given the increasing use of WWs by people with COPD, it is 
important that clinicians and researchers are able to obtain accurate measures of PA 
in this subgroup. To date, this study is the first to identify two motion sensors that 
yielded accurate measures of PA in people with COPD who use a WW. 
3.5.2 Responsiveness of the motion sensors 
For both motion sensors, there was a significant effect of walk speed, suggesting that 
the SAM and ActivPALTM could detect the difference in step rate associated with 
changing from the slow to normal walk speed, regardless of whether the participant 
was using a WW. The change in step rate between slow and normal walking, 
calculated via direct observation was 12±7 steps/min; a difference of similar 
magnitude as detected by the SAM (12±6 steps/min) and ActivPALTM               
(14±7 steps/min). A more impressive result is that there was a significant effect of 
use of a WW, suggesting that the SAM and ActivPALTM could detect the trivial 
decrease in step rate associated with changing to use a WW to assist with 
ambulation, regardless of walk speed. The change in step rate between using and not 
using the WW, calculated via direct observation was 3±3 steps/min; a difference of 
similar magnitude as detected by the SAM (3±4 steps/min) and ActivPALTM                    
(3±5 steps/min). Studies that have examined the measurement properties of motion 
sensors usually focus on accuracy or validity of the motion sensors. This study 
extends earlier work (11, 16-19) by confirming the excellent responsiveness of these 
two motion sensors to detect very small changes in step rate.  
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3.5.3 Limitations 
We examined the measurement properties of the SAM and ActivPALTM during static 
tasks (supine lying, sitting and standing), sit to stand activity as well as walking tasks 
as these are common activities of daily living (9). We did not explore the 
measurement properties of these motion sensors during other activities, such as 
cycling and also, did not determine the extent to which these motion sensors may 
mis-classify movement associated with travelling in a car as steps.  
3.6 Conclusions 
The stationary tasks and transitions between sit to stand were not detected as motion 
by either device. Both the SAM and ActivPALTM underestimated step rates in the 
participants with COPD, however the difference was very small. Both motion 
sensors were responsive to small changes in step rate. The SAM was accurate in 
detecting step rate regardless of walking speed or WW use. In contrast, the accuracy 
of the ActivPALTM to detect step rate was affected by walking speed but not WW 
use. These motion sensors can be used to assess PA in people with COPD, including 
those who use a walking aid such as a WW.
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CHAPTER 4 
EFFECT OF USING A WHEELED WALKER ON 
PHYSICAL ACTIVITY IN INDIVIDUALS WITH 
CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE 
4.1 Overview 
This chapter presents the results of a study that aimed to determine the effects of 
providing a wheeled walker (WW) to individuals with chronic obstructive pulmonary 
disease (COPD) on physical activity (PA), health-related quality of life (HRQoL) as 
well as the fear of falling. A WW, also known as a rollator, is a frame used to assist 
with walking that has four standard wheels where the front two are on swivel casters. 
It is equipped with hand brakes, a basket for carrying items and a fold-down seat 
(Figure 4-3) (21).  
Individuals with COPD who are characterised by marked functional limitation due to 
intolerable dyspnea may benefit from ambulating with a WW (20). In a randomised 
cross-over study, Solway et al (21) found a significant reduction in dyspnea (1.8±0.2 
[mean±standard deviation (SD)] unit change) and rest duration recorded (12±6 sec) 
during a 6-minute walk test (6MWT) when using a WW compared to walking 
without a WW, even though there was no significant increase in 6-minute walk 
distance (6MWD). However, in the study by Probst et al (22), individuals with 
COPD walked a median of 27 m (6%, p = 0.04) further during a 6MWT when 
provided with a WW while experiencing a non-significant reduction in dyspnea at 
the end of the 6MWT.  
The improvements in 6MWD and dyspnea have been demonstrated to be greater in 
individuals with COPD who have greater functional limitation. Solway et al (21) 
found that 6MWD significantly increased when a sample of  individuals with COPD 
who walked < 300 m in their 6MWT unaided were provided with a WW (with a 
WW, 6MWD = 243±14 m versus without a WW, 6MWD = 220±12 m; p = 0.02). 
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Further, in the individuals with a 6MWD of < 300 m, both dyspnea and rest duration 
during the 6MWT were further reduced (1.8±0.3 unit change; p < 0.001 and      
24±12 sec; p < 0.001 respectively) when a WW was used (21).  
The reasons for the improvements seen when walking with a WW most probably 
relate to the use of a forward lean position, the capacity to brace the arms on the WW 
and decreases in the metabolic cost of walking (23, 24). The following paragraphs 
will elaborate on these possible mechanisms.  
In individuals with COPD, hyperinflation of the lungs decreases the length of the 
diaphragm (23), resulting in impairment in the force-generating capacity of the 
diaphragm (253). Adopting a forward lean position optimises the pressure-generating 
capacity of the inspiratory muscles, most likely because it improves the length-
tension relationship of the diaphragm (171, 172) and reduces accessory muscle 
activation (23). This in turn is likely to decrease the level of neuromechanical 
dissociation, defined as the mismatch between the afferent input from the 
mechanoreceptors of the respiratory system and the efferent output or motor output 
to breathe, which is perceived by the individual as a reduction in dyspnea (173).  
The arm bracing posture adopted when using a WW has been shown to increase 
maximum voluntary ventilation (MVV) which may also contribute to the reduction 
in dyspnea felt when using a WW (22, 174). In the study by Probst et al (22), 
individuals with COPD significantly increased MVV when they braced their arms on 
the WW compared to without using a WW. Cavalheri et al (174) found that MVV 
was 4 L/min higher when individuals with COPD braced their arms on the WW 
compared to a period without a WW. This increase in MVV implied that the arm 
bracing posture improved ventilatory capacity. The increased ventilatory capacity 
associated with arm bracing is most likely due to the increased capacity to use 
accessory muscles of respiration, namely the serratus anterior, scalenes and 
sternocleidomastoid (175), which may also contribute to the relief of dyspnea in 
individuals with COPD when they use a WW. Thus, the arm bracing posture adopted 
when using a WW may allow individuals with COPD to rely on the accessory 
muscles to assist in respiration (176).   
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Besides the forward lean position with the arms braced on the WW, the reduction in 
dyspnea and improvement in 6MWD when using a WW may be partly due to a 
reduction in the metabolic cost of walking (22). Hill et al (24) investigated 
participants with COPD who undertook walking tasks that were 6 minutes in 
duration at a constant speed with and without a WW, finding a borderline 
relationship when using a WW between the reduction in dyspnea and the change in 
energy expenditure (Spearman correlation (r) = 0.50, p = 0.06). That is, the reduction 
in dyspnea had an association with the reduction in the metabolic cost of walking 
associated with using a WW. Interestingly, this reduction in the metabolic cost of 
walking when using a WW was seen in 75% of the individuals (n = 15) in this study 
who also reported a reduction in dyspnea (24). This implies that the reduction in the 
metabolic cost of walking was not the sole reason for the reduction of dyspnea when 
a WW is used (24), and supports the contribution of the physiological benefits of the 
forward lean position and the arm bracing when a WW is used (177). Further, it is 
possible that in some individuals with COPD who reported a reduction in dyspnea 
when using a WW the benefit was related, in part to a placebo effect (i.e. the 
participants’ expectation of benefit) as their dyspnea did not increase despite them 
demonstrating a greater energy expenditure or minute ventilation (24).  
This reduction in dyspnea and improvement in functional capacity when using a WW 
may enable individuals with COPD to increase their PA. Despite the acute 
improvements in dyspnea and functional capacity which have been documented in 
the laboratory setting, no study has evaluated the effects of a WW on daily PA in the 
community. Further, it is possible that using a WW will decrease the fear of falling 
and increase confidence when walking. This is particularly important given the 
evidence demonstrating a reduction in the balance and coordination of individuals 
with COPD (25-27) which is likely to result, at least in part, from an less active 
lifestyle (26). To date, only one randomised controlled trial (RCT) was identified that 
evaluated the impact of using a WW for 8 weeks on HRQoL in individuals with 
COPD, with no significant benefit demonstrated (178). This could be due to the 
infrequent use of the WW by the participants in this study by Gupta et al (178).  
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4.2 Methodology 
4.2.1 Overall aim 
The aim of this study was to determine the effects of providing a WW for home and 
community use on a variety of outcome measures for individuals with COPD.  
4.2.2 Research questions 
i. Does providing a WW for home and community use increase PA in 
individuals with COPD? 
ii. Do the clinical characteristics of individuals with COPD influence the effect a 
WW has on PA? 
iii. Does the use of a WW improve HRQoL and reduce fear of falling? 
iv. What is the average distance covered each day when a WW is used to assist 
with ambulation? 
v. What are the barriers to using a WW in the home and in the community? 
4.2.3 Research hypotheses 
The main hypothesis for this study was that individuals with COPD would benefit 
from the use of a WW in the home and community. Specifically, compared to a       
5-week period without a WW, the use of a WW for 5 weeks would result in 
significant improvements in: 
i. PA; 
ii. HRQoL and; 
iii. Fear of falling. 
4.2.4 Study design 
A prospective randomised cross-over study was conducted. Individuals with COPD 
were recruited from pulmonary rehabilitation programs (PRPs) within the Perth 
metropolitan area, namely, at Sir Charles Gairdner Hospital, Royal Perth Hospital, 
Bentley Hospital and Swan District Hospital. 
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4.2.5 Ethical approval 
Approval to conduct the study was granted by the Human Research Ethics 
Committees at Curtin University (HR 86/2009), Sir Charles Gairdner Hospital  
(2009-044), Royal Perth Hospital (RA-10/007), Bentley Hospital (S/10/192), and 
Swan District Hospital (Ref no: 032). Written, informed consent was obtained from 
all participants. The study was registered with the Australian New Zealand Clinical 
Trials Registry (ACTRN12609000332224). 
4.2.6 Participants 
The inclusion criteria were: (i) clinically stable with a medical diagnosis of moderate 
to severe COPD, (ii) marked functional limitation, which was defined as an unaided 
6MWD ≤ 450 m before commencement of the PRP and, (iii) deemed suitable for a 
WW by the physiotherapist(s) responsible for conducting the PRP. The exclusion 
criteria comprised: (i) prior use of a WW for more than 2 weeks before commencing 
the PRP and, (ii) any co-morbid condition that limited mobility such as severe 
arthritis or claudication. The last two inclusion criteria will now be described in more 
detail. 
The threshold of ≤ 450 m in an unaided 6MWD to define marked functional 
limitation was based on earlier work by Starobinet et al (241) who demonstrated that 
a 6MWD of > 450 m in individuals with COPD corresponded to a peak rate of 
oxygen consumption of 20 to 25 ml/kg/min, measured during a cardiopulmonary 
exercise test, which indicated mild functional impairment. Therefore, in this study, a 
6MWD threshold of ≤ 450 m was chosen in order to identify individuals with COPD 
of a severity that resulted in more than mild functional limitation.  
Factors used by the physiotherapist(s) to deem an individual suitable for a WW 
included: (i) the need to rest due to dyspnea during their pre-rehabilitation 6MWT, 
(ii) habitual upper limb bracing either during a 6MWT or supervised walking 
training, (iii) reporting less dyspnea or walking further when a WW was trialled 
during supervised walking training and, (iv) being receptive towards the idea of 
using a WW in their home. As part of usual clinical practice, the physiotherapist(s) 
responsible for conducting the PRP reviewed patients with COPD during their pre-
Chapter 4: Effect of a WW on PA 
   90 
rehabilitation assessment and over the first 2 weeks of supervised exercise training to 
determine their suitability for a WW.  
4.2.7 Protocol 
All participants completed an 8-week hospital-based PRP. This comprised two 
supervised exercise classes each week and an individually prescribed home exercise 
program to complete on an additional 2 or 3 days each week. The rehabilitation 
program consisted of 20 to 30 minutes of walking training, functional strength 
training exercises for the lower limbs and endurance training for the upper limbs. To 
increase familiarity with the WW, all participants were encouraged to use the WW 
(which weighed 7 kg) during the supervised walking program for 3 to 4 weeks 
during the PRP. However, the WW was not provided for use at home during 
participation in the PRP.  
During the final 2 weeks of the PRP, two assessment sessions were undertaken in 
order to: (i) familiarise the participants with wearing the motion sensors that would 
be used to collect PA data and, (ii) collect descriptive baseline data (i.e. height, 
weight, spirometry, 6MWD). On completion of the PRP, participants were then 
randomised to one of two groups using a computer-generated random number 
sequence. The randomisation sequence was stratified according to the use (or not) of 
ambulatory oxygen and location of the PRP (i.e. Northern Metropolitan Area Health 
Service [Sir Charles Gairdner Hospital and Swan District Hospital] or Southern 
Metropolitan Area Health Service [Royal Perth Hospital and Bentley Hospital]) and 
concealed using opaque envelopes. Those allocated to Group 1 were provided with a 
WW for 5 weeks immediately following completion of the PRP but not the next       
5 weeks. Participants allocated to Group 2 were not given a WW for the first 5 weeks 
but were thereafter provided with a WW for the next 5 weeks. The study design is 
illustrated in Figure 4-1.  
On completion of the PRP, the usual practice of the physiotherapists who run the 
PRPs, namely, to refer participants to maintenance PRPs upon completion of the     
8-week program, was undertaken. These maintenance programs offered a weekly 
exercise class, supervised by a physiotherapist, and were held in a non-medical 
community facility or a hospital. 
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Immediately following randomisation, participants allocated to Group 1 received a 
WW and were provided with standardised instructions regarding its use. They were 
instructed to use the WW to assist with daily activities that involved walking and to 
use the WW during the walking component of their home exercise program and 
maintenance PRP. Participants allocated to Group 2 were encouraged to continue 
with their home exercise program and attend the maintenance PRP, but were not 
provided with a WW. Four weeks later, two motion sensors were applied to 
participants in both groups to measure PA. These motion sensors were applied by a 
research assistant either as part of a home visit or during a maintenance class by a 
physiotherapist. Participants were instructed to wear both motion sensors 24 hours a 
day for 5 consecutive days. At the end of this 5-day period, all participants were 
visited at home to collect the motion sensors and complete questionnaires pertaining 
to their HRQoL and fear of falling. During this home visit, Group 1 participants had 
their WW removed and were encouraged to continue with their home exercise 
program and attend the maintenance PRP, whereas Group 2 participants were 
provided with a WW to use for the following 5 weeks and provided with 
standardised instructions regarding its use (as per Group 1).  
Four weeks later, the same motion sensors were applied to participants in both 
groups either as part of a home visit or during a maintenance class by a 
physiotherapist. They were instructed to wear both motion sensors 24 hours a day for 
5 consecutive days. At the end of this period, a final home visit was made to collect 
the motion sensors and repeat the questionnaires. Relevant information was provided 
to those participants who were keen to obtain or purchase a WW at the end of the 
data collection period. 
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Figure 4-1: Study design 
PRP, pulmonary rehabilitation program; WW, wheeled walker; 6MWD, 6-minute 
walk distance.
Final week of 8-week PRP: 
(i) participants familiarised with wearing the 
motion sensors and,  
(ii) descriptive baseline data collected (height, 
weight, spirometry and 6MWD) 
Randomisation 
WW issued for 5 weeks: 
• Motion sensors worn for 5 
days during the 5th week.  
• Home visit made to 
administer questionnaires 
and collect motion sensors 
and the WW. 
5 weeks without a WW: 
• Motion sensors worn for 5 
days during the 5th week.  
• Home visit made to 
administer questionnaires 
and collect motion sensors. 
5 weeks without a WW: 
• Motion sensors worn for 5 
days during the 5th week. 
• Home visit made to 
administer questionnaires 
and collect motion sensors 
and issue a WW. 
WW issued for 5 weeks: 
• Motion sensors worn for 5 
days during the 5th week.  
• Home visit made to 
administer questionnaires 
and collect motion sensors 
and the WW. 
GROUP 1 GROUP 2 
Referred to a PRP → assessed by a physiotherapist(s) and enrolled 
into a PRP → assessed for suitability for WW by a physiotherapist(s) 
 
Suitable participants approached for enrolment into study  
Participants recruited into the study familarised with WW 
during PRP 
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4.2.8 Outcome measures 
All outcome measures were collected during the home visits by a research assistant, 
who was unaware of participants’ group allocation before the first home visit. It was 
impossible to blind the research assistant or the participants as the intervention in this 
study was the provision of a WW. The WW provided were either the Seat Walker 
Cruiser Deluxe measuring approximately 600 by 275 by 830 mm or the Sprinter 
Maxi Seat Walker measuring 650 by 330 by 870 mm (Unicare Health, Perth, 
Western Australia). As this was a cross-over study where participants acted as their 
own controls, blinding was impossible. The primary outcome measure was PA. The 
secondary outcome measures were HRQoL, fear of falling, the distance travelled by 
the WW over the data collection period and barriers to using the WW. 
4.2.8.1 Primary outcome measure 
Physical activity 
Physical activity was measured concurrently using two separate motion sensors: the 
StepWatchTM Activity Monitor (SAM; OrthocareInnovations, Seattle, Washington, 
United Stated [US]) and the ActivPALTM (PAL Technologies Ltd, Glasgow, 
Scotland, United Kingdom [UK]) (Figure 4-2). A valid sample of PA was defined as 
a minimum of 3 days of data from the motion sensors. This definition was based on 
earlier work demonstrating that individuals with severe COPD showed little variation 
in daily step counts, thus a minimum of 3 days of PA data were considered sufficient 
to adequately capture average daily activity (106). Three full days of PA data has 
been demonstrated to have an acceptable level of reliability (106, 152), defined as an 
intra-class coefficient (ICC) of ≥ 0.7 (1). Further, individuals with moderate to severe 
COPD have been shown to have a smaller day-to-day variation in PA compared with 
their healthy counterparts (106) and earlier work has showed that there was little 
variability in PA between weekdays and weekends in sedentary individuals with 
COPD (50). A detailed evaluation of the measurement properties of these motion 
sensors has been provided in Chapter 3. 
The SAM was a sealed, waterproof, microprocessor controlled device that weighed 
38 g, and measured 20 by 75 by 50 mm. It was attached to the participant’s right 
ankle using a Velcro® strap. The SAM responded to time, acceleration and position 
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(16, 254). As the SAM has been shown to have an excellent capacity to accurately 
record the number of steps, irrespective of walking speed and WW use (240), it was 
selected as the outcome measure to investigate changes in the number of steps taken. 
The SAM detected the steps taken by the right leg, with this number doubled to 
provide the total number of steps taken per day (i.e. taken by both legs). During the 
calibration procedure undertaken prior to data collection, the participant’s height was 
entered onto the SAM and the settings that pertained to ‘range of walking speed’ and 
‘leg motion’ were selected as ‘moderate’ and ‘normal’ respectively. For each 
participant, the first 40 steps taken whilst wearing the SAM were observed to ensure 
that the device was detecting steps accurately, as indicated by a flashing light being 
emitted from a diode upon heel strike (242). The sampling frequency of the SAM 
was 128 Hertz (Hz) and data were available in 1 minute epochs. Thresholds for 
moderate and low intensity walking were defined at > 15 steps/min and                     
≤ 15 steps/min respectively (131). The SAM was chosen as one of the motion sensor 
as it has been shown in the study described in Chapter 3 to be accurate for detecting 
step rate regardless of walking speed or WW use. 
The ActivPALTM weighed 20 g and measured 7 by 35 by 53 mm. It was a uni-axial 
piezoresistive accelerometer that was attached to the anterior aspect of the right thigh 
and held in position using a 10 by 14 cm transparent film dressing (3M TegadermTM, 
3M, St. Paul, Minnesota, US). As the ActivPALTM has been shown to yield an 
excellent level of agreement (96%) and sensitivity (ranging from 90% to 100%) for 
the time spent in various postures (walking, standing and sitting) when compared to 
direct observation (137), the ActivePALTM device was used to measure the time 
spent walking, standing and sitting. The sampling frequency of the ActivPALTM was 
10 Hz and data were available in 15-second epochs. The ActivPALTM was used to 
complement the SAM in order to quantify the time spent being less active (sitting 
and lying down) compared to the time spent being active (standing and walking). 
Wearing both the SAM and ActivPALTM motion sensors for a period of                     
5 consecutive days was considered unlikely to impact on participants’ daily routine 
as these motion sensors are small, light and provided no feedback (255). Further, this 
was a randomised cross-over study, thus reducing any likelihood the motion sensors 
might have on participants’ daily routine.
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Figure 4-2: A StepWatchTM Activity Monitor (SAM) and an ActivPALTM device 
attached to the right leg.
ActivPALTM 
SAM 
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4.2.8.2 Secondary outcomes 
Health-related quality of life  
Health-related quality of life was measured using the self-administered, 
individualised version of the Chronic Respiratory Disease Questionnaire (CRDQ) 
(256). The same five activities chosen to quantify dyspnea during daily life were 
used at all time points.  
Fear of falling  
Fear of falling was assessed using the Survey of Activities and Fear of Falling in the 
Elderly (SAFE) scale (257). This questionnaire has been demonstrated to be valid in 
elderly populations and has acceptable internal consistency (257-259). This scale 
assigned scores associated with the fear of falling and activity restriction resulting 
from a fear of falling for 11 common activities of daily living. A 5-point (0-4) scale 
was used for each of the 11 activities and the scores were totalled to give a fear of 
falling score, where a score of > 0 indicated fear of falling (260). Scores ranged from 
0 to 44 with higher scores indicating a greater fear of falling. This questionnaire has 
been shown to be able to differentiate between those with a fear of falling that has 
resulted in activity restriction and those with a fear of falling with activity (257). 
Wheeled walker use and barriers to its use 
A magnetic odometer (Fargo Controls, Inc., Eatontown, New Jersey, US) was placed 
on the rear wheel of the WW to quantify the distance walked using this device 
(Figure 4-3). This odometer was attached to a lithium-powered, panel-mounted 
counter that measured 48 by 22 by 45 mm. This odometer device measured the 
number of revolutions of the wheel, enabling the distance over which the WW was 
used to be calculated. A similar device has been used previously to measure the 
distance walked during a 6MWT with a WW in individuals with COPD (21). 
Participants were asked to record the daily odometer readings in a diary during the  
5-week period when they had the WW (Appendix B). 
All participants were also asked four standardised closed questions regarding the use 
of the WW in their daily life at the end of the 5-week period when they had the WW. 
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These questions were modified from those used as part of an earlier study (252) and 
pertained to: (i) if they preferred having the WW, (ii) the type of activities that they 
used the WW for, (iii) the main barriers to using the WW and, (iv) whether the 
participant felt embarrassed using the WW (Figure 4-4). 
4.2.8.3 Descriptive measures 
Details were recorded pertaining to age, gender, height, weight, medication and 
ambulatory oxygen use. The 6MWD measured on completion of the PRP was 
recorded. The 6MWT was performed along a straight course within a level enclosed 
corridor in accordance with published guidelines (243). Standardised instructions 
were given prior to the test. Participants were informed each minute of the time 
remaining for the test, and were given standard phrases of encouragement. As 
previous research has shown that individuals with COPD do not demonstrate a 
change in 6MWD when two tests are performed at the end of an 8-week PRP (261), 
only one 6MWT was performed at the end of the PRP. Reference values for the 
6MWD were calculated using a regression equation published by Jenkins et al (247). 
Spirometry data were obtained from the medical records. The measures of 6MWD 
and spirometry were collected on completion of PRP to describe the sample and 
potentially look for characteristics of those individuals who showed the greatest 
change in PA. Functional limitation resulting from dyspnea was assessed using the 
Modified Medical Research Council (MMRC) dyspnea grade (262). The BODE 
index, a multi-dimensional score that comprises measures of forced expiratory 
volume in the first second (FEV1), body mass index, 6MWD and MMRC dyspnea 
grade was also calculated (263).  
4.2.8.4 Healthcare utilisation 
During the home visits by a research assistant to collect the motion sensors, 
participants were asked about changes in their medication and healthcare utilisation 
(for both respiratory and non-respiratory related problems), such as visits to the 
family doctor, an emergency department visit or hospital admission during each 
preceding 5-week time frame. Self-reports of emergency department visits and/or 
hospitalisations were verified using hospital databases.
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2. Which activities did you use the wheeled walker for?  
(Please check as many as apply): 
 
❒ Activities in the home (e.g. cooking, cleaning, in the bathroom) 
❒ Walking in the home 
❒ Walking outside of the home 
❒ Getting to and from the car 
❒ Walking indoors other than your home (e.g. in shopping centres or in a 
friend’s home or unit) 
❒ Activities outside your home (e.g. grocery shopping or running errands) 
❒ Others – please specify: ______________________________________ 
 
3. What, if any, were the main barriers to using the wheeled walker? (Please   
check as many as apply): 
 
❒ Difficult to push 
❒ Unable to use it within the home (e.g. not enough space, too large or bulky) 
❒ Stairs 
❒ Difficulty getting the wheeled walker in and out of the car 
❒ Too heavy 
❒ Didn’t use it because I was unwell and not able to walk 
❒ Others – please specify: ______________________________________ 
 




Figure 4-4: Questionnaire on the use and barr iers to using the wheeled walker .
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4.3 Data management and analyses 
4.3.1 Primary analyses 
All analyses were conducted using the Statistical Package for Social Sciences (SPSS 
version 18.0; Chicago, IL, US) with a probability value (p) ≤ 0.05 used to indicate 
statistical significance. Data are expressed as mean±standard deviation (SD) unless 
otherwise stated. Raw data from both motion sensors were exported into Excel® for 
further analyses. The assumption of normality was assessed using frequency 
histograms. Data that did not follow a normal distribution were analysed using non-
parametric statistical tests. Baseline characteristics of participants allocated to Group 
1 or 2 were compared using independent t-tests and Mann-Whitney U-tests for 
parametric or non-parametric data respectively. Gender and the use of ambulatory 
oxygen were compared between groups using Chi-squared analysis. Data are 
presented as mean±SD unless otherwise indicated. 
A linear mixed model was used to determine whether or not there was an order effect 
(i.e. whether group allocation had an impact on PA). The dependent variables were 
the outcomes measures from the motion sensors, namely, steps/day and time spent 
walking without a WW. Group allocation was the factor used in the analysis of fixed 
order effects. In the absence of an order effect, data from Group 1 and Group 2 were 
combined for the purpose of comparing outcomes between walking with a WW or 
without a WW. As these data were normally distributed, paired t-tests were used for 
the comparisons. The effect size was calculated for steps/day by dividing the 
difference in steps/day with the WW compared to without the WW by the pooled SD 
of the difference with and without the WW (203).  
4.3.2 Secondary analyses 
Secondary analyses were undertaken to explore factors that may have impacted on 
PA when the WW was provided. These factors comprised: (i) MMRC dyspnea 
grade, (ii) the use of ambulatory oxygen, (iii) 6MWD, (iv) the fear of falling, (v) 
gender and, (vi) the development of an acute exacerbation. These factors were 
selected based on data presented in earlier work as follows. A MMRC dyspnea grade 
of ≥ 3 categorises individuals with COPD who are markedly limited by dyspnea 
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during daily life (i.e. either needing to rest within 100 yards of walking or those who 
were too breathless to leave the house (225)). Compared with individuals with less 
marked limitation, those with an MMRC dyspnea grade of ≥ 3 have greatly reduced 
PA and thus may derive greater benefit from using a WW (106). The effect of 
ambulatory oxygen was investigated as the WW used in this study contains a basket 
that can be used to carry the oxygen cylinder. Hill et al (252) reported that a WW 
assisted 18 (67%) of the participants in their study who were on ambulatory oxygen 
to walk outdoors. The effect of 6MWD was explored as Solway et al (21) 
demonstrated that individuals with an unaided 6MWD of < 300 m had a greater 
increase in 6MWD when a WW was used compared with those who had a 6MWD of 
> 300 m (21). Regarding the fear of falling, a survey conducted on 266 elderly 
individuals found 78% of those who expressed a fear of falling curtailed their 
activities (264) and Solway et al (21) demonstrated that > 50% of the individuals 
with COPD felt safer when using a WW during the 6MWT. Therefore, using a WW 
may reduce the fear of falling and thus facilitate PA in individuals with COPD. 
Finally, the effect of gender on PA while using the WW was investigated as an 
earlier study that evaluated the effects of providing a WW for use in the home and 
community on HRQoL recruited slightly more women (58%) than men (178), 
suggesting that women may be more willing to participate in a study involving the 
use of a WW.  
In light of the results of these earlier studies, the magnitude of change in PA 
associated with WW use was compared between participants grouped as follows: (i) 
MMRC dyspnea grade 2 compared to 3 and 4, (ii) use (or not) of ambulatory oxygen, 
(iii) 6MWD < 300 m compared to ≥ 300 m, (iv) a fear of falling (score > 0) 
compared to no fear of falling (score = 0) and, (v) males compared to females. Given 
the limited sample sizes available for these analyses, they were undertaken using 
Mann-Whitney U tests.  
4.3.2.1 Sample size 
Sample size calculations were performed using data from a previous study of PA in 
individuals with COPD (9). A large population-based cohort study (n = 2,386) 
showed that a higher level of PA, equivalent to approximately ≥ 2 hours a week or   
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≥ 17 minutes a day, was associated with a 30 to 40% reduction in the risk of hospital 
admission and all-cause mortality in individuals with COPD (9). Using these data, a 
sample size of 19 participants was required in order to detect a difference in the 
average time spent walking each day with a WW of 17 minutes with a SD of            
34 minutes (alpha = 0.05 and 1-beta = 0.8) (263).  
4.4 Results 
4.4.1 Baseline characteristics 
Thirty-one individuals with COPD, who met the study criteria, were approached 
regarding participation. Of these, 12 (39%) declined to participate. A total of 19 
(61%) participants were recruited and randomised. Of these 19 participants, six 
(32%) were recruited from Sir Charles Gairdner Hospital, 11 (58%) from Bentley 
Hospital and one (5%) each from Royal Perth Hospital and Swan District Hospital. 
Baseline characteristics of the participants are summarised in Table 4-1. The 
majority of participants (n = 16; 84%) had severe or very severe airflow limitation 
(Global Initiative for Chronic Obstructive Lung Disease [GOLD] grade III [n = 6] or 
IV [n= 10] (56)) and markedly reduced 6MWD [243±85 m; 39±14 % predicted 
(247)]. Five (26%) participants required ambulatory oxygen and used the WW to 
transport their oxygen cylinder during supervised training and during the 5 weeks 
when allocated a WW at home. On completion of the PRP, 16 (84%) participants 
attended maintenance exercise classes once a week during the study period. The 
other three (16%) participants declined a referral to a maintenance class stating they 
preferred to continue with their exercises at home. Six (32%) participants had an 
exacerbation at some stage during their participation in the study: two (11%) of these 
participants had an exacerbation during the period when a WW was available and 
four (21%) had an exacerbation during the period when a WW was not available. 
These exacerbations were managed at home with antibiotic medications without the 
need for hospitalisation. The inclusion of those who had an exacerbation during the 
study period provides a more realistic estimate of the effect, given that many 
exacerbate with moderate-to-severe disease (265). One (5%) of the participants was 
hospitalised for 2 days for a gastroenterological condition during the period without a 
WW and removed the ActivPALTM, therefore his data were not included in the 
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analysis pertaining to ActivPALTM.  There were no significant differences in the 
baseline characteristics between participants allocated to Group 1 compared to Group 
2.
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Table 4-1: Character istics of the 19 par ticipants. 
 Group 1 (n=9) Group 2 (n=10) Total (n=19) 
Gender, n  5M / 4F 6M / 4F 11M / 8F 
Age (years) 75±6 70±9 72±8 
BMI (kg/m2) 25.1±5.2 25.0±5.8 25.0±5.4 
Smoking (pack years) 66±90 47±27 56±64 
MMRC dyspnea grade (0 – 4) 3 (2 to 3) 3 (2 to 4) 3 (2 to 4) 
BODE index (0 – 10) 6 (3 to 8) 6 (3 to 8) 5(3 to 8) 
Number using ambulatory O2 4 1 5 
Pulmonary Function 
FEV1 (L) 0.88±0.35 1.06±0.52 0.98±0.44 
FEV1 (% predicted)* 37±17 40±21 38±19 
FVC (L) 2.12±0.69 2.41±0.71 2.27±0.69 
FVC (% predicted)* 65±24 65±17 65±20 
FEV1/FVC ratio 0.42±0.13 0.43±0.12 0.43±0.12 
6-Minute Walk Test 
6MWD (m) 238±96 248±78 243±85 
% predicted 6MWD† 39±16 39±12 39±14 
Peak dyspnea 4 (3 to 8) 4 (2 to 6) 4 (2 to 8) 
Peak heart rate (bpm) 102±20 99±21 101±20 
Nadir oxygen saturation (%) 83±3 89±4 86±5 
Number who rested during test 9 9 18 
Number of rests  2 (1 to 2) 2 (1 to 2) 2 (1 to 2) 
Data are mean±standard deviation, median (interquartile range). *Predicted values 
based on National Health and Nutrition Examination Survey (NHANES) data (246). 
†Percent predicted based on regression equation published by Jenkins et al (247).  
BMI, body mass index; BODE, body mass index, airflow obstruction, dyspnea and 
exercise capacity index; bpm, beats per minute; F, female; FEV1, volume exhaled 
during first second of a forced expiration; FVC, forced vital capacity; kg, kilograms; 
L, litres; M, male; m, metres; MMRC, Modified Medical Research Council; n, 
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4.4.2 Effect of a wheeled walker on physical activity 
The following sections provide data pertaining to the effect of a WW on PA 
measured using the SAM and the ActivPALTM. Only data from the days when the 
SAM and the ActivPALTM were worn for at least 99% of the time were included in 
the analyses. For the SAM and ActivPALTM data, no order effect was found (F1, 16 = 
3.11; p = 0.10 and F1, 14 = 2.00; p = 0.18, respectively), thus data from both groups 
were combined for the analyses. 
4.4.2.1 Physical activity measured using the StepWatchTM Activity Monitor 
Fourteen (74%) of the 19 participants wore the SAM for at least 3 days during the  
5th week of each 5-week period. Of these 14 participants with valid PA data, four 
participants had an exacerbation or were hospitalised during the study period.    
Table 4-2 shows data for the mean number of steps/day and the time spent walking at 
low and moderate intensities. 
Compared with the period when the WW was not available, the mean number of 
steps taken daily significantly increased by 732±1,027 steps (p < 0.02) when the WW 
was available. This change was equivalent to an increase of 26 ± 36% compared with 
data collected when the WW was not available. The effect size for the change in 
steps taken daily was 0.2. The mean time spent walking at a moderate intensity 
increased by 9±13 min/day (p < 0.02) when the WW was available. This change was 
equivalent to an increase of 55±90% compared with data collected when the WW 
was not available. The mean time spent walking at a low intensity increased by 
18±36 min/day, which, whilst not significant, showed a statistical trend (p = 0.08). 
The magnitude of change in the mean number of steps/day and the time spent 
walking at low and moderate intensities was greater when the four participants who 
had an exacerbation or were hospitalized during the study period were removed in 
the subsequent analyses. Compared with the period when the WW was not available, 
the mean number of steps taken daily increased by 1,083±857 steps (p = 0.003) when 
the WW was available. This change was equivalent to an increase of 34±33%. The 
effect size determined was 0.26. The mean time spent walking at a moderate 
intensity increased by 13±12 min/day (p = 0.006). This change was equivalent to an 
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increase of 47±43% compared with measures collected when the WW was not 
available. There was an increase of 25±36 min/day in the mean time spent each day 
walking at a low intensity (p = 0.06). 
 
   
Table 4-2: Physical activity measured using the SAM with and without a wheeled walker  for  the 14 par ticipants with valid data. 
 Without WW  With WW With WW-Without WW p value 
 95% CI  
Number of days the SAM was worn 4.7±0.6 4.9±0.4 0.1±0.8 -0.3 to 0.6 0.50 
Number of hours (per day) the SAM 
was worn  
24.0±0.0 24.0±0.0 0.0±0.0 NA NA 
Steps/day 4,043±3,463  4,775±3,771  732±1,027  139 to 1,325 0.02 
 
Time walking at moderate intensity 
(min/day)  
40±43 49±49  9±13 
 
1 to 17 0.02 
Time walking at low intensity 
(min/day)  
156±51 175±62 18±36 
 
-3 to 39 0.08 
Data are mean±standard deviation. Probability (p) values pertain to comparisons of outcomes with a WW to without a WW. 
Moderate intensity walking was defined as > 15 steps/min. Low intensity walking was defined as ≤ 15 steps/min. 
CI, confidence interval; min, minutes; NA, not applicable; SAM, StepWatchTM activity monitor; WW, wheeled walker. 
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4.4.2.2 Physical activity measured using the ActivPALTM 
Sixteen (84%) participants wore the ActivPALTM for at least 3 days during the         
5th week of each 5-week period. Of these 16 participants with valid PA data, five 
participants had an exacerbation during the study period. Table 4-3 shows data for 
the mean time spent walking, standing as well as sitting and lying down.  
Compared with the period when the WW was not available, there was a trend for the 
mean time spent walking each day to increase by 7±16 min/day when the WW was 
available (p = 0.09). This trend was equivalent to an increase of 8±40% compared 
with measures collected when the WW was not available. The difference in mean 
time spent standing each day when the WW was available was 9±25 min/day. This 
difference was equivalent to 12±38% compared with measures collected when the 
WW was not available, but was not statistically significant (p = 0.18). The mean time 
spent sitting and lying down when the WW was not available did not differ from that 
measured when the WW was available (p = 0.11). 
The magnitude of change in the mean time spent walking, standing as well as sitting 
and lying down was greater when data from the five participants who had an 
exacerbation during the study period were removed from the analyses. Compared 
with the period when the WW was not available, there was a trend for time spent 
walking each day to increase by 10±17 min/day when the WW was available           
(p = 0.07). This trend was equivalent to an increase of 14±38% compared with 
measures collected when the WW was not available. The difference in mean time 
spent standing each day when the WW was available was 13±27 min/day. This 
difference was equivalent to a change of 20±44% compared with measures collected 
when the WW was not available, but was not statistically significant (p = 0.15). The 
mean time spent sitting and lying down when the WW was available decreased by 
23±34 min/day when compared to measures made when the WW was not available, 
just failing to reach statistical significance (p = 0.05). 
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Table 4-3: Physical activity measured using the ActivPALTM with and without a 





With WW-Without WW p 
value  95% CI 
Number of  days the 
ActivPALTM was worn 
4.9±0.3 5.0±0.0 0.1±0.3 -0.1 to 0.2 0.33 
Number of hours (per 
day) the ActivPALTM 
was worn 
24.0±0.1 24.0±0.0 0.0±0.1 0.0 to 0.01 0.14 
Time spent walking 
(min/day)  
37±32  44±37  7±16  
 
-1 to 16 0.09 
Time spent standing 
(min/day)  
189±151  180±144  9±25 
 
-4 to 22 0.18 
Time spent sitting and 
lying down (min/day) 
1,222±164 1,207±180 -15±35 -34 to 4 0.11 
Data are mean±standard deviation. Probability (p) values pertain to comparisons of 
outcomes with a WW to without a WW. CI, confidence interval; min, minutes; p, 
probability; WW, wheeled walker. 
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4.4.2.3 Secondary analysis of the participants grouped according to clinical 
characteristics that may have influenced the effect a wheeled walker has on 
physical activity 
The results of the secondary analyses that investigated the effect of various clinical 
characteristics on participants’ PA response to using a WW are presented in        
Table 4-4. Fourteen (74%) participants had valid data for ≥ 3 days for these analyses. 
Of the five factors investigated, functional limitation due to dyspnea (i.e. MMRC 
dyspnea grade) was the only factor which appeared to significantly influence the 
effect a WW had on the number of steps taken each day. Specifically, when the WW 
was available, participants with modest functional limitation due to dyspnea (i.e. 
MMRC dyspnea grade ≤ 2) decreased the number of steps taken each day by 
724±451 whereas those participants with more marked functional limitation due to 
dyspnea (i.e. MMRC dyspnea grade ≥ 3) increased the number of steps taken each 
day by 1,129±722. The difference in steps taken per day between these two groups of 
participants (MMRC dyspnea grade ≤ 2 compared to MMRC dyspnea grade ≥ 3) was 
significant (p = 0.01).  
4.4.3 Distance covered by the wheeled walker use 
Based on the odometer readings written by participants on their diary cards during 
the 5-week period the WW was provided, the WW was used by every participant at 
least three times a week and the mean distance recorded on the odometer was 
4,206±3,346 m/week. During the 5-day period during which the motion sensors were 
worn, the mean distance recorded on the odometer attached to the WW was   
958±805 m/day (95% confidence interval [CI]; 529 to 1,387 m/day). 
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Table 4-4: Steps taken per  day with par ticipants grouped according to clinical 
character istics. 











grade = 2  
(n = 3) 
MMRC dyspnea  
grade = 3 & 4  















(n = 10) 
On oxygen  











6MWD > 300m  
(n = 5) 
6MWD < 300m  











No fear of falling  
(n = 8) 
Fear of falling  











Gender (male)  
(n = 8) 
Gender (female) 











Data are median (interquartile range). (-) indicates that interquartile range was not 
determined due to small samples, i.e. n ≤ 3. 
MMRC, Modified Medical Research Council; p, probability; WW, wheeled walker; 
6MWD, 6-minute walk distance.
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4.4.4 Effect of a wheeled walker on health-related quality of life 
Eighteen (95%) of the 19 participants completed the CRDQ at the end of each         
5-week period. Compared with the period when the WW was not available, the 
magnitude of change in all domains of CRDQ when the WW was available did not 
reach statistical significance (Table 4-5). The magnitude of change associated with 
using a WW was also below the threshold for the minimal clinically important 
difference of 0.5 points per item determined for the domains of the CRDQ (41). 
4.4.5 Effect of a wheeled walker on fear of falling 
The SAFE scale only classifies individuals as fearful versus non-fearful. Nine (47%) 
of the 19 participants expressed a fear of falling (i.e. scored > 0 on the SAFE scale). 
The use of a WW reduced this fear in seven of these nine participants (78%). 
Amongst these seven participants who reported a reduction in the fear of falling, 
using the WW conferred gains in each domain of the CRDQ that exceeded the 
minimal clinically important difference. Specifically, compared with measures 
collected when the WW was not available, the domains of dyspnea, fatigue, 
emotional function and mastery improved by 1.1±1.3, 0.5±1.6, 0.5±1.0 and 0.6±1.3 
points per item respectively when the WW was available. However, none of these 
improvements were statistically significant. Two (11%) of the 19 participants 
reported activity restriction due to a fear of falling, but this fear was absent during 
the period when the WW was available. 
4.4.6 Barriers towards the use of a wheeled walker 
Table 4-6 lists the reported barriers to using a WW. Five (45%) of the 11 males and 
five (63%) of the eight females found that lifting a WW in and out of the car was the 
greatest barrier. Three (16%) participants (two males and one female) reported that 
they felt embarrassed using a WW.
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Table 4-5: Health-related quality of life with and without a wheeled walker  for  
the 18 par ticipants. 




With WW-Without WW  p 
value Mean±SD 95% CI 
Dyspnea  3.0±0.8 3.4±1.3 0.4±1.1 
 
-0.1 to 0.9 0.13 
Fatigue  3.7±1.5 4.1±1.3 0.4±1.3 
 
-0.3 to 1.0 0.25 
Emotional function 5.1±1.1 5.2±1.1 0.1±1.0 
 
-0.3 to 0.6 0.58 
Mastery  4.7±1.5 5.0±1.3 0.3±1.0 
 
-0.2 to 0.8 0.23 
Total score 4.2±1.0 4.5±0.9 0.3±0.9 -0.2 to 0.7 0.21 
Data are mean±standard deviation and expressed as points per item. Probability (p) 
values are presented for the comparison for CRDQ domains with a WW to without a 
WW. CI, confidence interval; HRQoL, health-related quality of life; WW, wheeled 
walker.
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Table 4-6: Reported barr iers towards the use of a wheeled walker . 
Barriers Number (%) of 
participants 
Difficulty getting WW in and out of the car 10 (53) 
Unable to use at home due to space constraints 6 (32) 
Preferred using a trolley at the shops 3 (16) 
Loss of independence 1 (5) 
WW, wheeled walker.
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4.5 Discussion 
This is the first study to evaluate the effect of a WW on PA in selected individuals 
with moderate to severe COPD. The most important finding of this study was that, in 
this population, having a WW available for use at home and in the community 
conferred a significant increase in the number of steps taken per day as well as the 
time spent walking at a moderate intensity. However, the use of the WW did not 
significantly impact on HRQoL as assessed using the CRDQ. This study also 
demonstrated that most of the participants who expressed a fear of falling found that 
using a WW reduced this fear. The main barrier for the use of a WW among the 
participants was lifting the WW in and out of the car.  
In this study, outcomes of PA were measured in several ways, including steps, and 
time spent walking, standing as well as sitting and lying down. The significant 
increase in the mean number of steps taken each day when a WW was provided, 
despite no significant change in the mean time spent walking, indicated that the 
increase in steps/day was likely the result of an increased pace of walking. In a 
published article on the measurement properties of the two motion sensors used in 
this study (Chapter 3), walking with a WW reduced the number of steps taken 
significantly as compared to walking unaided (240). Thus, a decrease in stride length 
when walking with a WW was unlikely to explain the increase in steps taken daily.  
The effect size quantifies the effectiveness of the use of a WW. In this study, the 
effect size determined for steps/day was 0.20, which is considered small (203). This 
effect size remained small (0.26) when data from those participants who had an 
exacerbation during the study period were excluded from the analyses. This finding 
of a change in the mean number of steps taken each day when using a WW is 
particularly notable given that previous studies of interventions aimed at increasing 
PA in individuals with COPD have demonstrated little or no benefit. For example, 
one study found that providing ambulatory oxygen for use in the home had no 
significant impact on PA despite a gradual increase in oxygen usage over an 8-week 
period (162). Furthermore, a meta-analysis on the effect of supervised exercise 
training programs in individuals with COPD, lasting between 6 weeks and 6 months, 
found only a trivial improvement in PA (effect size of 0.12) equivalent to an increase 
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of approximately 5 minutes of walking time per day (55). In this meta-analysis, 
providing supervised exercise training at least three times a week for a minimum of 8 
weeks and extending the intervention period for those who had an exacerbation, were 
suggested to increase the likelihood of demonstrating a positive effect on PA (55). 
However, there were no published RCTs in this meta-analysis (55). The study by de 
Blok et al (31), which had a 9-week comprehensive PRP as an intervention, was the 
only randomised trial to demonstrate an actual effect size and the reported 
improvement of 673 steps/day is similar to the results of the present study. That is, 
providing a device like a WW over a short period of 5 weeks was as effective as that 
of a 9-week comprehensive PRP that required a considerable level of commitment 
and personal investment.  
The only other intervention that has significantly increased PA in individuals with 
COPD is lung transplantation. In a cross-sectional study by Bossenbroek et al (166), 
lung transplant recipients were significantly more active compared to lung transplant 
candidates. Langer et al (167) found that the participants who did not participate in a 
supervised exercise training 3 months after lung transplantation, increased the 
number of daily steps by 750; a change of similar magnitude to that found in this 
study. However, lung transplantation is a costly, risky invasive surgical procedure 
that is available for only a minority of individuals with end stage COPD (266). In 
comparison, a WW is inexpensive and risk free, thus providing a WW that resulted 
in a similar change in daily steps as lung transplantation would be an alternative to 
improve PA in the majority of individuals with COPD with significant functional 
limitation due to dyspnea. Nevertheless, this comparison should be guarded as lung 
transplantation candidates had end stage COPD, unlike the participants in this study 
who were categorised as having moderate or severe COPD. 
In the secondary analyses, the only factor which appeared to influence the effect a 
WW had on the magnitude of change in PA was the extent of functional limitation 
due to dyspnea. Participants with a MMRC dyspnea grade ≥ 3 increased their 
steps/day significantly more than those with a MMRC dyspnea grade 2. This 
improvement observed in those participants with a MMRC dyspnea grade ≥ 3 is 
important as Watz et al (106) demonstrated a progressive reduction in PA with 
increasing MMRC dyspnea grade in individuals with COPD. The reasons why 
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individuals with greater functional limitation due to dyspnea appeared more likely to 
increase the number of steps taken per day when using a WW may be due to the 
physiological benefits of the forward lean with arm bracing position as well as the 
reduction in metabolic cost of walking with a WW (23, 24). The fact that the WW is 
equipped with a seat allowing participants to have a seated rest when required (as in 
those individuals with COPD who graded themselves as MMRC dyspnea grade ≥ 3) 
might also have explained the ability of participants to walk further, but the number 
of seated rests taken was not able to be measured in this study. Thus, an individual’s 
need for a rest due to intolerable dyspnea, after walking for only a few minutes, may 
be an important criterion for physiotherapists to consider when deciding whether to 
recommend a WW to individuals with COPD with the aim of increasing PA. This 
finding is supported by the study by Solway et al (21) where the need to rest during 
an unaided 6MWT was a significant predictor of improved 6MWD and perception of 
dyspnea when a WW was used. 
The three participants with a MMRC dyspnea grade 2 had a reduction in mean 
steps/day when a WW was provided. This result probably reflects that two of the 
three participants (67%) experienced an acute exacerbation of their COPD during the 
WW 5-week period. In the primary analysis, the magnitude of change in PA was 
greater when the participants who had an exacerbation were removed from the 
analysis. Given that  exacerbations have been shown to reduce daily activity in 
individuals with COPD, both during the exacerbation and after recovery (36), this 
finding was unsurprising.  
We found that the use of a WW had no significant impact on the domains of the 
CRDQ. This is consistent with the findings of Gupta et al (178). However, Gupta et 
al (178) found a higher score in the mastery domain of the CRDQ in those who used 
the WW at least three times a week during their 8-week study period compared to 
those who used the WW infrequently (5.2±0.8 versus 4.7±0.6 points per item,           
p = 0.014). Based on their activity diary, the participants in the present study used the 
WW frequently (at least three times a week). Thus, while frequency of use in the 
current study was acceptable, it is possible that the 5-week study period might have 
been too short to register an improvement of HRQoL with the use of a WW. 
Sandland et al (162) found in an 8-week RCT investigating the  provision of 
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ambulatory oxygen following 7 weeks of rehabilitation, no significant change in 
CRDQ. This suggests that participants may require more time to realise any benefit 
in HRQoL following interventions that require no effort from them, such as the 
provision of ambulatory oxygen (162), or in this study, a WW. 
In this study, the majority of the participants who expressed a fear of falling found 
the use of the WW reduced this fear. However, no change was observed in PA in 
these individuals when provided with a WW. This implies that although the fear of 
falling was reduced when using a WW, this did not necessarily empower individuals 
with COPD to be more active. The issue of falls is important in this population, as 
falls have negative consequences for older adults such as activity avoidance, 
fractures and even death (267). Individuals with COPD are at increased risk of falls 
for several reasons including muscle weakness, multiple medications and reduced PA 
(26). Furthermore, individuals with COPD have a higher prevalence of osteoporosis 
than those without COPD (268), increasing their risk of fall-related fractures (25). 
The fear of falling has been shown to result in a loss of autonomy and thus limit 
activity, which in turn can reduce quality of life (269). A study by Beauchamp et al 
(270) demonstrated that reduced confidence in performing activities without losing 
balance was a predictor of falls risk in individuals with COPD. The present study 
demonstrated that the use of a WW reduced the fear of falling in most individuals 
with COPD. It is likely that is also improved balance confidence and might play a 
role in reducing falls. Thus, although it is possible that the use of a WW reduced falls 
risk in these study sample of individuals with COPD, the impact of this reduced falls 
risk on PA was not significant.  
In this study, only three (16%) participants felt embarrassed using a WW during their 
daily life. This percentage is lower than that reported in earlier work where 19% to 
48% of participants felt embarrassed about using a WW (252, 271). Embarrassment 
using the WW appeared to be related to it being viewed as a visual indication of 
disability and aging (271). The fact that participants in the present study underwent a 
period of familiarisation with the WW during supervised walking training may have 
contributed to the low number of participants reporting that they felt embarrassed 
using a WW. 
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Barriers to using the WW in the current study included difficulty getting the WW 
into and out of the car and an inability to use it home at due to space constraints. 
These findings are similar to those reported previously (252). Specifically, in the 
study by Hill et al (252), 15 (56%) individuals reported difficulty moving the WW 
into and out of the car independently. These barriers could be overcome by reducing 
the weight of the WW using light weight yet durable materials and having smaller 
wheels. 
4.5.1 Implications 
Providing a WW to suitable individuals with COPD and familiarising them with the 
use of the WW during supervised walking training as part of a PRP has the potential 
to increase the number of steps taken each day and the time spent walking at a 
moderate intensity. Given these results, using a WW during the walking training 
component of a PRP may enable some individuals with COPD to increase their 
walking pace and might therefore be a useful training adjunct, particularly in those 
with the marked functional limitation due to dyspnea.  
4.5.2 Limitations 
The major limitations of this study related to the small sample size for some of the 
analyses and the fact that the participants in this study were highly selected. A larger 
sample size of a broader spectrum of COPD severity would have been beneficial. 
However, the sample size was sufficient to demonstrate a significant difference in 
steps taken per day when the WW was available. Despite the increase in the number 
of average daily steps taken, there was no change in time spent in sedentary 
behavior, namely time spent supine, sitting or standing. This suggests that additional 
strategies are required to reduce sedentary behavior. Although the participants were 
highly selected, they were representative of individuals with COPD who undergo 
pulmonary rehabilitation. The duration of 5 weeks to establish the effect of a WW on 
HRQoL may have been insufficient. 
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4.6 Conclusion 
To date, this is the only study to show an increase in the number of steps taken per 
day and the time spent walking at a moderate intensity when a WW was provided to 
selected individuals with COPD who had used it previously during supervised 
exercise training. The use of a WW had no significant impact on HRQoL, a finding 
which may be attributed to the short duration of 5 weeks where the participants had a 
WW. The main barrier towards the use of a WW was difficulty lifting the WW into 
and out of the car. 
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CHAPTER 5 
WALKING AND FEEDBACK TRAINING (WAFT) 
5.1 Overview 
This chapter summarises the data pertaining to a multi-centre randomised controlled 
trial (RCT) of an 8-week ground walking training program conducted in Sydney, 
New South Wales and Perth, Western Australia. The methodology employed in the 
trial is described in detail within this chapter. The reporting of outcome data is 
restricted to those variables which are relevant to the doctoral program of research 
presented in this thesis. The data reported in this chapter are further analysed in the 
following chapter to determine the minimal detectable difference (MDD) for 
endurance shuttle walk test (ESWT) performance (Chapter 6). 
Pulmonary rehabilitation has been shown to be effective in increasing exercise 
capacity, improving health-related quality of life (HRQoL) and reducing hospital 
admissions in individuals with chronic obstructive pulmonary disease (COPD) (5). In 
pulmonary rehabilitation, exercise training is of paramount importance (5). The 
lower limb muscles in individuals with COPD are weak and metabolically inefficient 
(28), thus endurance exercise of the leg muscles, such as walking (ground-based or 
treadmill) and stationary cycling is an essential component of exercise training 
during pulmonary rehabilitation (5). Walking training is particularly suitable as a 
method of exercise training for individuals with COPD as it is an activity that is part 
of their daily lives (29), inexpensive as no specialised equipment is required, serves 
as a form of transport and protects against mobility loss in older adults (30).  
Walking exercise has been recommended to be incorporated into the exercise 
training component of pulmonary rehabilitation (5). There are only six randomised 
studies that examined the effectiveness of ground walking training as the sole 
training modality in individuals with COPD (40, 192, 272-274). 
In the first randomised study, one of the intervention group was doing solely 20 
minutes of ground walking training in which the intensity was not specified, yet 
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reported a significant improvement in 6-minute walk distance (6MWD) of 122 m 
after 8 weeks of training (40). The second randomised study prescribed the intensity 
of ground walking training at 70% of the maximum speed attained on the 
incremental shuttle walk test (ISWT), demonstrated no change in incremental shuttle 
walk distance (ISWD) after 12 weeks of training (272). In these two studies, the 
walking training was unsupervised. The third study that prescribed unsupervised 
ground walking at an intensity of approximately 3 to 4 km/h demonstrated no 
significant change in peak rate of oxygen consumption (VO2peak) after 8 weeks (273). 
The fourth study randomised participants after recovery from an exacerbation of 
COPD to supervised walking training or a control arm (192). The walking training 
group covered 125% of their best 6MWD performed on a treadmill in a 15 minute 
period three times a day and improved their 6-minute walk distance (6MWD) at the 
3- and 6-month assessment (192).The fifth study had participants walking at 80% of 
their estimated VO2peak derived from the ISWD. The group who undertook walking 
training paced by music installed on a cell phone showed a significant improvement 
in their ISWD at 8-week period compared to the group who undertook walking 
training without pacing (274). In the sixth study, the participants randomised to 
ground walking at an intensity of 75% of the peak walking speed achieved in the 
ISWT improved ESWT performance to a greater extent than occurred in a group 
randomised to supervised cycling training (39).    
Of the above studies that have examined ground walking training as the sole training 
modality in individuals with COPD, one used a very small sample size (n = 6) (40), 
and in four studies, the training was unsupervised so the exercise intensity was not 
controlled (192, 272-274). Although the last study (39) included supervised walking 
training, it had a small sample of participants in the walking training group (n = 17) 
and the cycling training group (n =15) to compare. 
Despite the strong evidence that supervised exercise training reduces dyspnea and 
fatigue (5, 6), increases exercise capacity as well as improves HRQoL (5-7), the 
impact on physical activity (PA) seems modest. Exercise training is muscle and 
activity specific. Walking training has been shown to improve outcomes in field 
walking tests to a greater extent than cycling training (39) and upper limb training 
(40). Thus, it is possible that walking as a sole modality of exercise training may 
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confer greater gains in daily PA than other exercise modalities such as cycling as 
walking is an integral part of daily life for individuals with COPD (9). 
In summary, there is little evidence that supervised, individually tailored ground 
walking training alone, in which the exercise intensity is progressed with the aim of 
achieving optimal training responses, is effective at improving exercise capacity and 
PA in individuals with COPD. This gap in evidence is important to address as, if 
found to be effective, a walking program has the advantage that it is low cost and 
requires few resources. This in turn would support the widespread establishment of 
walking training programs, particularly in rural and remote areas, as well as in 
programs run in metropolitan areas. This would potentially provide a large number of 
individuals with COPD access to such programs, which could be conducted 
independent of expensive exercise equipment.  
The current study was part of a multi-centre trial conducted in Sydney, New South 
Wales and Perth, Western Australia, examining the effect of supervised ground 
walking training on the exercise capacity and HRQoL of individuals with COPD. 
The study had two primary aims. The first aim was to evaluate the effect of short-
term, supervised, individually tailored, ground walking training compared to usual 
care in individuals with COPD, on exercise capacity and HRQoL. The second aim 
was to evaluate whether, after the short-term walking training, the use of feedback, 
progressive goal setting and participant support during a program of long-term home-
based walking training could maintain any gains conferred in exercise capacity and 
HRQoL compared to simple instructions about maintaining regular exercise. The 
findings of this study in relation to these two aims forms the basis of a thesis by a 
PhD student enrolled at the University of Sydney. The remainder of this chapter 
summarises the findings of the study that are relevant to the doctoral program of 
research presented in this thesis; namely, the impact of a short-term, supervised, 
individually tailored, ground walking training as a sole exercise modality on ESWT 
performance and PA in individuals with COPD. 
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5.2 Methodology 
5.2.1 Overall aim 
The aim of this study was to examine the magnitude of change in clinical outcomes 
such as functional exercise capacity and PA after a short-term, supervised, 
individually tailored, ground walking training program in individuals with COPD.  
5.2.2 Research questions 
i. Does an 8-week supervised, individually tailored, ground walking training 
program change ESWT performance in individuals with COPD? 
ii. Does an 8-week supervised, individually tailored, ground walking training 
program change PA in individuals with COPD? 
5.2.3 Research hypotheses 
In individuals with COPD, functional exercise capacity, namely ESWT performance, 
as well as PA will improve after participating in an 8-week supervised, individually 
tailored, ground walking training program. 
5.2.4 Study design 
A prospective, single-blind, RCT was undertaken with participants randomised into 
one of three groups: a walking training group (WG), a walking training with post-
training feedback group (WFG) and a usual care group. Both the WG and WFG 
underwent an identical ground walking training intervention over an 8-week period. 
All participants were recruited from Sydney or the Perth metropolitan area. After the 
8-week period, the participants in both the WG and WFG were followed up over a 
12-month period. The participants in the WG were provided with written instructions 
to walk 45 minutes on at least 3 days a week and a weekly diary to record the 
duration of each walk. The participants in the WFG received biofeedback in the form 
of a pedometer and regular phone calls to set goals and provide support, in addition 
to the same written instructions and weekly diary to record the steps taken during 
each walk. However, this long term study form the basis of a thesis by the PhD 
student enrolled at the University of Sydney and will not be included in this thesis.  
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5.2.5 Ethical approval 
In Sydney, approval to conduct the study was granted by the Human Research Ethics 
Committees of the University of Sydney (2012/523), Royal Prince Alfred Hospital 
(HREC 09/RPAH/31), Manly Hospital (1008-306M), Concord Hospital 
(09/CRGH/70), Hornsby Hospital (0907-192M) and Prince of Wales Hospital (09-G-
055). In Perth, approval to conduct the study was granted by the Human Research 
Ethics Committees of Curtin University (HR 50/2009), Sir Charles Gairdner Hospital 
(2009-026), Bentley Hospital (S/10/320) and Royal Perth Hospital (RA-10/010). 
Written, informed consent was obtained from all participants. The study was 
registered with the Australian New Zealand Clinical Trials Registry 
(ACTRN12609000472279). 
5.2.6 Participants 
All participants were recruited from patients who had been referred to the pulmonary 
rehabilitation programs (PRP) in Sydney and Perth. The inclusion criteria comprised 
aged > 40 years, medical diagnosis of COPD and a smoking history of ≥ 10 pack-
years. The number of pack years was defined as the number of cigarettes smoked per 
day divided by 20, then multiplied by the number of years that the participant had 
smoked (58). Exclusion criteria comprised: (i) musculoskeletal, cardiovascular or 
neurological conditions likely to adversely affect performance during assessments or 
training, (ii) participation in supervised exercise training within the last 12 months, 
(iii) prescription of long term oxygen therapy or ambulatory oxygen during exercise 
training, (iv) inability to maintain an oxygen saturation > 83% during the ESWT and, 
(v) body mass index > 35 kg/m2. 
Participants were randomly allocated to groups using a computer-generated random 
number sequence with stratification for: (i) location (Sydney or Perth) and hospital, 
(ii) total score obtained on the Saint George’s Respiratory Questionnaire (SGRQ) 
(score < 45 or ≥ 45), (iii) disability level based on 6MWD (≤ 70% or > 70% 
predicted normal value [(247)]) and, (iv) severity of COPD (volume exhaled during 
the first second of a forced expiration [FEV1] < 40% or ≥ 40% predicted normal 
value) (246). 
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All participants had their medical management optimised at baseline in accordance 
with the COPD-X Plan (275). This included a COPD action plan with the aim of 
educating participants about managing their condition when stable and during an 
exacerbation (275). Participants randomised to the usual care group did not perform 
any exercise training and were not given any instructions regarding exercise. At the 
end of the 8-week period these participants were offered the standard PRP, at which 
point their involvement in the study ceased. 
5.2.7 Walking training 
The initial training intensity prescribed was equivalent to 80% of the average 
walking speed achieved during the better of two 6-minute walk tests (6MWTs) (169, 
276). The 6MWT represents a maximal or near maximal symptom-limited test in 
individuals with moderate to severe COPD (277, 278), thus data from the 6MWT can 
be used to prescribe the intensity for walking training (169).This prescription was 
consistent with evidence-based guidelines (5) which recommend that exercise 
training, in order to achieve an adequate training stimulus, should be performed at a 
high-intensity, at least three times a week for 20 to 60 minutes per session (279), at 
an intensity exceeding 60% of peak exercise capacity (6). The training intensity used 
in this study was appropriate for individuals with COPD (169) and has demonstrated 
efficacy as measured by an improvement in 6MWD and HRQoL (276, 280). Across 
the training sites, the walking program took place on flat walking tracks that ranged 
in lengths from 26 to 100 m. Each participant was given an individualised goal 
representing the number of track lengths to complete for a set duration (Appendix C) 
(280). The track length was consistent for each individual.   
The 8-week exercise program consisted of either three supervised sessions a week, or 
two supervised sessions and one unsupervised exercise session a week for 
individuals who were unable to commit to travelling to the hospital three times a 
week for supervised training. This resulted in a maximum of 24 training sessions 
(supervised and unsupervised). The unsupervised sessions were recorded in a diary. 
This number of exercise sessions has been shown to be sufficient to confer a benefit 
in HRQoL and 6MWD (281) for most patients with moderate to severe COPD 
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(Global Initiative for Chronic Obstructive Lung Disease  [GOLD] grade II –IV, (56)) 
and dyspnea (Modified Medical Research Council [MMRC] dyspnea grade 2-4).  
In the event of a respiratory exacerbation, training was postponed until the 
participant was clinically stable (275). An exacerbation was defined as a sustained 
worsening of the patient’s symptoms from his or her usual stable state that was 
beyond normal day-to-day variations, was acute in onset and necessitated a change in 
regular medication (282). If participants had an exacerbation or were unwell, the 
training period was extended to a maximum of 10 weeks to allow participants to 
complete a minimum of 16 sessions (supervised and unsupervised).  
Participants were permitted to take short rests during walking training in the event of 
intolerable symptoms. The total exercise time (excluding rests) was 30 minutes at the 
commencement of walking training. This was progressed by increasing the distance 
walked during training by increasing the duration of exercise by 5 minutes after 
every sixth session to a maximum of 45 minutes by session 19. A constant walking 
pace was maintained during each walking training session. During walking training, 
a rating of three (moderate breathlessness) to four (somewhat severe) on the 
modified Borg scale for dyspnea (283) was used to titrate exercise intensity. Once 
the required duration was reached, if symptoms permitted, the intensity of exercise 
was increased by increasing walking speed or, if walking speed became limited by 
stride length, progression was achieved by adding weights in 2 kg increments worn 
on a waist belt.  
Percutaneous oxygen saturation and pulse rate were measured before and after 
walking training using a hand-held pulse oximeter (Respironics/Novametrix 513, 
Murrysville, Pennsylvania, United States [US] or RAD-5v, Masimo Corp, Irvine, 
California, US). Ratings of perceived dyspnea (283), perceived exertion and leg 
fatigue (284) on a scale of 0 to 10, were recorded at the conclusion of each training 
session.  
5.2.8 Outcome measures 
In all participants, the outcome measures were assessed before and immediately after 
the 8-week intervention period. All assessments following the intervention period 
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were performed by a research assistant who was blinded to the participant’s group 
allocation. Participants were instructed not to reveal their group allocation to the 
research assistant.  
The sequence of exercise testing and administration of questionnaires is shown in 
Figure 5-1. Both before and after the intervention period, assessments were 
completed over 2 days separated by at least 24 hours. In total, three exercise tests and 
four questionnaires were completed (Figure 5-1). On the first day of assessment, the 
participant’s medical history (including smoking history) was recorded, and height, 
weight and spirometry (EasyOne Plus, new Diagnostic Designs Medical 
Technologies Inc., Andover, Massachusetts, US) were measured. Both before and 
after the 8-week intervention period, a SenseWear armband (BodyMedia Inc., 
Pittsburgh, Pennsylvania, US) was given to all participants on the second day of 
testing with instructions to wear the armband for 7 complete days.    
5.2.8.1 Exercise capacity 
Three field walking tests, namely the ISWT, ESWT and 6MWT were used to 
measure exercise capacity. Each of these field walking tests was repeated twice 
(Figure 5-1). These tests are responsive to change following exercise training in 
individuals with COPD (7, 44, 285). During the walking tests, percutaneous oxygen 
saturation using a hand-held pulse oximeter with a finger probe 
(Respironics/Novametrix 513, Murrysville, Pennsylvania, US or RAD-5v, Masimo 
Corp, Irvine, California, US) and heart rate (Polar a1 heart rate monitor; ©Polar 
Electro, Kempele, Finland) was continuously monitored. The ISWT was performed 
over a 10 m course and externally paced with walking speed increasing every minute 
(286). The ESWT was performed on the same track as the ISWT at a speed 
equivalent to 85% of the participant’s VO2peak estimated from the distance walked 
during best of two ISWTs (287). The 6MWT was performed in accordance with 
published guidelines (243), but modified to include standardised encouragement 
every 15 sec during rests (288). Dyspnea was measured using the modified Borg 
scale before each walking test (283). At the end of each walking test, dyspnea, rating 
of perceived exertion and leg fatigue (284) on a scale of 0 to 10 were recorded. Data 
from the best test (i.e. maximum distance walked) were used in the analyses. Each 
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test was separated by a 30-minute rest period to allow recovery from dyspnea and 
fatigue elicited from the previous test (169, 243).  
Within this chapter, only data relating to the change in ESWT and PA are reported in 
detail. The rationale for selecting the ESWT as the primary outcome measure is 
provided in the following paragraph. 
Endurance shuttle walk test 
The ESWT is an externally paced, constant workload field walking test that has been 
shown to be more responsiveness than other field-based assessments of exercise 
capacity (285, 287). The ESWT is performed over a 10 m course (287). Participants 
were instructed to walk around two cones, positioned 0.5 m from each end, following 
the speed dictated by an audio signal. The ESWT was performed at a walking speed 
equivalent to 85% of the participant’s VO2peak. This VO2peak was predicted from the 
distance walked during best of two ISWTs, using the equation: 4.19 + (0.025 x 
ISWD) (287). The walking speed and level for the ESWT that corresponded to 85% 
of the predicted VO2peak was determined using a graph of the relationship between 
predicted VO2peak (ml/min/kg) and ESWT walking speed (km/h). The ESWT has a 
total of 16 levels, each relating to a specific walking speed, ranging from 1.78 km/hr 
to 6 km/hr. Dyspnea (modified Borg scale) (283) and rating of perceived exertion 
(284) on a scale of 0 to 10 were recorded at the end of each minute during the test. 
The ESWT was terminated if participants were not able to keep up with the speed 
after being given a warning to keep pace when they were behind the speed for the 
first time (e.g. due to dyspnea or leg fatigue). Each participant performed two 
ESWTs which were performed on separate days as two ESWTs performed on the 
same day has demonstrated little variability (289), which could be due to fatigue or 
boredom with the test. As the ESWT was the last walking test conducted on the first 
day of testing, having the ESWT as the first walking test on a separate day could 
negate fatigue, boredom or learning effect. The ESWT has a pre-determined 
maximum duration of 20 minutes (287). A study by Revill et al (287) found that 
seven (30%) of their 21 participants walked for more than 17 minutes on the ESWT 
at their baseline assessment prior to pulmonary rehabilitation. Further, in another 
study, six (35%) participants with COPD reached the 20-minute completion time of 
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the ESWT at the end of a walking training program (39). Thus, in an attempt to avoid 
a ‘ceiling effect’ (i.e. participants reaching the 20-minute maximum post-training), 
any participant who, at baseline, was able to complete more than 5 minutes on the 
ESWT and expressed that this pace was comfortable and had the ability to continue 
walking, had their ESWT intensity increased to the next level. The higher level or the 
faster speed of the ESWT was selected for post intervention ESWT.  
5.2.8.2 Health-related quality of life 
The SGRQ and interviewer-administered Chronic Respiratory Disease Questionnaire 
(CRDQ) with an individualised dyspnea domain were used to measure HRQoL. In 
the individualised dyspnea domain of the CRDQ, the participants were asked at 
baseline to elicit the five most important activities during which they had 
experienced dyspnea in the past weeks and these activities were used during the 
administration of CRDQ post intervention period. The SGRQ measures symptoms, 
activities and impact (214), while the CRDQ measures dyspnea, fatigue, emotional 
functioning and mastery (213). Both have been shown to be valid, reliable and 
responsive to changes following exercise training in participants with COPD (290, 
291). The changes in HRQoL outcomes following the intervention period are not 
reported in this chapter as they are not related to the aims of this thesis. 
5.2.8.3 Anxiety and depression 
Anxiety and depression were measured using the Hospital Anxiety and Depression 
Scale (HADS) (292). Scores range from 0 (no anxiety or depression) to 21 
(maximum score for anxiety or depression) (293). The HADS has been shown to be 
responsive to exercise interventions in individuals with COPD (218). The changes in 
HADS scores following the intervention period are not reported in this chapter as 
they are not related to the aims of this thesis. 
5.2.8.4 General self-efficacy 
Self-efficacy was measured using a validated General Self-efficacy Scale         
(GSES-12). This consisted of 12 items, subdivided into initiative, effort and 
persistence subscales (294). Scores range from 3 to 15 for the initiative subscale, 5 to 
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25 for the effort subscale and 4 to 20 for the persistence subscale; with higher scores 
indicating greater self-efficacy (295). The changes in GSES-12 scores following the 
intervention period are not reported in this chapter as they are not related to the aims 
of this thesis. 
5.2.8.5 Physical activity 
Daily PA was measured using the SenseWear armband (version Pro 3). The rationale 
for selecting PA as the secondary outcome measure was to determine whether 
supervised ground walking training could result in an increase in activity compared 
to usual care.  
Participants wore the SenseWear armband (Figure 5-2) on the bulk of the triceps 
brachii muscle of the right arm over 9 days, however, the data collected during the 
first and last day were excluded as measures were not available over a full 24 hour 
period (148). The SenseWear armband measures 2.4 by 8.8 by 5.6 cm, weighs 82 g 
(135), and is a portable metabolic monitor that integrates bi-axial accelerometry with 
non-invasive physiologic sensors that detect galvanic skin resistance, heat flux, body 
temperature and near body ambient temperature (138). The SenseWear armband has 
been shown to provide accurate data when measuring energy expenditure in 
individuals with COPD, while undertaking five tasks comprising supine lying, 
sitting, standing and walking at two different speeds (13). The SenseWear armband 
has also been shown to be able to detect small changes in average energy expenditure 
resulting from a moderate increase in average walking speed of 14 m/min (13). 
Studies pertaining to the use of the SenseWear armband have been reviewed in 
Chapter 2 (part 2). The SenseWear armband, being a multi-sensor motion device, is 
able to estimate energy expenditure across a spectrum of activities of daily living 
compared to a uni-axial motion sensor such as the ActivPALTM or a step counter such 
as the StepWatchTM Activity Monitor. Data provided by the SenseWear armband 
comprised total energy expenditure (TEE) in kilocalories, steps per day and active 
energy expenditure (AEE) in kilocalories (kcal). Only data from days when the 
SenseWear armband was worn for at least 85% of the time were included in the 
analyses. 
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A position statement by American College of Sports Medicine (ACSM) defined 
moderate intensity activity for adults aged ≥ 65 years as requiring between 3.2 to 4.7 
metabolic equivalents (METs) (99). Thus, in this study, PA above 3 METs was used 
as a cut-off point to define AEE for individuals with COPD.  
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Figure 5-1: Sequence of walking tests and questionnaires on the two separate 
days pre and post 8-week per iod. 
* This questionnaire was only given at the end of the 8-week period. 
CRDQ, Chronic Respiratory Disease Questionnaire; ESWT, endurance shuttle walk 
test; GSES, General Self-efficacy Scale; GRC, Global Rating of Change; HADS, 
Hospital Anxiety and Depression Scale; ISWT, incremental shuttle walk test; SGRQ, 
Saint George’s Respiratory Questionnaire; 6MWT, 6-minute walk test.
Sequence of tests and questionnaires 
conducted on 1st day: 
1. ISWT 1st test 
2. HADS 
3. GRC scale for walking 
ability and activity level* 
4. ISWT 2nd test 
5. SGRQ 
6. ESWT 1st test 
Sequence of tests and questionnaires 
conducted on 2nd day: 
1. ESWT 2nd test 
2. CRDQ 
3. 6MWT 1st test 
4. GSES 
5. 6MWT 2nd test 
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Figure 5-2: SenseWear armband worn on the r ight arm.
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5.2.8.6 Global rating of change 
A global rating of change (GRC) scale was used for participants to rate if they had 
improved or worsened in their walking ability (Appendix D) and PA (Appendix E) 
over time (45). This was administered after the 8-week intervention period to all 
participants.  
For walking ability, participants were asked “Since you started this research 
program, has there been any change in your walking ability?” Participants were then 
asked to indicate if their walking ability had ‘improved’, ‘worsened’ or ‘stayed the 
same’. For PA, participants were asked “Since you started this research program, has 
there been any change in how active you are in your daily life?” Participants were 
then asked to indicate if their PA had ‘increased’, ‘decreased’ or ‘stayed the same’. If 
the response was ‘improved’ or ‘worsened’ and ‘increased’ or ‘decreased’, they were 
required to rate the degree of change on a 7-point Likert scale. The degree of change 
ranged from: 1 - almost the same or hardly any change at all, 2 - a little change;        
3 - somewhat change, 4 – moderate change, 5 - a good deal change, 6 - a great deal 
change and 7 - a very great deal change.  
5.2.8.7 Descriptive measures 
Details pertaining to age, gender, height, weight, smoking history and current 
medication were recorded. Spirometry was measured before and after the 8-week 
intervention period. The number of respiratory-related hospital admissions in the 
previous 12 months was also recorded at baseline. 
5.3 Data management and analyses 
All analyses were carried out using the Statistical Package for Social Sciences (SPSS 
version 18.0; Chicago, IL, US) with a probability value (p) ≤ 0.05 used to indicate 
statistical significance. Data are expressed as mean±standard deviation (SD) unless 
otherwise stated. The assumption of normality was assessed using frequency 
histograms. Data that did not follow a normal distribution were analysed using non-
parametric statistical tests. The primary analysis compared outcomes in the training 
groups with the usual care group. Analysis of covariance (ANCOVA) was conducted 
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for the between-group comparisons with baseline values as the covariate to account 
for selection bias. Intention-to-treat analyses were conducted regardless of the 
participants’ attendances of the exercise sessions with no imputation of missing 
values.  
As not every participant wore the SenseWear armband for at least 85% of the time 
for 7 whole days, an analysis was undertaken to determine the minimum number of 
days of PA data required to provide a valid representation of the PA of the 
participants to account for missing data. The variability in outcome measures of PA 
has been shown to increase with reduced severity of COPD (106) and 3 to 5 days of 
accelerometer monitoring is recommended to obtain a reliable measure of PA (148). 
In order to assess whether 3 or 5 days of SenseWear data were required to provide 
valid data representation for PA, a list of random numbers (ranging from 1 to 7) was 
generated using Random.org and this list was used to select 3 random days and         
5 random days of PA data in order to compare if there was any significant difference 
in TEE, steps per day and AEE > 3 METs using paired t-tests. Similarly, testing was 
conducted to compare any 2 random weekdays to 2 weekend days. 
5.3.1 Sample size 
A sample size calculation revealed that 132 participants were required to provide 
80% power to detect a minimum 10 point difference in the mean total CRDQ score 
between the short-term supervised walking training groups (n = 88) and the usual 
care group (n = 44) (after adjusting for group size imbalance). This calculation 
assumed a standard deviation (SD) of 17 points as previously reported (117). This 
number was increased from 132 to 159 to allow for 20% loss to follow-up. 
5.4 Results 
The baseline characteristics (including results of the three walking tests and scores 
from the four questionnaires) of all participants are summarised in this section. The 
data pertaining to the impact of a short-term, supervised, individually tailored, 
ground walking training program as the sole exercise modality on ESWT 
performance and PA in individuals with COPD are presented in the following 
sections.  
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5.4.1 Participants 
A total of 399 individuals with COPD were screened of whom 256 were excluded as 
they did not meet the inclusion criteria or refused to participate in the study. A total 
of 143 participants were recruited from patients who had been referred to the PRPs in 
Sydney (86 participants) and Perth (57 participants). A flow diagram illustrating the 
recruitment of participants to this study and their follow-up is presented in         
Figure 5-3. The number of participants randomised to the walking training groups 
(WG and WFG) was 95 and 48 participants were randomised to the usual care group. 
A total of 45 (47%) participants in the walking training groups and 28 (58%) 
participants in the usual care group had a respiratory-related hospital admission in 
the 12 months prior to the intervention period. In the walking training groups, 50 
(53%) participants attended supervised exercise training three times per week and 17 
(18%) participants attended supervised exercise training twice a week for 10 weeks. 
A total of 20 (21%) participants attended two supervised sessions each week and 
completed one unsupervised exercise session each week. 
5.4.2 Baseline characteristics 
Baseline characteristics of the participants are summarised in Table 5-1. The 143 
participants were aged 69±8 years and comprised 84 (59%) males and 59 females 
(41%). There was no significant difference in baseline characteristics between the 
walking training group and the usual care group. At baseline, 36 (25%) of the 143 
participants performed a second ESWT at a faster speed.
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Figure 5-3: Flow diagram of par ticipants through the study. 
* The re-assessments may not have included all three walking tests and four 
questionnaires that were conducted at baseline. COPD, chronic obstructve pulmonary 
disease; CRDQ, chronic respiratory disease questionnaire; ESWT, endurance shuttle 
walk test; ISWT, incremental shuttle walk test; SGRQ, Saint George’s Respiratory 
Questionnaire; WAFT, walking and feedback training; WFG, walking training with 




for 8 weeks 
 
WG (n=46) WFG (n=49) 
Participants with COPD who had been referred to pulmonary 
rehabilitation programs screened for participation into the study: 
– 276 from Sydney (5 sites) and 123 from Perth (2 sites) 
Total randomised (n = 143): Sydney (n=86); Perth (n=57) 
 
Controls (n=48) 





training intervention for 




• Did not meet inclusion criteria 
(n=98) 
• Refused to participate (n=65) 




ISWT (n=121); ESWT 
(n=125); 6MWT  
(n=122); CRDQ 
(n=129); SGRQ (n=125) 
Week 8 
Baseline testing (n=143) 
 
Total drop outs  
(n=13): WG (n=8); 
WFG (n=5). 
 
• Did not attend 2nd 
day testing (n=4) 
• Refused all 
walking tests (n=4) 
• Refused shuttle 
walk tests (n=1) 
• Refused ISWT 
(n=4) 
• Refused to fill out 
either CRDQ or 
SGRQ (n=2) 
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Table 5-1: Baseline character istics of the par ticipants. 
Demographic data  Walking training 
groups  
(n=95) 




Gender, n (%) 56M (59%) /  
39F (41%) 
28M (58%) /  
20F (42%) 
84M (59%) /  
59F (41%) 
Age (years) 69±8 68±9 69±8 
BMI (kg/m2) 25.3±4.6 27.3±6.0 26.0±5.2 
Smoking (pack-
years) 
49±29 49±42 49±34 
MMRC dyspnea 
grade 
1 (1 to 2) 2 (1 to 2) 1 (1 to 2) 
Grade 0, n (%) 6 (6%) 4 (8%) 10 (7%) 
Grade 1, n (%) 46 (49%) 18 (38%) 64 (45%) 
Grade 2, n (%) 25 (26%) 19 (40%) 44 (31%) 
Grade 3, n (%) 18 (19%) 6 (12%) 24 (17%) 
Grade 4, n (%) 0 1 (2%) 1 (<1%) 
BODE index  3 (2 to 4) 3 (1 to 4) 3 (2 to 4) 
Pulmonary 
Function  
   
FEV1 (L) 1.13±0.42 1.19±0.47 1.15±0.44 
FEV1 (% predicted)* 43±15 43±15 43±15 
FVC (L) 2.71±0.84 2.76±0.83 2.73±0.84 
FVC (% predicted)* 76±17 75±18 75±18 
FEV1/FVC ratio 0.43±0.14 0.43±0.12 0.43±0.13 
Walking Tests     
ISWD (m) 316±109 328±120 320±112 
ESWT speed (m/s) 4.4±0.8 4.4±0.9 4.4±0.8 
ESWT distance (m) 395±306 373±253 388±289 
ESWT time (sec) 310±198 292±167 304±187 
6MWD (m) 462±83 464±95 463±87 
6MWD % predicted  74±13 74±14 74±13 
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Dyspnea  3.5±1.1 3.6±1.0 3.6±1.1 
Fatigue  4.2±1.3 4.2±1.1 4.2±1.2 
Emotional function  4.9±1.3 4.9±1.2 4.9±1.3 
Mastery  5.2±1.3 5.1±1.2 5.2±1.3 
Total score  4.5±1.0 4.5±0.9 4.5±1.0 
Saint George’s 
Respiratory Questionnaire  
   
Symptoms 55.8±22.1 60.8±22.5 57.5±22.3 
Activity 63.6±19.6 64.3±20.2 63.8±19.7 
Impact 33.1±18.0 32.4±16.6 32.9±17.5 
Total score 46.5±17.1 46.7±15.9 46.6±16.6 
Hospital Anxiety and 
Depression Scale  
Walking training 
groups (n=95) 




Anxiety 7±4 6±4 6±4 
Depression 5±4 5±3 5±4 
General Self-efficacy Scale  Walking training 
groups (n=93) 




Initiative 12±3  11±3  11±3  
Effort 19±4 20±3 19±4 
Persistence 15±3 15±3 15±3 
Total score 46±9 45±7 46±8 
Data are mean±standard deviation or median (interquartile range). *predicted values based on 
NHANES (246). # scores expressed as points per item.  
BMI, body mass index; BODE, body mass index, airflow obstruction, dyspnea and exercise capacity 
index; ESWT, endurance shuttle walk test; F, female; FEV1, volume exhaled during first second of a 
forced expiration; FVC, forced vital capacity; ISWD, incremental shuttle walk distance; kg, 
kilograms; L, litres; M, male; m, meters; MMRC, Modified Medical Research Council (grade 0 to 4); 
n, number of participants; sec, seconds; %, percentage; 6MWD, 6-minute walk distance.
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5.4.3 Primary outcome: change in exercise capacity after walking training 
program 
The ESWT was completed both before and after the 8-week intervention period by 
78 (82%) participants randomised to the walking training groups (WG and WFG) 
and 47 (98%) participants in the usual care group. The duration and distance 
achieved in the ESWT significantly increased for participants in the walking training 
groups after the 8-week period (Table 5-2) by 245±313 sec and 289±376 m 
respectively, representing an improvement of 92±148 %. In contrast, the duration 
and distance achieved in the ESWT for the usual care group did not change 
significantly over time (38±229 sec and 54±325 m respectively; representing a 
difference of 34±102 %) (Table 5-2). In total, 18 participants reached the 20-minute 
limit of the ESWT (walking training groups [n=16; 17%] and usual care group [n=2; 
4%]) at the follow-up assessment. 
Of the 78 participants in the walking training groups, 69 (88%) completed the GRC 
scale for walking ability after the intervention period and 40 (85%) of the 47 
participants in the usual care group completed the GRC scale for walking ability after 
the 8-week control period (Table 5-3). The median score from the GRC scale for the 
walking group was 4 (i.e. moderately better) whereas the median score from the 
GRC scale for the usual care group was 0 (i.e. no change). Based on the GRC ratings 
provided by the participants after the 8-week period, none of the participants who 
completed the walking training reported deterioration in their walking ability.  
 
   
Table 5-2: Endurance shuttle walk test per formance for  the walking training groups versus the usual care group. 





















-29 to 106 0.26 208 
(104 to 313) 
<0.001 
               












-42 to 149 0.26 237 




77# 115±17 114±16 -1±13 -4 to 2 0.60 47 122±16 120±16 -2±14 -6 to 2 0.30 -1 




77# 89±5 88±5 -1.1±4.5 -2.2 to -0.1 0.03 46# 89±5 89±4 0.5±4.2 -0.8 to 1.8 0.43 1.6 




77# 5.1±2.1 5.3±2.0 0.2±1.9 -0.3 to 0.6 0.44 47 4.9±1.9 5.4±1.8 0.5±2.0 -0.1 to 1.1 0.12 0.3 




77# 2.7±2.5 3.4±2.6 0.8±2.1 0.3 to 1.2 0.002 46# 3.0±2.3 3.7±2.7 0.7±2.0 0.1 to 1.3 0.03 -0.1 




77# 5.3±2.3 5.4±2.1 0.1±2.1 -0.3 to 0.6 0.59 46# 5.1±2.1 5.7±1.8 0.6±2.2 -0.1 to 1.3 0.07 0.5 
(-0.3 to 1.3) 
0.243 
Data are mean±standard deviation or median (interquartile range). * p (probability) values are given for the comparison of ESWT performance between the 
walking training groups and the usual care group. #Some of the participants at baseline were not able to have their heart rate or percutaneous oxygen saturation 
detected by the heart rate monitor or pulse oximeter at the end of the ESWT or were not able to provide a rating for dyspnea or leg fatigue at the end of the 
ESWT. bpm, beats per minute; CI, confidence interval; ESWT, endurance shuttle walk test; HR, heart rate; m, metres; n, number of participants; RPE, rating 
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Table 5-3: Number of par ticipants who rated their  walking ability on each point 




GRC categories Walking training 
groups  
(n=69) 
Usual care group  
 
(n=40)  
-7 A very great deal 
worse 
0 0 
-6 A great deal worse 
 
0 0 
-5 A good deal worse 
 
0 3 (7.5%) 
-4 Moderately worse 
 
0 2 (5%) 
-3 Somewhat worse 
 
0 0 
-2 A little worse 
 
0 1 (2.5%) 
-1 Almost the same, 
hardly any worse at all 
0 0 
0 No change 
 
6 (8.7%) 19 (47.5%) 
1 Almost the same, 
hardly any better at all 
2 (3%) 0 
2 A little better 
 
9 (13%) 2 (5%) 
3 Somewhat better 
 
10 (14.5%) 5 (12.5%) 
4 Moderately better 
 
15 (21.7%) 4 (10%) 
5 A good deal better 
 
21 (30.4%) 2 (5%) 
6 A great deal better 
 
5 (7.2%) 2 (5%) 
7 A very great deal 
better 
1 (1.5%) 0 
GRC, global rating of change; n, number of participants.
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5.4.4 Secondary outcome: change in physical activity after walking training 
program 
Physical activity data of 129 participants were reviewed to determine the minimum 
number of days of PA data required for analysis. Of these, 115 (89%) participants 
had at least 5 days of valid PA data. Physical activity outcomes, namely TEE, steps 
per day and time spent at AEE > 3 METs were analysed. There was no significant 
difference in PA outcomes over any 3 random days compared to any 5 random days 
(p > 0.1). A total of 114 (88%) participants had valid PA data over 2 weekend days, 
and no significant difference was found in PA over 2 random weekdays compared to 
2 weekend days (p > 0.2) (Table 5-4). A minimum of 3 days of PA data was accepted 
as a valid sample for the analyses on the effects of the walking training on PA in this 
study. Thus, participants with ≥ 3 days of PA data were analysed. 
A total of 61 (64%) participants in the walking training groups and 38 (79%) 
participants in the usual care group had at least 3 days of valid PA data before and 
after the 8-week intervention period, during which the SenseWear armband had been 
worn for at least 85% of each day. Over time, the walking training groups and usual 
care group showed a non-significant increase in PA in the form of TEE, AEE and 
total steps taken per day (Table 5-5).  
Of the 61 participants in the walking training groups with valid PA data, 53 (56%) 
participants completed the GRC scale for PA after the 8-week training period    
(Table 5-6). Of the 38 participants in the usual care group with valid PA data, 34 
(71%) participants completed the GRC scale for PA after the 8-week control period 
(Table 5-6). The median score from the GRC scale for the walking group was 3 
(somewhat increased) whereas the median score from the GRC scale for the usual 
care group was 0 (no change). None of the participants who completed the walking 
training reported a decrease in activity levels. 
 
 
Table 5-4: Compar ison between different number of days as well as between weekdays and weekend days of outcomes in PA. 
PA variable n 3 days 5 days Difference p 
value 




TEE (kcal) 115 2,085±426 2,091±414 6±90 0.48 114 2,074±406 2,064±426 10±199 0.59 
Steps/day 115 5,080±2,818 5,108±2,839 28±820 0.72 114 4,963±2,873 4,756±2,986 208±1,881 0.24 
AEE ≥ 3 METs (kcal) 115 213±164 227±166 13±88 0.11 114 205±183 205±158 0.1±158 0.99 
Duration ≥ 3 METs (min) 115 47±34 50±37 3±20 0.13 114 47±37 46±41 0.1±34 0.97 
Data are baseline PA, presented as mean±standard deviation. AEE, active energy expenditure; kcal, kilocalories; METs, metabolic equivalents; 








Table 5-5: Physical activity outcomes for  the walking training groups versus the usual care group. 






value Baseline  Week 8 Change 95% CI p 
value 
Baseline Week 8 Change 95% CI p 
value 














-25 to 80 0.29 11 

















-263 to 799 0.31 113 
(-557 to 782) 
 
0.74 
AEE ≥  
3 METs 
(kcal) 
234±207  262±251 28±134 -6 to 62 0.11 217±186 247±226 29±124 -11 to 70 0.15 1 






54±44 60±55 6±31 -2 to 14 0.13 46±41 52±51 6±27 -3 to 15 0.16 0 
(-12 to 12) 
0.96 
Data are mean±standard deviation. *p (probability) value represents between-group comparisons. AEE, active energy expenditure; CI, 
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Table 5-6: Number of par ticipants who rated their  physical activity levels on 




GRC categories Walking training 
groups  
(n=53) 
Usual care group  
(n=34)  
-7 A very great deal 
decreased 
0 0 
-6 A great deal decreased 
 
0 0 
-5 A good deal decreased 
 
0 1 (2.9%) 
-4 Moderately decreased 
 
0 1 (2.9%) 
-3 Somewhat decreased 
 
0 1 (2.9%) 
-2 A little decreased 
 
0 2 (5.9%) 
-1 Almost the same, 
hardly decreased at all 
0 0 
0 No change 
 
17 (32.1%) 17 (50%) 
1 Almost the same, 
hardly increased at all 
1 (1.9%) 0 
2 A little increased 
 
3 (5.7%) 1 (2.9%) 
3 Somewhat increased 
 
6 (11.3%) 5 (14.8%) 
4 Moderately increased 
 
14 (26.4%) 4 (11.8%) 
5 A good deal increased 
 
7 (13.2%) 2 (5.9%) 
6 A great deal increased 
 
5 (9.4%) 0 
7 A very great deal 
increased 
0 0 
GRC, global rating of change; n, number of participants. 
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5.5 Discussion 
This RCT demonstrated that an 8-week supervised, individually tailored, ground 
walking training program in individuals with COPD significantly improved ESWT 
performance (p < 0.001) whereas the usual care group showed no significant change 
in ESWT performance (p = 0.26). Thus the improvement in ESWT performance 
between the walking training groups and the usual care group was significant           
(p < 0.001). However, the 8-week walking training program had no significant 
impact on PA outcomes. The usual care group also demonstrated no change in PA 
outcomes. There was thus no significant difference in all PA outcomes between both 
groups.    
In this 8-week supervised walking training study, ESWT duration improved by 245 
sec (95% CI, 174 to 315 sec) and 289 m (95% CI, 204 to 373 m) from baseline. 
These results are comparable to four studies that used ESWT performance as an 
outcome after a 7 or 8-week comprehensive PRP which included aerobic and 
strength training as well as education sessions (296-299). One of the studies 
demonstrated that a 4-week PRP was equally effective as a 7-week PRP in improving 
ESWT performance (223 sec [95% CI 152 to 294 sec] versus 217 sec [95% CI 132 to 
301 sec] respectively) (296). The similarity between the findings of the above studies 
and those observed in the current study suggest that walking training alone is 
sufficient for improving walking endurance.  
However, there are two studies that demonstrated a greater change in ESWT 
performance after a PRP. The first study by Revill et al (287) reported an 
improvement in ESWT time of 404 sec (95% CI 264 to 544 sec) after a 7-week PRP 
consisting of two supervised classes each week comprising exercise training (circuit 
of strength training and thoracic mobility exercises) and education in conjunction 
with a daily home-based walking program with individuals encouraged to increase 
the time spent walking throughout the 7 weeks. The greater magnitude of increase in 
ESWT found in Revill et al’s study (287) could be due to the high dose of walking 
training in addition to the supervised circuit training and education sessions. The 
second study by Leung et al (39) demonstrated that an 8-week program of supervised 
walking training in 17 participants with COPD improved ESWT time by 439±346 
sec (39). In the current study, a participant was progressed to the next level of the 
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ESWT if they were able to complete more than 5 minutes (300 sec) of the ESWT, 
expressed that the pace was comfortable and they had the ability to continue walking. 
As noted previously, this was done with the aim of avoiding participants reaching the 
20-minute ESWT maximum after the intervention period. In the current study, 16 
(21%) participants with COPD in the walking training groups who completed the 
ESWT reached the 20-minute completion time of the ESWT at the end of the 8-week 
intervention period versus six (35%) participants with COPD in the study by Leung 
et al (39) who reached the 20-minute completion time of the ESWT at the end of the 
walking training. It is possible that increasing the speed of the ESWT in this current 
study might have adversely affected participants’ ESWT performance following 
supervised walking training due to the hyperbolic relationship between endurance 
and speed (300). Thus, if a participant was walking at a higher work rate located at 
the lower end of the hyperbolic curve, despite the positive impact of exercise training 
on exercise capacity, the improvement in endurance capacity would be minimal. 
Dolmage et al (300) recommended that a target baseline performance on the ESWT 
equivalent to 8 minutes was likely to maximise the responsiveness to change. Thus 
capping the ESWT duration to approximately 5 minutes at baseline in this current 
study could have reduced the magnitude of change in ESWT performance after the  
8-week intervention period. Therefore, in future studies, participants should only be 
progressed to the next level of the ESWT if they are able to complete more than 8 
minutes of the ESWT. However, this may increase the number of participants 
reaching the 20-minute completion time of the ESWT at the end of an intervention. 
The only study that attempted to determine the MDD for the performance of ESWT 
in response to pulmonary rehabilitation in individuals with COPD estimated that 
value to be 186 sec, or 203 m (48). The mean improvement in ESWT performance of 
the participants in current study who received supervised walking training group 
exceeded this threshold while the usual care group did not show any significant 
change over time. 
The reduced PA in individuals with COPD (1) appears to be related to important 
healthcare outcomes such as the frequency of exacerbations, hospitalisations and 
mortality (118, 155). Thus, optimising PA is an important aim in the management of 
these individuals (9). This study found that 3 days of PA data from the SenseWear 
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armband was sufficient to accurately estimate daily PA as there was no significant 
difference in PA outcomes over any 3 random days compared to any 5 random days 
(p > 0.1). This finding concurs with that of Hart et al (149) who demonstrated that    
3 days of accelerometer data were needed to provide an accurate assessment of PA 
levels in older adults. Despite being confident that the data collected by the 
SenseWear armband were accurate, as this monitor has been validated in individuals 
with COPD (13), there was no significant impact on PA outcomes after 8 weeks of 
supervised walking training. In other words, training these individuals in a solely 
high-intensity walking training did not appear to translate into a more active lifestyle. 
This was similar to the findings of a 7-week PRP which consisted of aerobic and 
strength training program (301).  
There are several possible reasons for the lack of positive change in PA after walking 
training. One possible reason is that the 8-week duration of the walking training 
program was too short to have an impact on PA. Pitta et al (33) showed significant 
improvements in walking time only after 6 months of supervised exercise training. 
Similarly, a minimum duration of at least 12 weeks has been recommended for 
rehabilitation for most individuals with COPD to allow a change of a habit, in this 
case, increasing their activity levels (208). Physical activity is affected by a multitude 
of factors which include behavioural, personality characteristics, environmental 
circumstances, community settings, social and cultural factors and symptoms related 
to activity (302). Another possible reason for the failure to show a significant 
improvement in PA include the absence of a behavior modification program,  
education sessions or home exercise program in addition to supervised walking 
training as motivation may empower lifestyle modification to increase activity (303). 
Large variability in all of the measures of PA could also explain the lack of a 
significant change in PA. Thus, the only PA outcome that showed a trend towards 
improvement after walking training was steps taken per day. There was however no 
significant difference in the improvement in PA outcomes between the walking 
training groups and the usual care group after the 8-week intervention or control 
period. 
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5.5.1 Limitations 
A third of participants in the walking training groups had insufficient PA data, thus 
the PA data obtained in this study may not be a representation of the change after 
walking training. As the SenseWear armband is unable to identify specific type of 
activity, other motion sensors such as the Dynaport Activity Monitor or the 
StepWatchTM Activity Monitor should be considered to be used together with the 
armband to provide a more accurate and comprehensive assessment of PA. The 
sensor in the Dynaport Activity Monitor, a tri-axial accelerometer, detects movement 
in multiple directions and detects change in posture (1). The SenseWear armband 
appears to significantly underestimate steps compared to manual counting and video 
observation (12-14). As the StepWatchTM Activity Monitor, a dual axis 
microprocessor-controlled step counter, has been shown to accurately measure steps 
in individuals who walk very slowly (11, 16), this monitor would complement the 
SenseWear armband.  
5.6 Conclusion 
Walking training is suitable as a mode of exercise training for individuals with 
COPD and has been recommended to be incorporated into the exercise training 
component of pulmonary rehabilitation (5). An 8-week supervised, individually 
tailored, ground walking training was effective at improving ESWT performance. 
However the ground walking training has not been shown to significantly impact on 
outcomes of PA.  
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CHAPTER 6 
MIMIMAL DETECTABLE DIFFERENCE FOR 
ENDURANCE SHUTTLE WALK TEST 
PERFORMANCE 
6.1 Overview 
The minimal detectable difference (MDD) for endurance shuttle walk test (ESWT) 
performance is described in this chapter, using data from the walking and feedback 
training (WAFT) study described in Chapter 5. The MDD is defined as the smallest 
difference in the outcome of interest that individuals perceive or detect as either 
beneficial or harmful, and this can lead the individual or clinician to consider a 
change in the management (41, 212). This term is often used interchangeably with 
terms such as the minimal important difference (MID) and minimal clinically 
important difference (MCID). The main difference between these terms is that the 
MDD is the smallest difference noticeable (or detectable) by an individual, whereas, 
both the MID and MCID aim to ensure that the magnitude of this difference is 
important to the individual (8). Importance is related to a judgement by the 
individual that the magnitude of benefit is considered to be worth the effort, 
inconvenience or cost associated with completing the treatment (8). Alternatively, 
importance may be related to a reduction in the risk of some clinical event (e.g. 
mortality or hospitalisation). For example the MID for the Saint George’s 
Respiratory Questionnaire was determined from the difference in scores between 
individuals with chronic obstructive pulmonary disease (COPD) who were admitted 
to hospital or died over a 1-year period, and those who did not have any major 
health-related events (224). The MDD does not link the magnitude of change with 
whether or not the individual perceives the change to be important; it is simply the 
magnitude of change that is noticeable or detectable by the individual (8).  
The MDD is a separate construct to statistical significance. Specifically, for a change 
in an outcome following an intervention to be considered statistically significant, 
three factors are considered; the magnitude of change, variability in response and 
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sample size (8). If the variability is modest and / or the sample size is large, even a 
relatively small change may achieve statistical significance (8). A statistically 
significant finding implies that the difference is unlikely to be the result of chance 
(210). However, such a finding does not inform clinicians whether or not the 
individuals in the study would have noticed or detected the difference.  
The MDD has been determined using two approaches, namely anchor- and 
distribution-based approaches (8). The anchor-based approaches relate the magnitude 
of change in an outcome measure following an intervention to an objective external 
criterion (8). For example, several studies have related the magnitude of change in 
field-based measures of exercise capacity, following pulmonary rehabilitation, with 
self-report scores on the global rating of change (GRC) scale (42-44). Specifically, a 
GRC scale is simple to use and administer, and asks individuals to rank their 
improvement or deterioration using a balanced 7-point numerical scale with written 
descriptors ranging from a very great deal worse (-7) to a very great deal better (+7) 
(45). Earlier work has suggested that in order for some anchor-based approaches for 
establishing the MDD that use the GRC to be reliable, the magnitude of change in 
the outcome measure needs to have a correlation (r) of    > 0.5 with the individual’s 
perception of change reported using the GRC score (213). This is because a r > 0.5 is 
a sufficiently high threshold  to demonstrate validity between the magnitude of 
change and the GRC scores to determine a reliable estimate of the MDD (304). Once 
a moderate association has been established between the magnitude of change in an 
outcome measure and an individual’s GRC score (i.e. r ≥ 0.5), the MDD can be 
calculated as either the; (i) mean change and 95% confidence interval (CI) for a 
given GRC score (e.g. ‘slightly better’) or, (ii) slope of the line between the mean of 
change and the GRC scores, determined via linear regression analysis (8). In people 
with COPD, these anchor-based approaches using the GRC have been used to 
determine the MDD for the distance walked during the incremental shuttle walk test 
(ISWT) (44) and 6-minute walk test (6MWT) after pulmonary rehabilitation (43). 
These methods have also been used to determine the MDD for performance during 
the ESWT after bronchodilatation (48).  
In the absence of a moderate association between the magnitude of change in an 
outcome measure and an individual’s GRC score, others have used a receiver 
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operating characteristic (ROC) curve to estimate the MDD (43, 220, 305). 
Specifically, individuals are categorised, based on their GRC scores as ‘slightly 
improved’ versus ‘no change’, and an ROC curve is used to determine the magnitude 
of change in the outcome measure of interest that had the optimal capacity to 
separate these two groups of individuals (8, 306). The point selected is that with the 
best blend of sensitivity (true positive) and specificity (true negative) (8). 
Distribution-based approaches establish the MDD using some measure of variability 
in the outcome of interest. Distribution-based approaches are not anchored to a GRC 
scale and therefore do not take into consideration an individual’s perception of the 
change. In the distribution-based approach, there have been several methods used to 
determine the MDD for outcomes commonly used to evaluate the effects of 
pulmonary rehabilitation. These comprise calculating an effect size, the standardised 
response mean (SRM) or standard error of measurement (SEM) (8). The effect size 
has been defined as the standardised measure of change obtained by dividing 
differences in the outcome measure of interest (i.e. from baseline to post-
intervention) by the SD of the baseline value (8). An effect size of 0.5 is considered 
to be moderate (8) and the MDD is calculated by multiplying the SD of the baseline 
measure by 0.5. The SRM has been defined as the changes in a group of values or 
scores obtained by dividing differences in the outcome measure of interest (i.e. from 
baseline to post-intervention) by the SD of the change in the outcome measure (46). 
The SRM is also known as another form of effect size (226) and some authors have 
used the definition of SRM synonymously with the term effect size (217, 223). The 
SEM is a measure of within individual variability (8), as it estimates the standard 
error in a set of repeated scores. It is defined as variability between an individual’s 
observed score and the true score, and can be calculated using an intra-class 
correlation coefficient (ICC) or via repeated measures analysis of variance 
(ANOVA) (47). In contrast with other estimates of the MDD, established using 
anchor- or distribution-based approaches, the SEM can be used to determine the 
minimum detectable change (MDC) that is likely to exceed measurement error (47). 
In this way, it can be used to assist clinicians to determine a threshold that is likely to 
represent a true change following treatment that is beyond the natural variability 
inherent in all measures (47).  
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The MDD for the distance walked during field walking tests after pulmonary 
rehabilitation, namely the 6MWT and the ISWT, have been previously established in 
individuals with COPD (43, 44, 217) using both anchor- and / or distribution-based 
approaches. However the MDD for ESWT performance, which has been found to be 
more sensitive to change than distance walked during the ISWT (287) and 6MWT 
(285), has not been convincingly established. The ESWT is a standardised, externally 
paced walking test used for the assessment of endurance walking capacity (287). 
This test is performed at a walking speed equivalent to 85% of the participant’s peak 
rate of oxygen consumption that has been estimated from the distance walked during 
the ISWT (287). The only study to date to attempt to estimate the MDD for ESWT 
performance reported the SRM which is a distribution-based approach (48). The 
planned anchor-based approach could not be used as the relationship between the 
ESWT performance and the GRC scores after rehabilitation was weak (r < 0.4) (48). 
The authors attributed this weak relationship to be due to either recall bias arising 
due to the 7-week duration of the pulmonary rehabilitation program or the high level 
of commitment and personal investment required to complete the pulmonary 
rehabilitation program; both of which were likely to affect the individual’s 
perception of his or her exercise performance (48). 
6.2 Methodology 
6.2.1 Overall aim 
The aim of this study was, in individuals with COPD, to determine the MDD for the 
change in performance during the ESWT on completion of an 8 week supervised, 
individually tailored, ground walking training program; expressed as both time (sec) 
and distance (m).   
6.2.2 Research questions 
i. What is the MDD for ESWT performance using an anchor-based approach in 
individuals with COPD? 
ii. What is the MDD for ESWT performance using distribution-based approach 
in individuals with COPD? 
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6.2.3 Research hypotheses 
The hypothesis for this study was that there would be a significant relationship  
(r ≥ 0.5) between objective measurement of the change in ESWT performance and 
the subjective GRC ratings as perceived by the individuals with COPD after an        
8-week supervised, individually tailored, ground walking training program. It was 
hypothesised that the estimate of the MDD derived using an anchor-based approach 
would be similar to the estimate of the MDD derived using the distribution-based 
approaches.     
The data from the WAFT study (Chapter 5) were used to determine the MDD for the 
change in performance during the ESWT, expressed in both time (sec) and distance 
(m). This study has been briefly summarised below, with additional details provided 
in Chapter 5. 
6.2.4 Study design 
A prospective, single-blind, randomised controlled trial was undertaken with 
participants randomised into one of three groups; a walking training group (WG), a 
walking training with post-training feedback group (WFG) and a usual care group. 
Both the WG and WFG underwent the supervised ground walking training 
intervention over an 8-week period. All participants were recruited from the Sydney 
or Perth metropolitan area. All participants completed the ESWT before and after the 
8-week intervention period. On completion of the 8-week period, participants were 
asked to complete a GRC scale in order to record their perceptions of the magnitude 
of change in their walking ability. Only the data from the intervention groups (WG 
and WFG) who completed the ESWT before and after the 8-week walking training 
were used in this chapter to calculate SRM and apply anchor-based approaches to 
determine the MDD for ESWT performance, while their baseline ESWT data were 
used to calculate the effect size and SEM for ESWT performance.  
6.2.5 Ethical approval 
Approval to conduct the study was granted by the Human Research Ethics 
Committees from five sites in Sydney and two sites in Perth. Written, informed 
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consent was obtained from all participants. The study was registered with the 
Australian New Zealand Clinical Trials Registry (ACTRN 12609000472279). 
6.2.6 Participants 
All participants were recruited from patients who had been referred to pulmonary 
rehabilitation programs (PRPs) in Sydney and Perth, Australia. The inclusion criteria 
comprised aged > 40 years, medical diagnosis of COPD and a smoking history of ≥ 
10 pack years. Exclusion criteria comprised: (i) musculoskeletal, cardiovascular or 
neurological conditions likely to adversely affect performance during assessments or 
training, (ii) participation in supervised exercise training within the last 12 months, 
(iii) prescription of long term oxygen therapy or ambulatory oxygen during exercise 
training, (iv) inability to maintain percutaneous oxygen saturation > 83% during the 
ESWT and (v) body mass index > 35 kg/m2. All participants had their medical 
management optimised at baseline in accordance with the COPD-X Plan which 
included a COPD action plan with the aim of educating participants in managing 
their condition and an exacerbation (275).  
6.2.7 Protocol 
Participants allocated to the intervention groups (WG and WFG) completed an 8-
week, individually tailored, ground walking training program that comprised either 
three supervised sessions a week or two supervised sessions and one unsupervised 
exercise session each week for individuals who were unable to commit to travelling 
to the hospital three times a week for supervised training. Thus the maximum 
number of training sessions completed over the 8-week period was 24 (supervised 
and unsupervised sessions). The initial training intensity prescribed was equivalent to 
80% of the average walking speed achieved from the better of two 6-minute walk 
distances (6MWDs) (169, 276). The total exercise time (excluding rests) was 30 
minutes at the commencement of walking training. This was progressed by 
increasing the duration of exercise by 5 minutes after every sixth session to a 
maximum of 45 minutes by session 19. The supervised training took place along a 
flat corridor that ranged in length between centres from 26 to 100 m. The 
unsupervised sessions were recorded in a diary. In the event of a respiratory 
exacerbation, training was postponed until the participant was clinically stable (275) 
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and the training period extended to a maximum of 10 weeks to allow participants to 
complete a minimum of 16 sessions. At each supervised exercise session, 
percutaneous oxygen saturation and pulse rate were measured before and after 
walking training using a hand-held pulse oximeter (Respironics/Novametrix 513, 
Murrysville, Pennsylvania, United States [US] or RAD-5v, Masimo Corp, Irvine, 
California, US). 
6.2.8 Outcome measures 
The outcome measures relevant to the analyses presented in this chapter are the 
ESWT performance expressed as time (sec) and distance (m). 
6.2.8.1 Endurance shuttle walk test 
The ESWT is an externally paced field walking test that was performed over a 10 m 
course. Participants were instructed to walk around two cones, each positioned 0.5 m 
from each end, to a cadence dictated by an audio signal. The ESWT was performed 
at a walking speed equivalent to 85% of the participant’s peak rate of oxygen 
consumption (VO2peak) estimated from the distance walked during the best of two 
ISWT (287). During the test, percutaneous oxygen saturation using a hand-held pulse 
oximeter (Respironics/Novametrix 513, Murrysville, Pennsylvania, US or RAD-5v, 
Masimo Corp, Irvine, California, US) and heart rate (Polar a1 heart rate monitor; 
©Polar Electro, Kempele, Finland) were continuously monitored. Dyspnea (modified 
Borg scale) (283) and rating of perceived exertion (284) on a scale of 0 to 10 were 
recorded at the end of each minute during the test. The ESWT was terminated if 
participants were not able to keep up with the speed after being given a warning to 
keep pace when they were behind the speed for the first time (e.g. due to dyspnea or 
leg fatigue). At the end of each walking test, dyspnea, rating of perceived exertion 
and leg fatigue were recorded on a scale of 0 to 10 (284). 
Prior to training, two ESWTs were performed on separate days, to account for any 
improvements resulting from familiarisation (307). In order to optimise the 
responsiveness of the ESWT, speeds for the test performed prior to training were 
manipulated with the goal of achieving an average test duration of 8 minutes as this 
duration has been shown to be most likely to maximise the responsiveness to change 
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(300). Specifically, prior to training, the second ESWT was performed at a faster 
walking speed for participants who were able to complete more than 5 minutes of the 
ESWT, and expressed that this pace was comfortable and they had the ability to 
continue walking. If both tests performed prior to training were conducted at the 
same speed, the test which resulted in the longest time was recorded as the test result. 
If the tests performed prior to training were conducted as different speeds, the test 
performed at the faster speed was recorded as the test result.   
Following training, either one or two ESWTs were performed depending on 
participants’ willingness to come on separate days to repeat the ESWT. If both tests 
performed prior to training were conducted at the same speed, this same speed was 
selected for the test done following the intervention period. If the tests performed 
prior to training were conducted as different speeds, the faster speed was selected for 
the test done following the intervention period. Tests performed following training 
were terminated after reaching the 20-minute completion time of the ESWT.  
6.2.8.2 Global rating of change 
The GRC scores were used as an external criterion in the anchor-based approach of 
determining the MDD (308). On completion of the walking training, participants 
were asked to indicate if their walking ability had ‘improved’, ‘worsened’ or ‘stayed 
the same’. Those participants who rated their walking ability as ‘improved’ or 
‘worsened’ were then asked to rate the degree of change on the GRC scale (45). In 
this study, the GRC scale was a 7-point Likert scale. Improvements were scored as 
follows: 1 - almost the same or hardly any better at all, 2 - a little better; 3 - 
somewhat better, 4 - moderately better, 5 - a good deal better, 6 - a great deal better 
and 7 - a very great deal better. None of the participants reported a worsening of their 
walking ability (refer to Chapter 5, Section 5.3.2.1). The change in the ESWT 
performance was calculated for each rating on the GRC scale. Given the limited 
number of participants in some categories, the GRC scores were collapsed to three 
categories, where no change or a GRC score of 1 were categorised as no change, 
GRC scores of 2 to 3 were categorised as small change and GRC scores of 4 to 7 
were categorised as substantial change. 
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6.3 Data management and analyses 
Analyses were conducted using the Statistical Package for Social Sciences (SPSS 
version 18.0; Chicago, IL, USA) with a probability value (p) ≤ 0.05 used to indicate 
statistical significance.  
6.3.1 Anchor-based approach 
Changes in ESWT performance after walking training were expressed as time (sec) 
and distance (m). With participants grouped according to their responses on the GRC 
scale following training, the magnitude of change in ESWT performance between 
measures collected before and after training were compared using paired t-test.  The 
anchor-based approach to determine the MDD comprised two components. First, 
responses to the GRC scale were collapsed from seven categories to three categories 
as noted in section 6.2.8.2. This was done as some of the categories were chosen by 
very few participants. Further, collapsing of the GRC scale to three categories had 
been previously used by authors to determine meaningful change in exercise capacity 
among older adults (43, 309). Second, the strength of the relationship between the 
collapsed GRC responses (x-axis) and the magnitude of change in ESWT 
performance following training (y-axis) was determined. If this relationship was 
reasonably strong (i.e. r > 0.5), a linear regression model would be plotted between 
the collapsed GRC responses and the change in ESWT performance (48). The 
resultant slopes would represent the change needed in ESWT performance for the 
participants’ ratings to move one unit on the collapsed GRC scale, which were 
considered as estimates for MDD (48). If the relationship was weak (i.e. r < 0.5), a 
ROC curve would be constructed to determine the optimal operating point which 
resulted in the best blend of sensitivity and specificity to discriminate between 
participants who rated their walking ability following training as ‘changed’ versus 
‘unchanged’. This point was defined as the data point closest to the upper left corner 
of the ROC curve (43). For these analyses, participants were classified as ‘changed’ 
if they reported scores of ≥ 2 on the GRC scale versus ‘unchanged’ if they reported 
scores of < 2 on the GRC scale. The software package ‘R’ was used to establish the 
95% CI for this optimal operating point, using bootstrapping methods (310). 
Specifically, for all data points plotted on the ROC curve, 2,000 samples were 
obtained by re-sampling the ‘changed’ and ‘unchanged’ groups. Thereafter, the 
Chapter 6: MDD for ESWT 
161 
optimal operating point was obtained from each of the 2,000 samples. The limits of 
the 95% CI were then taken to be the 2.5th and 97.5th percentile of the 2,000 
samples. The CI derived using this technique was not necessarily symmetric around 
the optimal operating point determined from the ROC curve.  
6.3.2 Distribution-based approach 
Three separate distribution-based approaches were used to estimate the MDD: half 
the SD of baseline measure (i.e. the effect size); half the SD of change in measures 
collected before and after training (i.e. the SRM) and; the MDC, derived from the 
SEM (311).  
Specifically, the MDD determined using effect size was calculated as follows: 
0.5 × SD of measures of the ESWT performance performed prior to exercise 
training. 
The MDD determined using SRM was calculated as follows: 
0.5 × SD of change in measures of the ESWT performance (i.e. post-training 
measure – pre-training measure). 
Calculation of the MDC comprised three components. First, participants who 
performed both ESWTs, prior to exercise training, at the same speed were selected as 
this allowed comparison between the two measures of the baseline ESWT 
performance. Second, the SEM was calculated as the square root of the mean square 
error derived from ANOVA (47). The ANOVA was selected to determine SEM as 
the ESWT was repeated on separate days and thus may have been influenced by 
systematic and random errors (i.e. a learning effect) (47). Third, the determined SEM 
was placed into a formula derived using the methods described by Beckerman et al 
(312) to calculate the coefficient of repeatability. The formula for MDC was 
calculated as follows: 
1.96 × √2 × SEM.  
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As the MDC derived using this method was based on measures collected during only 
two ESWTs at baseline, this estimate was equivalent to the smallest measurement 
change where 1.96 was derived from the 95% CI of no change while √2 is included 
in the formula as two repeated ESWTs were conducted at baseline (312). This value 
for the MDC is the value beyond which a clinician or researcher can be confident 
95% that the difference for any individual was beyond measurement error inherent 
within the test, and therefore represents a true ‘training’ effect (210).  
6.3.3 Sample size 
A minimum of 55 participants was required for an anticipated area under the ROC 
curve (AUC) of 0.70 with a standard error of 0.05. The AUC represents the 
probability that the data correctly discriminate between participants who have and 
who have not improved, where an AUC of 0.7 to 0.8 is considered acceptable (8).  
6.4 Results 
A total of 143 participants were recruited and 95 of these were randomised to 
walking training. Thirteen (14%) participants who were randomised to walking 
training withdrew from the study (Chapter 5, Figure 5-3). A total of 78 (82%) 
participants who were randomised to walking training completed the ESWT before 
and after the 8-week walking training. Seventeen (18%) participants declined to 
complete the ESWT at the end of the 8-week walking training period. Of the 78 
participants, 69 (73%) rated their walking ability on the GRC scale. Of these 69 
participants, only data from 55 (58%) participants were used to determine the MDD 
using the anchor-based approach as 14 of these 69 participants had an exacerbation 
during their walking training and therefore their data were excluded from the 
analysis. This was because of recall bias from the long time span of the rehabilitation 
as participants would have difficulty remembering how they were prior to the 8-week 
rehabilitation period and thus their perception of their walking ability were more 
likely to be influenced by a recent event such as an exacerbation (48). 
The data from all 78 participants were used in the analysis for the distribution-based 
approach to determine the effect size. Of the 78 participants randomised to walking 
training who completed the ESWT before and after the 8-week walking training, 20 
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of them had an exacerbation during the intervention period and were excluded from 
analysis for SRM. Data from 13 (14%) participants were not used in the calculation 
of the SEM. This was because these participants were progressed at baseline to the 
next level of the ESWT on the second day of testing as according to methodology, 
they were able to complete more than 5 minutes of the ESWT and had the ability to 
continue walking. In summary, 58 and 65 participants contributed data to the 
distribution-based determination of the MDD and MDC, respectively. 
The characteristics of the participants who contributed data for the analyses 
undertaken in this chapter are presented in Table 6-1.  
6.4.1 Effect of walking training on endurance shuttle walk test performance 
The 78 participants allocated to the walking training group completed 19±4 exercise 
sessions. As presented in Chapter 5 (Section 5.3.2.1), the duration and distance 
achieved in the ESWT by the 78 participants increased significantly by 245±313 sec 
and 289±376 m respectively after the 8-week period; an improvement of 92±148 % 
(Table 6-2). Sixteen (21%) participants reached the 20 minute limit of the ESWT at 
the 8-week assessment. Figure 6-1 illustrates the change in ESWT performance 
plotted against responses to the GRC scale. Compared with measures taken prior to 
training, the improvement in ESWT following training was statistically significant 
for those who rated themselves 3 (somewhat better), 4 (moderately better) or 5 (a 
good deal better) (Figure 6-1). 
Table 6-3 summarises the magnitude of change in performance during the ESWT 
with participants grouped according to their responses on the collapsed GRC scale. 
The seven participants whose GRC scores were classified as no change, did not 
change their ESWT performance (1±52 sec [p = 0.9] or 5±58 m [p = 0.8]). The 13 
participants whose GRC scores were classified as small change, improved their 
ESWT performance by 186±275 sec or 212±313 m (p = 0.03). The 35 participants, 
whose GRC scores were classified as substantial change, improved their ESWT 
performance by 326±338 sec or 397±419 m (p < 0.001).  
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6.4.2 Estimates of minimal detectable difference determined using the anchor-
based approach 
A significant relationship was observed between the collapsed GRC scores and the 
ESWT performance expressed as time (r = 0.36; p = 0.008) and distance                   
(r = 0.35; p = 0.008) (Figure 6-2). As the strength of these relationships were modest               
(0.3 < r < 0.5) (217), an ROC curve was used to determine the optimal operating 
point to discriminate between participants who rated themselves as changed versus 
unchanged at the end of the exercise training program (8).  
The AUC for ESWT performance expressed as time was 0.703 (95% CI; 0.561 to 
0.845) (Figure 6-3). The AUC for ESWT performance expressed as distance was 
0.716 (95% CI; 0.576 to 0.856) (Figure 6-3). The sensitivity and specificity for the 
optimal operating point of the ROC curve ESWT performance expressed as time 
were 0.629 and 0.250, respectively. The sensitivity and specificity for the optimal 
operating point of the ROC curve for ESWT performance expressed as distance were 
0.629 and 0.200 respectively. The optimal operating point for the ESWT 
performance expressed as time and distance was 113 sec (95% CI; 23 to 139 sec) and 
192 m (95% CI; 60 to 200 m), respectively. 
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Table 6-1: Character istics of par ticipants who were randomised to walking 
training and completed the 8-week intervention per iod (n = 82). 
Characteristics  
Gender 48 M (59%) / 34 F (41%) 
Age (yr)  70±8 
BMI (kg/m2)  25.3±4.5  
MMRC dyspnea grade (n [%]) 
 Grade 0 
 Grade 1 
 Grade 2 
 Grade 3  
  




BODE index (median [IQR]) 3 [2 to 4] 
FEV1 (L)  1.14±0.42  
FEV1 (% predicted)* 44±15  
FVC (L) 2.68±0.86 
FVC (% predicted)* 75±17 
FEV1/FVC (%)  44±14  
ISWT distance (m)  322±112  
ESWT distance (m)  417±318  
ESWT time (sec) 326±205 
6MWD (m)  466±84  
Data are mean±standard deviation unless otherwise stated. *predicted values based 
on Hankinson et al (246). BMI, body mass index; BODE, body mass index, airflow 
obstruction, dyspnea and exercise capacity index; ESWT, endurance shuttle walk 
test; F, female; FEV1, volume exhaled during first second of a forced expiration; 
FVC, forced vital capacity; IQR, interquartile range; ISWT, incremental shuttle walk 
test; kg, kilograms; L, litres; M, male; m, metres; MMRC, Modified Medical 
Research Council (grade 0 to 4); n, number of participants; sec, seconds; yr, years; 
%, percent; 6MWD, 6-minute walk distance.
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Table 6-2: Endurance shuttle walk test per formance for  the walking training 
groups. 
 n Baseline  Week 8 Change 95% CI p value 
ESWT (sec)  78 330±208 574±389 245±313 174 to 315 <0.001 
       
ESWT (m)  78 422±324 710±504 289±376 204 to 373 <0.001 
 
End test HR 
(bpm) 
77# 115±17 114±16 -1±13 -4 to 2 0.60 
End test SpO2 
(%) 
77# 89±5 88±5 -1.1±4.5 -2.2 to -0.1 0.03 
End test 
dyspnea 
77# 5.1±2.1 5.3±2.0 0.2±1.9 -0.3 to 0.6 0.44 
End test leg 
fatigue 
77# 2.7±2.5 3.4±2.6 0.8±2.1 0.3 to 1.2 0.002 
End test RPE 77# 5.3±2.3 5.4±2.1 0.1±2.1 -0.3 to 0.6 0.59 
Data are mean±standard deviation. #Some of the participants at baseline were not 
able to have their heart rate or percutaneous oxygen saturation detected by the heart 
rate monitor or pulse oximeter at the end of the ESWT or were not able to provide a 
rating for dyspnea or leg fatigue at the end of the ESWT. bpm, beats per minute; CI, 
confidence interval; ESWT, endurance shuttle walk test; HR, heart rate; m, metres; n, 
number of participants; p, probability; RPE, rating of perceived exertion; sec, 
seconds; SpO2, percutaneous oxygen saturation; %, percent. 






Figure 6-1: The change in ESWT (a) duration and (b) distance (y-axis) for  
par ticipants in the walking training groups, with par ticipants grouped 
according to their  global rating of change scores (x-axis) in walking ability after  
training.  
There was no significant change in ESWT performance for ratings 6 and 7 due to 
small n values. Data are mean±standard deviation. * indicates a significant change 
from baseline (p<0.05) in ESWT performance. ESWT, endurance shuttle walk test; 
n, number of participants.






Figure 6-2: Relationship between the change in ESWT performance expressed 
as (a) time and (b) distance (y-axis) and global rating of change scores collapsed 
as previously descr ibed (309) (x-axis).  
A score on x-axis of ‘0’ corresponded to GRC categories of ‘not changed’ and 
‘almost the same, hardly better at all’. A score on x-axis of ‘1’ corresponded to GRC 
categories of ‘a little better’ and ‘somewhat better’ (or small change). A score on x-
axis of ‘2’ corresponded to GRC categories of ‘moderately better’, ‘a good deal 
better’, ‘a great deal better’ and ‘a very great deal better’ (or substantial change). 
Data are mean±standard deviation.






































































Figure 6-3: Receiver  operating character istic (ROC) curve for  ESWT 
performance expressed as (a) time and (b) distance.
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Table 6-3: Endurance shuttle walk test per formance based on collapsed GRC 
categor ies. 
Variable GRC collapsed categories n MDD 
Time (sec) No change 7 1±52 
 Small change 13 186±275 
 Substantial change 35 326±338 
    
Distance (m) 
 
No change 7 5±58 
Small change 13 212±311 
Substantial change 35 397±419 
   
Data are mean±standard deviation. GRC, global rating of change; m, metres; MDD, 
minimal detectable difference; n, number of participants; sec, seconds. The GRC 
ratings of 0 to 1, GRC ratings 2 to 3 and GRC ratings 4 to 7 were grouped as no 
change, small change and substantial change respectively.
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6.4.3 Estimates of the minimal detectable difference determined using 
distribution-based approach 
6.4.3.1 Effect size 
According to this approach, the MDD, expressed as time and distance were estimated 
to be 104 sec and 162 m, respectively.  
6.4.3.2 Standardised response mean 
Using this approach, the MDD, expressed as time and distance were estimated to be 
156 sec and 188 m, respectively. 
6.4.3.3 Minimal difference derived from standard error of measurement 
The SEM, expressed in terms of time and distance, was 86 sec and 120 m 
respectively. The MDC, expressed in terms of time and distance, was 238 sec and 
333 m, respectively. 
6.5 Discussion 
The MDD for ESWT performance expressed in time and distance as determined 
using an anchor-based approach (i.e. the ROC curve) were 113 sec (95% CI, 23 to 
139 sec) and 192 m (95% CI, 60 to 200 m) respectively. The MDD for ESWT 
performance expressed in time and distance as determined by the distribution-based 
approaches ranged between 104 to 156 sec and 162 to 188 m. The MDC was 
considerably larger, being 238 sec and 333 m. 
The MDD is the threshold value for a change in an outcome of interest that is 
considered noticeable to the individual (8). The estimates obtained by the anchor-
based approach do not consistently correspond to the estimate obtained by the 
distribution-based approach (49). Anchor-based approaches to determine the MDD 
are often considered to be superior to distribution-based approaches as the latter are 
solely based on statistical criteria and may be more influenced by the characteristics 
of the study sample (212). Distribution-based approaches essentially represents an 
effect estimate based on measures of variability (217). In contrast, anchor-based 
approaches involve comparing the magnitude of change in an outcome measure 
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following an intervention to an external criterion for which the GRC scores are 
widely used (49). Thus anchor-based approaches determine if the clinical outcome is 
perceived by the participant. However, anchor-based approaches using the GRC 
scores may be influenced by recall bias (222) as participants often scored on the 
GRC scales based on their current status rather than the measuring transition as 
intended (45). The concurrent use of both approaches is recommended to increase the 
confidence in the final estimate of the MDD (215). 
To date, the only study which attempted to determine the MDD for ESWT 
performance for patients undergoing pulmonary rehabilitation used a distribution-
based approach and derived the estimate as one half a SD of the change in ESWT 
(pre to post rehabilitation), expressed as time and distance (48). The distribution-
based approach of using SEM was not possible in the study by Pepin et al (48) as the 
ESWT was not repeated at least twice before or after rehabilitation. There was also a 
weak correlation between the GRC ratings and the change in ESWT performance 
(0.35 ≤ r ≤ 0.37) in the study by Pepin et al (48), thus anchor-based approaches such 
as using a linear regression model to determine the relationships between the GRC 
and the change in ESWT performance were not undertaken. 
The MDD derived as half a SD of the changes in ESWT, expressed as time and 
distance in the study by Pepin et al (48) was somewhat different from that derived in 
the present study (186 versus 156 sec or 203 versus 188 m). This could be due to 
variability in the exercise regimens between the two studies. Specifically, the 
addition of resistance training to aerobic training as in the study by Pepin et al (48) 
might be more effective in improving outcomes in ESWT performance as resistance 
training has the potential of increasing muscle mass and strength (313).  
Another possible reason for the discrepancy is the methodology used to determine 
the speed for undertaking the ESWT. The true effect of the walking training may be 
underestimated as earlier works suggests between 14% to 35% of participants are 
able to complete the full 20 minutes of the ESWT after rehabilitation (39, 287), with 
a resultant ‘ceiling effect’. In an attempt to avoid a ‘ceiling effect’ (i.e. participants 
reaching the 20-minute maximum post walking training) in the current study, the 
ESWT was performed at a faster walking speed for participants who were able to 
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walk more than 5 minutes during the ESWT at baseline. This may have reduced the 
responsiveness of the ESWT. Previous research has shown that the critical power, 
which represents the maximum sustainable rate of aerobic capacity, occurs at a lower 
work rate in individuals with COPD than age-matched healthy adults (314). This 
reduced critical power might be due to a ventilatory limitation, namely progressive 
hyperinflation with exercise (160), and inefficient gas exchange quantified by the 
amount of dead space to tidal volume ratio (315). Further, Dolmage et al (300) 
demonstrated that exercise training in individuals with COPD only shifted the 
maximum walking speed that could be endured indefinitely, without changing the 
hyperbolic curve constant. The implication of this was if a participant was walking at 
a speed located at the lower end of the hyperbolic curve, despite the positive impact 
of exercise training on exercise capacity, this improvement would be minimal. Thus, 
in order to optimise the responsiveness of the ESWT, speeds for the test performed 
prior to training should be manipulated with the goal of achieving an average test 
duration of 8 minutes as this duration has been shown to be most likely to maximise 
the responsiveness to change (300). The baseline ESWT time for the rehabilitation 
group and bronchodilatation group in the study by Pepin et al (48) was 
approximately 3.8 minutes (230 sec) and 8 minutes (484 sec) and the SRM 
calculated was 186 sec and 70 sec, respectively. The baseline ESWT time in the 
current study was 5.5 minute (330 sec) and the SRM calculated was 156 sec. This 
suggests that the MDD is influenced by the baseline ESWT duration due to the 
relationship between power and endurance capacity (314).   
In the current study after supervised walking training program, the participants’ GRC 
ratings correlated significantly with the change in ESWT time expressed in seconds 
(r = 0.36) and ESWT distance expressed in metres (r = 0.35). These were likely to be 
insufficient to produce robust estimates of the MDD using many of the established 
anchor-based methods (232). The modest correlation (r < 0.5) between the GRC 
ratings and change in ESWT performance after walking training program may be due 
to possible recall bias as the walking training program was 8 weeks in duration and a 
considerable amount of effort and time was invested in the rehabilitation which 
would affect the participant’s perception of health (48). As such, the ROC curve was 
used to discriminate between individuals who rated themselves as changed versus 
unchanged at the end of an intervention (8). In addition to not being dependent on a 
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moderate to strong relationship between GRC ratings and improvement in ESWT, 
using the ROC method has the advantage of accommodating all available data and 
not being influenced by a small number of values within a category of the GRC scale 
(49).  
The MDC values (238 sec and 333 m) provide an estimate of the random variation of 
the ESWT and suggests that an individual would need to change by 238 sec or 333m 
to be 95% confident that this change was beyond natural variability in the ESWT 
performance (8, 226). These values are larger than the estimates of MDD calculated 
using both anchor- and distribution-based approaches, thus highlighting the 
limitations of using the MDD to interpret changes in individuals (234). 
The strength of the estimate of the MDD for ESWT performance in the present study 
is that the difference in values obtained with the approaches did not appear to be 
important as estimates obtained via distribution-based approaches (effect size and 
SRM) were within 95% CI of the anchor-based approach (218). Further, the estimate 
of MDD with the 95% CI using the ROC curve did not include zero, thus increasing 
the confidence in the anchor-based estimate for ESWT performance in the present 
study.  
6.5.1 Implications 
Determining the MDD is useful as it can identify improvements which can lead 
clinicians to consider a change in the clinical management (212). The benefits of the 
MDD include linking the magnitude of change to treatment decisions in clinical 
practice and helping with the choice of sample size (212, 233). However, the 
estimates obtained from the ROC, effect size and SRM are useful for interpreting 
changes in groups of individuals (233), while the MDC derived from SEM is useful 
for determining whether the change in an individual exceeds the measurement error 
and is therefore likely to represent a training effect (312). 
6.5.2 Limitations 
The limitation was having a baseline ESWT time that was not at the most responsive 
point of the power-endurance curve, thus possibly providing a larger estimate of the 
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MDD than that would have been expected if the ESWT time at baseline was closer to 
8 minutes. 
6.6 Conclusions 
Although the ESWT has been found to be more sensitive to change than measures 
made during other field walking tests, the MDD for ESWT performance using an 
anchor-based approach has not been established. Using an anchor-based approach, 
the estimated MDD for ESWT performance on completion of an 8 week supervised, 
individually tailored, ground walking training program was  approximately 113 sec 
(95% CI, 23 to 139 sec) or  192 m (95% CI, 60 to 200 m). 
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CHAPTER 7 
CONCLUSIONS AND RECOMMENDATIONS 
The aim of this program of research was to investigate the measurement properties, 
namely accuracy and responsiveness of two motion sensors to measure physical 
activity (PA) in individuals with chronic obstructive pulmonary disease (COPD), 
identify strategies to optimise their PA, determine the effects of a supervised ground 
walking training on the performance of the endurance shuttle walk test (ESWT) and 
PA, and determine the minimal detectable difference (MDD) for the ESWT. 
This chapter summarises the novel findings presented in this thesis as well as the 
implications these findings have in the clinical setting. 
7.1 The measurement properties of StepWatchTM Activity Monitor and 
ActivPALTM 
The stationary tasks and transitions between sit to stand were not detected as motion 
by either device. This is consistent with the properties of the StepWatchTM Activity 
Monitor (SAM) which only recorded steps. In contrast, the ActivPALTM is able to 
record time spent being inactive versus active, outcomes related to posture changes, 
but it was not able to detect the task of sit to stand. Therefore, the data of this study 
suggests that the ActivPALTM was not sensitive to measure transitions between 
sitting and standing if the new posture was not sustained for 2 minutes.  
Accuracy of the StepWatchTM Activity Monitor and ActivPALTM 
Regarding data collected using the SAM, there was no interaction (wheeled walker 
[WW] x walking speed), effect of WW or walking speed on the difference between 
step rates derived using the SAM and via direct observation during all four walking 
tasks. Regarding data collected using the ActivPALTM, there was no interaction (WW 
x walking speed) or effect of WW, but there was a significant effect of walking 
speed (p = 0.03) on the difference between step rate derived using the ActivPALTM 
and direct observation. Thus, the novel finding of this study is that the use of a WW 
did not affect the capacity of the SAM or the ActivPALTM to detect step rate. 
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Although the data indicates that the ActivPALTM underestimated step rate at slow 
walk speeds, this difference is very small compared to other popular, more 
expensive, commercially-available motion sensors. 
Responsiveness of the StepWatchTM Activity Monitor and ActivPALTM 
For data collected using the SAM, there was no interaction (WW x walking speed) 
but a significant effect of WW and walking speed on step rate. Likewise, for data 
collected using the ActivPALTM, there was no interaction (WW x walking speed) but 
a significant effect of WW and walking speed on step rate. This suggests that the 
SAM and ActivPALTM could detect the difference in step rate associated with 
changing from the slow to normal walk speed, regardless of whether the participant 
was using a WW. 
Thus, both of these motion sensors can be used to assess PA in individuals with 
COPD, including those who use a walking aid such as a WW. 
7.2 The impact of a wheeled walker on physical activity, health-related quality 
of life (HRQoL) and fear of falling 
The most important finding of this study was that, in this population, having a WW 
available for use at home and in the community conferred an increase in the number 
of steps taken per day (732±1,027 steps/day; p < 0.02) as well as the time spent 
walking at a moderate intensity (9±13 min/day; p < 0.02). To date, this is the only 
study to show that a WW provided as an intervention to selected individuals with 
COPD, who had recently completed training with a WW during supervised exercise 
classes, was able to increase PA. The use of the WW had no impact on HRQoL, a 
finding which may be attributed to only a short period (5 weeks) of using a WW. The 
main barrier towards the use of a WW is its weight which makes it difficult to lift the 
WW into and out of the car. 
The main barrier towards the use of the WW is related to its weight, thus it would be 
beneficial to develop a WW that is significantly lighter than those currently available 
or add upper limb resistance exercises to the PRP to increase upper limb strength.   
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7.3 Summary of the walking and feedback training (WAFT) study 
This randomised controlled trial demonstrated that an 8-week supervised, 
individually tailored, ground walking training program in individuals with COPD 
improved ESWT performance by 245 sec (95% CI, 174 to 315 sec) and 289 m (95% 
CI, 204 to 373 m) from baseline (p < 0.001) whereas the usual care group showed no 
significant change in ESWT performance (p = 0.26). Thus the improvement in 
ESWT performance between the walking training groups and the usual care group 
was significant (p < 0.001).  
However, the 8-week walking training program only showed a trend towards 
improvement in steps taken per day that was not significant. The possible reason for 
the lack of significant improvement in PA after walking training could be that the 8-
week duration of the walking training program was too short to change habits and 
have an impact on PA. This is because PA is affected by a multitude of factors which 
include behavioural, personality characteristics, environmental circumstances, 
community settings, social and cultural factors and symptoms related to activity 
(302). Further, a third of participants in the walking training groups had < 3 days of 
valid PA data to be included in the analyses, thus the PA data obtained in this study 
may not be a representation of the change after walking training. Future study is 
required to address the impact of exercise training on PA in individuals with COPD.   
7.4 The minimal detectable difference of the endurance shuttle walk test 
performance 
The MDD has been defined as the smallest difference in the outcome of interest that 
is noticeable to an individual after treatment (41). As ESWT has superior 
responsiveness to other field-based walking tests (287), determining its MDD will 
allow clinicians to evaluate the impact an exercise program may have from a 
patient’s perspective. The MDD for ESWT performance was determined, using 
ESWT outcomes obtained from the 8-week supervised, individually tailored, ground 
walking training program of the walking and feedback training (WAFT) study. 
The MDD for ESWT performance on completion of an 8-week supervised, 
individually tailored, ground walking training program as determined by the anchor-
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based approach using the ROC curve was  approximately 113 sec (95% CI, 23 to 139 
sec) and 192 m (95% CI, 60 to 200 m). Determining the MDD is useful as it can 
identify improvements which can lead clinicians to consider a change in the clinical 
management (212), linking the magnitude of change to treatment decisions in clinical 
practice and helping with the calculation of sample size (212, 233).  
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APPENDICES 
Appendix A : Table of Audio signals speeds for setting consistent 
walking pace 
6MWD(m) Speed(m/min) Speed (m/s) Seconds per beep 
150 25.0 0.417 12.00 
165 27.5 0.458 10.91 
180 30.0 0.500 10.00 
195 32.5 0.542 9.23 
210 35.0 0.583 8.57 
225 37.5 0.625 8.00 
240 40.0 0.667 7.50 
255 42.5 0.708 7.06 
270 45.0 0.750 6.67 
285 47.5 0.792 6.32 
300 50.0 0.833 6.00 
315 52.5 0.875 5.71 
330 55.0 0.917 5.45 
345 57.5 0.958 5.22 
360 60.0 1.000 5.00 
375 62.5 1.042 4.80 
390 65.0 1.083 4.62 
405 67.5 1.125 4.44 
420 70.0 1.167 4.29 
435 72.5 1.208 4.14 
450 75.0 1.250 4.00 
465 77.5 1.292 3.87 
480 80.0 1.333 3.75 
495 82.5 1.375 3.64 
510 85.0 1.417 3.53 
525 87.5 1.458 3.43 
540 90.0 1.500 3.33 
555 92.5 1.542 3.24 
570 95.0 1.583 3.16 
585 97.5 1.625 3.08 
600 100.0 1.667 3.00 
615 102.5 1.708 2.93 
630 105.0 1.750 2.86 
645 107.5 1.792 2.79 
6MWD, 6-minute walk distance; m, metres; min, minutes; s, seconds. 
 
Appendices 
   
216 
Appendix B : Activity diary for wheeled walker study 
 
When? Try to do your walking exercise daily 
If you are provided with the wheeled walker, please use it. 
 
Odometer Reading: Record the number displayed on the screen. 
 
Outdoor Walking: Refers to walking outside the house/home. 
 
Indoor Walking: Refers to normal walking in and around the house. 
 
Week Commencing   /   /20    to     /   /20    
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Appendix C : Walking Training Study Training Sheet 
This is an example of the walking training study training sheet of the first 6 
sessions 
 
Name                Age _________ Telephone ___________ 
Doctor _______________ Doctor’s Telephone _________________ 
Class days _________________Commencement _______________ 
Relevant past medical history                                                         
                                                                                                                                   
Relevant Medications                                 ____  
Initial prescription (metres) _______ 
Target Intensity Breathlessness level 3-4 and/or Effort level 3-4 
Class No. 1 2 3 4 5 6 
Date       
Time (minutes)       
Distance / laps       
SpO2       
Pulse rate       
Breathlessness       
       
Time walked       
Distance / laps       
Rests       
SpO2       
Pulse Rate       
Breathlessness       
Effort       
Leg fatigue       
Comments 
 
      
Rests: Participants are permitted to take short rests in the event of intolerable 
symptoms, with the total exercise time being exclusive of rests 
Progression: increase duration by 5 minutes after every 6th session (i.e. session 7, 
13 and 19) to a maximum of 45 minutes by session 19. Once the required duration is 
reached, if symptoms permit, the intensity will be increased by increasing walking 
speed or, if walking speed becomes limited by stride length, further increases will be 
achieved by adding weights in 2 kilograms increments in a weight belt.  
SpO2, percutaneous oxygen saturation. 
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Appendix D : Global rating of change for walking ability 
Since you started this research program, has there been any change in your walking 
ability?  
My walking ability has:  
     □ Improved  
    □ Worsened 
    □ Not changed 
If your walking ability has improved, give a rating stating how much improvement 
has been achieved.  
□ Almost the same, hardly better at all 
□ A little better 
□ Somewhat better 
□ Moderately better 
□ A good deal better 
□ A great deal better 
□ A very great deal better 
If your walking ability has worsened, select the statement which best matches how 
much it has worsened.  
□ Almost the same, hardly any worse at all  
□ A little worse 
□ Somewhat worse 
□ Moderately worse 
□ A good deal worse 
□ A great deal worse 
□ A very great deal worse  
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Appendix E : Global rating of change for physical activity 
Since you started this research program, has there been any change in how active you 
are in your daily life?  
My activity has:  
    □ Increased  
    □ Stayed the same 
    □ Decreased 
If your activity has increased, select the statement which best matches by how much 
it has increased.  
□ Hardly increased at all, almost the same, 
□ A little increased 
□ Somewhat increased 
□ Moderately increased 
□ A good deal increased 
□ A great deal increased 
□ A very great deal increased 
If your activity has decreased, select the statement which best matches by how much 
it has decreased.  
□ Hardly decreased at all, almost the same,   
□ A little decreased 
□ Somewhat decreased 
□ Moderately decreased 
□ A good deal decreased 
□ A great deal decreased 
□ A very great deal decreased  
 
